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1.1 The Nature of the Clinical Problem
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia.
It is diagnosed electrocardiographically by the absence of 'P' waves and
the presence of irregular coarse fibrillation or 'f waves and irregular QRS
complexes (Figure 1.1). The loss of sinus rhythm and the development of
AF is characterised by random incoordinate movement of the atria
resulting in impairment of atrial function. Data from the UK general
practice database suggest that AF affects approximately 1.2% of the UK
adult population, or an estimated 650,000 adults in England and Wales.1 A
recent study from Birmingham2 found a prevalence of 2.4% in patients
older than 50 years, and workers in Sheffield3 noted an incidence of 5.4%
in patients over 65 years of age. Wheeldon et al3 also highlighted the
increase in prevalence with age from 2.3% in those aged 65-69 years up to
8.1% in those over 85 years of age. Data from the USA shows a similar
prevalence of AF (5.5%) in patients over the age of 65 years.4 AF has been
described as the epidemic of the future as its prevalence will increase with
the aging of the population in developed countries. The age standardized
prevalence of AF has also increased through the 1990s1 suggesting that in
addition to an increase in AF due to the aging of the population more




Figure 1.1 Onset of atrial fibrillation (AF). SR - sinus rhythm
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Epidemiological data from The Framingham Study has shown a clear link
between AF and cardiovascular disease.5 Hypertension, especially in
association with left ventricular hypertrophy, was the most common risk
factor identified, although a history of rheumatic heart disease or cardiac
failure were stronger risk factors. AF in the absence of cardiovascular
disease (lone AF) represented 11% of AF patients in the Framingham
study.6 A more recent population analysis of AF in France7 has shown
some change in the epidemiology of AF in the last two decades.
Rheumatic valvular disease remains a common cause in women, but not in
men. More commonly nowadays AF is being identified in patients without
heart disease, with approximately 30% of the population in this study
having Tone AF', especially those with paroxysmal AF.
The association between AF and cardiovascular disease initially made the
study of AF related complications difficult. It became clear though, from
age and risk factor controlled studies, that AF itself carried a risk
independent of the underlying cardiovascular condition. The initial
Framingham data5 showed a doubling of overall mortality (Table 1.1) in
patients with AF compared to age and sex matched controls, and further
studies of AF in association with coronary artery disease8 and heart





Controls RR AF Cases
Women
Controls RR
Total Deaths 59.2%* 34.3% 1.7 44.9%* 25.3% 1.8
Cardiovascular 42.9%* 21.2% 2.0 40.8%* 15.1% 2.7
deaths
Average time 5.9 years* 7.7 years 4.6 years 6.7 years
to death
* Significant difference between values for AF cases and controls among all subjects 38 to 78 years old
at death (p < 0.05). RR - relative risk. Adapted from Kannel et al, NEJM 1982;306:P1021.
Table 1.1 Mortality data from the Framingham Study showing the increased risk of AF.
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The increased mortality with AF is at least in part due to an excess risk of
thrombo-embolic episodes. The association of AF with thrombo-embolism
was clearly defined in the early 1980s.10 This led to several studies of the
effectiveness of oral anticoagulants and aspirin as prophylactic agents to
prevent thrombo-embolism in the late 1980s.11"16 Pooled analysis from
these studies shows that aspirin at a dose of 300-325mg/day reduces the
risk of thrombo-embolism by approximately 20% and that warfarin at an
INR of 2.0-3.0 reduces the risk by 68%.17 The risk of stroke with placebo
was 4.5% per annum and with warfarin 1.4% per annum. The calculated
number needed to treat (NNT) with warfarin therapy over 1-year in order
to prevent 1 stroke is 32.
1.2 The Progressive Nature of Atrial Fibrillation
In clinical practice the presentation of AF is variable. Some patients
present with short-lived episodes of AF that resolve spontaneously. Others
develop AF that can only be converted to sinus rhythm by chemical or
electrical cardioversion, and in some patients sinus rhythm cannot be
restored. This led to the 3 'P' classification18 of Paroxysmal, Persistent
and Permanent forms of AF.
An important aspect of the 3 'P' classification is that it bears a strong
relationship to the observed natural history of AF. Clinical observation has
suggested that AF is a progressive condition. As early as 193019 the
transition from paroxysmal to persistent AF was identified, with
progression to persistent AF in -25% of patients with paroxysmal AF over
several years of follow-up. A survey of the natural history of AF in 1212
patients found the transition rate from paroxysmal to persistent AF to be
33% over a three-year period.20 Although this might be explained by a
deterioration of the underlying heart disease the progression from
paroxysmal to persistent forms of AF has also been noted in patients with
7 21 22lone AF, ' ' suggesting that AF itself is progressive regardless of any
underlying cardiac condition. In addition to the recognition that AF is a
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progressive condition, the transition rate from paroxysmal to persistent AF
appears to be increasing over the last decade. The study from Olmsted
County, Minnesota published in 198721 found the rate of transition was
12% over 13.4 years. Two studies published in 1999 showed higher rates
of progression of AF with a transition rate of 23% over a mean of 7-years
in a study from Trieste, Italy,22 and recent data from France7 has shown a
transition rate of 8% in 6-months. This suggests that recent advances in
therapy have done little to alter the natural history of AF.
Despite medical treatment many patients will progress from paroxysmal to
persistent AF. At this point most physicians will attempt restoration of
sinus rhythm by pharmacological or electrical cardioversion. Akin to the
progressive nature ofparoxysmal AF over time, the success of
cardioversion in restoring long-term sinus rhythm is related to the prior
duration of AF. This is particularly true for chemical cardioversion.
Flecainide results in successful restoration of sinus rhythm in around 90%
of patients with recent onset AF (<24 hours), whereas the success rate of
23 25cardioversion of chronic AF (>24 hours) is only around 40%. " The
same pattern is seen for other drugs such as propafenone.26 Increased
difficulty in restoring long-term sinus rhythm with lengthy durations of AF
is also noted in patients undergoing DC cardioversion. Longer durations of
AF require higher shock energies to restore sinus rhythm at the time of DC
cardioversion27 and recurrence of AF is more common with a longer
duration of AF prior to DC cardioversion.28"32
Atrial fibrillation is a progressive condition independent of the underlying
cardiac condition. With the passage of time paroxysmal AF will often
develop into persistent AF, and if not cardioverted promptly persistent AF
to permanent AF. This led researchers to ask whether AF itself was
important in its own maintenance. It was on this basis that Maurits Allessie
asked the question "Does AF beget AF? " i.e. is it self-perpetuating? In
combination with Maurits Wijffels he developed a chronically
8
IT
instrumented goat model of AF ~ in order to study the effect of repetitive
paroxysms of AF on a healthy heart. Using a left intercostal thoracotomy
approach goats were fitted with silicon strips containing unipolar
electrodes on the surface of both atria and across Bachmann's bundle. The
wires from the electrodes were tunneled to the back of the goat's neck
where they were exteriorised. A cable then connected the wires to a
personal computer. The computer acted as a fibrillation pacemaker
inducing AF by burst pacing. Following the onset of AF the burst pacing
was inhibited and the computer simply monitored the atrial rhythm.
Whenever sinus rhythm was detected further burst pacing was performed
to reinduce AF. AF could thus be maintained for prolonged periods. This
landmark work went on to show that repetitive reinduction of AF resulted
in a gradual prolongation of the duration of the induced AF episodes and
eventually the onset of stable chronic AF (Figure 1.2).
pacleg — AF 1 StaM Rhylhm
2 sec
Figure 1.2 Prolongation of the duration of episodes of electrically induced AF after
maintaining AF for respectively 24 hours and 2 weeks. The three tracings show a single
atrial electrogram from the same goat during induction of AF by a 1-second burst of
stimuli (50Hz, 4 x threshold). In the upper tracing the goat has been in sinus rhythm all
the time and AF self-terminated within 5 seconds. The second tracing was recorded
after the goat had been connected to the fibrillation pacemaker for 24 hours and shows a
clear prolongation of the duration of AF to 20 seconds. The third tracing was recorded
after 2 weeks of electrically maintained AF. After induction of this episode AF became
sustained and did not terminate. From Wijffels et al. Circulation 1995;92:1954-68.
Associated with the prolongation of AF episodes there is a reduction in the
atrial effective refractory period (AERP) and loss of its adaptation to rate,
a process termed atrial electrical remodelling (Figure 1.3). The importance
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of atrial electrical remodelling and the associated reduction in AERP is the
resultant reduction in atrial wavelength (Atrial wavelength = atrial
refractory period x conduction velocity). According to Moe's multiple
wavelet hypothesis of AF34 a shorter atrial wavelength promotes the
maintenance ofAF. The recognition of atrial electrical remodelling as a
'substrate' for the maintenance of stable AF has directed research into the
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Figure 1.3 Four examples of
changes in atrial refractoriness in
the course of the first 24 hours of
fibrillation. In all goats the
refractory period shortened
markedly at all pacing intervals. In
general the amount of shortening
was higher at slower heart rates,
resulting in reversal or attenuation
of the normal physiological rate
adaptation of the refractory period.
From Wijffels et al. Circulation
1995;92:1954-68.
In addition to the identification of a 'substrate' for the self-perpetuation of
AF there has been renewed interest in the importance of atrial ectopy as a
'trigger' for AF. This surge of interest in the triggers for AF was generated
following the description by Haissaguerre and coworkers of a 'focal' form
of AF dependent on frequent repetitive discharges from a single source,
predominately within the pulmonary veins, and amenable to treatment by
radiofrequency ablation.35'36 Figure 1.4 shows mapping of a focal source
of AF. This 'focal' fonn of AF has generally been described in young




Figure 1.4 Electrograms and Angiogram of a Left Inferior Pulmonary Vein
Depicting the Source and Exit of Ectopic Activity. The radiograph (centre panel)
shows the position of electrographic recordings inside the pulmonary vein. There are
changes in timing of the electrogram depending on the position of the recording
catheter in the pulmonary vein. With an increasingly distal catheter position (toward
the source), the spike was recorded progressively later during sinus rhythm (left-hand
panel, arrows) and correspondingly earlier during ectopic activity (arrowhead).
Conversely, in a proximal position at its exit into the left atrium (right-hand panel),
the spike was not as delayed during sinus rhythm (arrows) but also not as early
during ectopic activity (arrowhead). Figure and text adaptedfrom Haissaguerre M et
al. NEJM 1998;339:659-66
1.3 Aims of the thesis
Substrate
The aim of the first part of the study was to study atrial electrical
remodelling in two situations:
(1) In an animal model.
(2) In patients with clinical AF undergoing cardioversion for persistent AF.
1. Animal model
In order to study the process of atrial electrical remodelling we developed
an animal model based on the original Allessie goat model. Using adult
female goats implanted with pacemakers, we developed and validated a
new fully implantable goat model of AF. Having confirmed the
reproducibility of data from the new model we were able to study the
effects of drugs on the process of atrial electrical remodelling. Data from
animals37 and humans38 had shown that the L-type calcium channel
blocker verapamil attenuated atrial electrical remodelling induced by short
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durations of AF or rapid atrial pacing. It was not clear, however, whether
this effect on atrial electrical remodelling had any meaningful
antifibrillatory effect on the atria. Our initial studies confirmed that
verapamil attenuated atrial electrical remodelling, but despite this action
verapamil had a profibrillatory action on the atria (Dr W. J. C. Hobbs, MD
Thesis). Despite the profibrillatory action of verapamil in the experimental
setting clinical data suggested a beneficial effect of verapamil combined
with propafenone in preventing recurrent AF following DC cardioversion
"XQ
of persistent AF. In view of this the first part of the thesis was to study
the effects of propafenone on the profibrillatory action of verapamil.
The second part of the thesis required longer durations of AF. A particular
advantage of the fully implantable version of the Allessie goat model was
the ability to study the effects of longer durations of AF on the atria
without the risk of infection. In his initial work Wijffels noted a
discrepancy between the time course of atrial electrical remodelling and
the onset of stable AF. Despite the onset of maximal changes in atrial
refractoriness in a relatively short time following activation of the
fibrillation pacemaker, stable AF often did not occur till several days later.
Gaspo and colleagues40 made the same observation in their canine model
of AF and this led Zipes to question whether factors other than atrial
refractoriness may be important in the self-perpetuation of AF.41 The
discrepancy in the effects of verapamil with attenuation of atrial electrical
remodelling but promotion of AF stability also led us to question whether
a 'second factor' independent of atrial refractoriness might be involved in
the onset of stable AF.
A previous study42 using sequential 5-day episodes of maintained AF
found no evidence of a 'second factor'. In this study, using the original
Allessie chronically instrumented goat model, Garratt and coworkers42
studied repetitive 5-day periods of AF reinduction to examine the
hypothesis that an AF-induced increase in AF stability might be due to a
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mechanism (a so-called second factor) with a longer time course than that
of changes in atrial refractoriness. No progressive increase in AF
inducibility, vulnerability or stability was demonstrable in this study,
indicating either that a second factor did not exist or had a longer onset
than the 5 days selected in the protocol.43 Our aim was to retest the above
hypotheses using 4-week periods of AF. This duration of AF was chosen
because it has been shown that AF of this duration in addition to causing
atrial electrical remodelling leads to ultrastructural changes in atrial
myocardium,44 a possible candidate for the 'second factor'.
2. Clinical Study
The study of atrial electrical remodelling in patients with persistent AF
focused on the question of whether atrial electrical remodelling reversed
following cardioversion of persistent AF. Atrial electrical
remodelling33'40'45 and its reversal following conversion to sinus rhythm
had already been demonstrated in animal models of AF. Atrial electrical
remodelling had also been shown in man,46 but only in the setting of short¬
lived, pacing-induced episodes of AF in patients without a prior history of
AF. We sought to determine first, whether atrial electrical remodelling was
present in patients with persistent AF, and second whether periods in sinus
rhythm resulted in reversal of atrial electrical remodelling. In order to do
this atrial fibrillation cycle length and atrial refractoriness were determined
in patients undergoing internal DC cardioversion for persistent AF. If a
patient required repeat cardioversion for recurrent AF the measurements
were repeated at this time. In patients with recurrent AF requiring repeat
internal DC cardioversion we demonstrated reversal of atrial electrical
remodelling as indicated by an increase in atrial fibrillation cycle length
and a prolongation of atrial refractoriness.47(Dr W. J. C. Hobbs, MD
Thesis) As part of this study I measured the coupling intervals of atrial
premature beats in the first 2-minutes following cardioversion at the time
of the initial cardioversion and again after repeat cardioversion(s). In
addition, using the coupling intervals of atrial premature beats detected on
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Holter monitoring as an index of atrial refractoriness, I also assessed
reversal of atrial electrical remodelling in the initial 72-hours following
cardioversion in patients without AF recurrence.
Triggers
In addition to studying the substrate' of atrial electrical remodelling the
internal DC cardioversion procedure allowed us to closely analyse atrial
ectopy following cardioversion to sinus rhythm. Recurrence of AF
following DC cardioversion is due not only to the persistence of a suitable
atrial substrate (atrial electrical remodelling) but also the triggering effect
of premature atrial ectopic beats 48 It is believed that critically timed
premature atrial beats ('triggers') result in AF due to division of the atrial
wavefront as it meets areas of atrial refractoriness. If repeated division of
the wavefront occurs the result is the formation of multiple wavelets of
atrial activation i.e. multiple wavelet reentry. Intracardiac electrogram
recordings from the distal poles of catheters placed in the right atrium and
coronary sinus allow accurate recording of all atrial ectopy following
cardioversion. The coupling intervals of all atrial premature beats were
measured for the first 2-minutes following cardioversion. The coupling
interval of atrial premature beats in the first 2-minutes following the
patients first cardioversion was also assessed as a predictor of the timing
and likelihood of AF recurrence.
Further analysis of the intracardiac electrograms recorded following
cardioversion found evidence of frequent short-lived episodes of atrial
arrhythmia following cardioversion and that some patients were prone to
repeated episodes of immediate reinitiation of AF (IRAF). Focal atrial
tachycardias have been recognised for many years as a trigger for AF and
recently reproducible episodes of IRAF have also been shown to have a
focal origin amenable to treatment by radiofrequency ablation.49 We
sought to determine whether there was evidence of focal atrial
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arrhythmias, and the significance of such findings, in patients undergoing
DC cardioversion ofpersistent AF.
The final part of the study was to determine whether prolonged periods of
AF resulted in changes in heart rate variability following DC cardioversion
of persistent AF either by influencing sinus node function or the
autonomic nervous system input to the atria. It was postulated that a long
period of persistent AF might result in changes in sinus node function
secondary to atrial electrical remodelling or that changes in atrial
autonomic innervation might occur during AF that could be important in
recurrent AF or in the recovery of atrial electrical remodelling following
cardioversion. Holter tapes were analysed to determine measures of heart
rate variability at various time periods following cardioversion.
15
1.4 Summary of the thesis
1. Introduction
2. History and Overview of Atrial Fibrillation
3. A New Fully Implantable Goat Model of Atrial Fibrillation
4. The Profibdilatory Action of Verapamil is Not Prevented by
Propafenone
5. Repetitive Four-Week Periods of Atrial Electrical Remodelling
Promote Stability of Atrial Fibrillation - Evidence for a Second
Factor Independent of Atrial Refractoriness in the Self-Perpetuation
of Atrial Fibrillation
6. Atrial Ectopy - The Coupling Interval of Atrial Premature Beats
Following DC Cardioversion of Persistent AF Predicts Subsequent
Recurrence of AF
7. Atrial Ectopy - Evidence for Reversal of Atrial Electrical
Remodelling
8. Prevalence and Significance of Focal Sources of Atrial Arrhythmia
in Patients Undergoing Cardioversion of Persistent Atrial Fibrillation
9. Changes in Heart Rate Variability Following Cardioversion of
Persistent Atrial Fibrillation in Man
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2.1 The History of Atrial Fibrillation - from Delirium Cordis
to DC Cardioversion
Delirium Cordis
The initial description of atrial fibrillation (AF) was probably given by
William Harvey in 1628.1 In his animal work Harvey noted fibrillatory
movement of the right atrium at the time of death. The recognition of an
irregularly irregular pulse in humans was first made in 1827 when Adams,
using the recently developed stethoscope of Laennec, described it as a sign
of mitral stenosis. At this time AF was termed 'delirium cordis'. Further
observations of the clinical characteristics of AF were made by Hope in
1839 when he noted that on exercise the irregularity of the pulse was
increased. The first recording of AF was a pulse tracing by Marey
published in 1863 from a patient with mitral stenosis and AF. In the late
19th century James McKenzie, a Scottish general practitioner working in
Burnley, using an ink-writing polygraph to record jugular venous pulses
made important observations in patients with AF.2 He noted the loss of the
'a' wave in patients who changed from a regular to an irregular pulse, but
initially attributed this to a change from sinus rhythm to an atrioventricular
nodal rhythm.3 He was later to recognize that the underlying aetiology for
the loss of the 'a' wave was the onset of auricular fibrillation when shown
electrocardiographic tracings by Thomas Lewis. The initial link between
the clinical finding of AF in humans (delirium cordis) and experimental
AF in animals was made by Arthur Cushny4 when he noted the similarity
of pulse tracings from a dog with auricular fibrillation and a lady with
'delirium cordis' and suggested that the two conditions may be the same.
The single most important breakthrough in recording AF came with the
development of the string galvanometer and the recording of the first
electrocardiograms (ECG) by Einthoven in 1900. Thomas Lewis then went
on to record an ECG of AF in 19095 and did initial work on the
mechanism of the arrhythmia. His conclusion that the irregular pulse
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observed in patients with mitral stenosis was due to AF was based on a
mixture of clinical and experimental evidence.6 He noted that the irregular
pulse was reproduced by experimentally induced AF, that
electrocardiograms from patients with AF showed fibrillation waves
between QRS complexes and that if a regular pulse returned these
disappeared (probable paroxysmal AF), and finally that the 'a' wave of
venous flow was lost in patients with AF. At around the same time in
Vienna, Rothberger and Winterberg published electrocardiograms from
patients with 'pulsus irregularis perpetuus' observing the irregular nature
of the QRS complexes, absence of 'P' waves and the presence of
fibrillatory waves.7
Pharmacological Therapy
The recognition of atrial fibrillation then led to interest in its treatment. It
is likely that the first description of successful therapy for AF was the
description in 1785 by William Withering of the therapeutic properties of
the foxglove plant (Digitalis pupurea). The improvement in cardiac failure
likely represented improved rate control of the ventricular response in AF,
although this was not appreciated at the time. Wenkebach made the first
description of pharmacological cardioversion of AF to sinus rhythm with
quinine in 1914.8 Frey extended this work and found that quinidine, an
isomer of quinine, was the most effective of the cinchona alkaloids in
converting AF.9 Drury, a pupil of Lewis, reported results from a series of
patients undergoing pharmacological cardioversion at University College
Hospital, London in 1921.10 In this paper cardioversion of AF to sinus
rhythm using oral quinidine was achieved in 6 of 13 cases. The authors
showed slowing of the fibrillatory rate by carefully recording serial ECGs.
The risk of conversion to flutter with 1:1 ventricular conduction, due to the
associated anticholinergic actions of quinidine, was also appreciated. In an
accompanying editorial11 Thomas Lewis goes on to explain that the action
of quinidine is dependent on its prolongation of the atrial refractory period.
He also notes the slowing of conduction velocity by quinidine and
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comments that this will favour reentry. Although at this time Lewis
believed AF to be due to a single wandering wavelet with a random path
(thus distinguishing it from flutter where the path of the wavelet is
constant, see Figure 2.3) his understanding of the underlying
electrophysiological mechanisms for persistence of re-entry was
remarkable. Following the early descriptions of efficacy the use of
quinidine entered into clinical practice. Initial enthusiasm was followed
relatively quickly by disappointment when the risk of serious adverse
effects and the frequency of relapse in unselected cases was realised. With
further experience the choice of patients where the danger is least and the
potential for benefit greatest established a clinical role for quinidine in
chemical cardioversion of AF,12 a similar scenario to the adoption of focal
AF ablation in the 21st century.
DC Cardioversion
The most important advance in the management of AF came when Lown
described DC cardioversion in the 1962.13 Interest in the use of DC
cardioversion for AF followed the refinement of cardioversion for life
threatening ventricular arrhythmias. The first description of electrical
cardioversion of ventricular fibrillation (VF) was a successful AC
cardioversion in 1956.14 AC cardioversion was then used for drug resistant
ventricular tachycardia but was associated with a high risk of
proarrhythmia and the development of VF. The advent of DC
cardioversion allowing synchronization of the shock to the R-wave so
reducing the risk of provoking ventricular fibrillation extended the use of
DC cardioversion to non-life threatening cardiac arrhythmias such as AF.
The first experience of DC cardioversion in AF was in 10 patients
undergoing mitral valvotomy and 2 patients with mitral regurgitation and
AF resistant to cardioversion with quinidine.13
Reports from the UK of the successful use of DC cardioversion of AF
soon followed. In 1964 McDonald and coworkers15 reported successful
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DC cardioversion of 43 of 50 patients resistant to quinidine, illustrating the
superior efficacy of electrical cardioversion to chemical cardioversion. An
appreciation that, as with pharmacological cardioversion, recurrence of AF
following DC cardioversion was also a problem was highlighted by Oram
et al16 who reported successfully cardioverting 84 of 100 patients, but with
recurrence in 44 cases. They noted that younger patients tended to have a
better outcome. Other authors found evidence for reduced risk of
recurrence in patients with a short duration of AF17 and in patients with
Tone' AF.18 Patients with significant left atrial enlargement were also
shown to have a higher risk of recurrent AF.19 With the appreciation of the
significant chance of recurrent AF following cardioversion studies on the
role of drug therapy in maintaining sinus rhythm soon followed. Quinidine
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was shown to result in a longer duration of sinus rhythm than placebo but
recurrence was still common in both groups. Since the 1970's there have
been many studies on DC cardioversion of AF, but to this day we have still
not found a reliable way to maintain sinus rhythm following cardioversion.
2.2 History of Theories on the Mechanism of Atrial Fibrillation
Throughout the latter part of the 20th century the 'multiple wavelet'
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hypothesis developed by Moe in 1962 and confirmed experimentally by
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Allessie in 1985 was the generally accepted hypothesis to explain the
underlying mechanism of AF. Prior to Moe's landmark work, however,
there had been two schools of thought on the underlying mechanism of
AF: the circus movement theory and the ectopic focus theory. Following
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the description of focal AF by Haissaguerre and coworkers the debate as
to the underlying dominant mechanism in AF has again arisen.
Circus Movement Theory
Workers in the UK primarily supported the circus movement theory. In
1906 Mayer demonstrated circus movement in a ring of paralysed jellyfish
tissue. Once stimulated a circulating contraction could continue for days.
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Inspired by this work Mines repeated the findings in ring preparations of
tortoise atrium. Mines recognized that the circulating excitation was
dependent on the combination of a short refractory period and slow
conduction.24 (Figure 2.1) Garrey25 then went on to demonstrate the
importance of tissue mass in the process of fibrillation. Using fibrillating
turtle ventricle he noted that when the ring size was reduced from 2cm
diameter to 1cm diameter the incoordinate fibrillatory contractions
organized into a single circus wave of contraction. Garrey realized that
multiple circus movements (multiple wavelets) could exist in the larger
tissue masses thereby giving the appearance of fibrillation and correlated
this with an observation that large hearts were more likely to fibrillate.
(Figure 2.2) Extending the findings of Mines and Garrey, Sir Thomas
Lewis26 went on to induce experimental atrial flutter in dogs and
demonstrate that the arrhythmia was due to a single re-entrant circuit
around the caval veins. Following this he determined that the atrial
activation pattern in human atrial flutter was similar to that observed in
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dogs by studying the electrical axis of the atria. Lewis believed that
fibrillation was also due to a circus movement but one where the
circulating wave does not run a constant course. (Figure 2.3)
Figure 2.1 Illustration of anatomical re-entry. The light grey area indicates
excitable myocardium and the dark grey area indicates the atrial wavefront with its
non-excitable tail. If the conduction velocity is fast the wavefront will catch its own
tail and be extinguished. If the refractory period is long the myocardium will not
have recovered excitability by the time the wavefront next arrives, excitation will
not occur and the wavefront will die out. Therefore re-entry in a ring of tissue of a
certain size is dependent on a slow conduction velocity and/or a short refractory
period.
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Figure 2.2 Illustration of the importance of atrial size. For a given atrial
wavelength (as indicated by the length of the arrows) more wavelets of excitation
can exist in the larger atria on the right. RA - right atrium, LA - left atrium.
Figure 2.3 The mechanism of atrial fibrillation as proposed by Thomas Lewis.
The pathway of electrical activation of the atria is constant in atrial flutter,
indicated by identical diagrams at time points 1 and 2. In atrial fibrillation Lewis
proposed that the single wave of atrial excitation had a random coarse resulting
in the fibrillatory waves on the ECG. This is illustrated by the difference between
time points 1 and 2 in the diagrams on the right.
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Ectopic Focus Theory
The ectopic focus theory had its origins in Germany. Engelmann first
proposed the theory in 1896 and further work by Scherf in 1947 led him
to support the ectopic focus theory and strongly oppose the circus
movement theory. Scherf found that after he injected aconitine into the
atrial wall rapid irregular activation of the atria occurred that disappeared
when the area injected with aconitine was cooled and reappeared when
cooling was interrupted. He concluded that fibrillation was initiated by
rapid impulse formation in a single centre.29 The work of Gordon Moe30 in
the late 1950's and his formulation of the 'multiple wavelet hypothesis' in
the early 1960s21 resulted in the ectopic focus theory being disregarded.
However, it has returned to prominence in the last few years following the
work of Haissaguerre23 and others on the pulmonary vein initiation of AF.
Multiple Wavelet Hypothesis
Moe was the first to link the ectopic focus and circus movement theories
into one experimental model. Although both theories had a sound
experimental basis, Moe believed that neither could result in the sustained
arrhythmia of AF. His experimental work on dogs30 led to an
understanding of the importance of factors for both 'triggering' and
'perpetuating' AF. Using an open chest dog model he induced AF by
either rapid atrial pacing or aconitine injection in the right atrial
appendage. AF persisted as long as rapid atrial pacing was continued.
Following aconitine injection AF persisted until the base of the right atrial
appendage was clamped off. If vagal stimulation was applied AF persisted
when atrial pacing was discontinued or a clamp applied to the base of the
right atrial appendage. In the absence of vagal stimulation the induced
fibrillation was non-sustained (Figure 2.4). Moe had demonstrated that AF
could be a self-sustaining arrhythmia independent of focal discharge, and
he emphasised the importance of dispersion of atrial refractoriness induced
by vagal stimulation for the maintenance of AF. Based on this
experimental work Moe and colleagues developed a computer model of
29
AF which showed that self-sustained atrial electrical activity could be
induced.31
LA LA LA
A. Rapid right atrial B. Cessation of rapid right
pacing / aconitine atrial pacing / clamping of
injection. * site of site of aconitine injection in
pacing / injection the absence of vagal
C. Cessation of rapid right
atrial pacing / clamping of
site of aconitine injection
with continued vagal
stimulationstimulation
Figure 2.4 Illustration of Moe's experimental work.30 In panel A rapid right atrial pacing
or aconitine injection (*) results in focal activation of the atria with fibrillatory conduction.
Panel B illustrates the situation following cessation of pacing or clamping of the aconitine
injected area. In the absence of vagal stimulation the wavelets die out. Sinus rhythm will
soon resume. Panel C shows the situation following cessation ofpacing or clamping of the
aconitine injected area in the presence of vagal stimulation. AF persists as long as vagal
stimulation continues.
It took a further 25 years to confirm Moe's computer model
experimentally. Allessie and coworkers studying AF induced by
acetylcholine in isolated Langendorff perfused canine hearts were able to
22record the atrial activation pattern during AF. By recording
simultaneously from 192 electrodes they were able to reconstruct the atrial
activation pattern during sustained AF. Allessie showed that the atria were
activated by multiple wavelets which behaved in a random fashion,
occasionally meeting another wavelet and extinguishing themselves and at
other times dividing into daughter wavelets. He concluded that between
three and six wavelets were required over the atria to result in stable AF
and also noted that the stability of the induced AF was inversely related to
"j
the number of wavelets. Subsequently experimental work in dogs and
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intra-operativc mapping studies in patients33 have also supported Moe's
hypothesis.
The importance of a short atrial wavelength for the maintenance of AF has
been understood since the observations of Thomas Lewis in the early
1920s. With a shorter wavelength more wavelets may co-exist in atria of
any size and the more likely AF is to be sustained34 (Figure 2.5). Atrial
wavelength is the product of the conduction velocity and the refractory
period. Thus either slowing of atrial conduction or shortening of atrial
refractoriness will result in a reduction in atrial wavelength and an increase
in AF stability. It is on this basis that the process of atrial electrical
remodelling35 with its associated shortening of atrial refractoriness has
such a strong theoretical basis for being important in the self-perpetuation
Figure 2.5 Illustration of the importance of atrial wavelength on the
perpetuation of AF. It can be seen that with a shorter wavelength (B) many more
wavelets of excitation may coexist in atria of a given size, compared to the longer
wavelength (A), thus promoting the maintenance of AF. The atrial wavelength
may be reduced by slowing conduction velocity or shortening atrial
refractoriness.
Reentry
The onset and maintenance of AF depends on the production of stable
multiple wavelet reentry in atrial tissue. This in turn is determined by a
combination of the atrial wavelength and the available size of the atrial
of AF.
A. Longer wavelength B. Shorter wavelength
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tissue. Until recently it was considered that two forms of reentry
predominated in AF.
(1) Anatomical reentry occurs following unidirectional block of an
extrastimulus, and is sustained around an anatomical barrier, such as
the orifice of a pulmonary vein or an atrioventricular valve ring (Figure
2.1). It persists as long as the length of the excitation wave is shorter
than the anatomical path around which it runs. The difference in this
length makes up the excitable gap.
(2) Functional reentry occurs in the absence of an anatomical barrier. This
was demonstrated by Allessie in a preparation of rabbit atrium36,37
where excitation waves were seen to circulate around areas of
functional conduction block. The induction of functional reentry is
dependent on heterogeneities of the electrophysiological properties of
cardiac muscle resulting in unidirectional conduction block. In
functional reentry there is no excitable gap and the size of the circuit is
equal to the length of the excitation wave. In the context of persistent
AF both types of reentry are likely to be important.
More recently another form of reentry, called spiral waves, has been
described. Spiral waves represent a form of functional reentry, but without
centripetal activation of the central area. They have been demonstrated in
experiments in isolated hearts38'39 to exist as self-sustaining rotors that
cause high-frequency activation of the atria. These rotors predominately
exist in the posterior left atrium, are stable and can have a very short
wavelength (~70ms). The remainder of the atria are activated by
Figure 2.6 Illustration of functional reentry.
The circuit passes around an area which
remains refractory at all times, due to the
collision of centripetal wavefronts from the
circuit. The excitation wavelength (dark
grey) is approximately equal to the length of
the circuit.
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fibrillatory conduction with some degree of organisation. It has been
proposed that spiral waves are important in the maintenance of AF and
that the left atrium, as the source of these waves, acts as the predominant
driver of AF.
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2.3 Factors Important in Promoting Atrial Fibrillation
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In accordance with Moe's multiple wavelet hypothesis ' of AF the
inducibility and stability of AF are dependent on at least 3 factors:
(1) atrial wavelength (refractory period x conduction velocity)
(2) atrial size (atrial surface area),
(3) dispersion of atrial refractoriness
Clinical and experimental work has shown that in addition to these
important determinants of AF the autonomic nervous system, localised
abnormalities of atrial conduction and atrial ischaemia may also play a role
in the onset and maintenance of AF.
Reduced Atrial Wavelength
As discussed above, during AF the atria are activated by multiple reentrant
circuits (the multiple wavelet hypothesis).22'31 The stability of AF is related
to the number of wavelets of activation that can exist simultaneously in the
atria. The shorter the atrial wavelength the more wavelets will be able to
coexist in a defined area of atrium. Therefore a shorter wavelength will
result in a larger number of wavelets so reducing the chances of all the
wavelets simultaneously dying out, and increasing the stability of AF.
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Based on the experimental work of Allessie, the number of wavelets
required to maintain stable AF is felt to be somewhere between three and
six.
The atrial wavelength (WL) is the product of the conduction velocity (CV)
and the refractory period (RP). (WL = CV x RP) Factors, which reduce
either of these, will also reduce wavelength and hence promote AF (Figure
2.5). It is reasonable to suppose that a reduction in atrial wavelength might
be the 'final common pathway' for factors that promote AF.
(i) Atrial Refractory Period
The link between short atrial refractory periods and clinical AF is well
established. As early as 1971 Olsson et al40 demonstrated short
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monophasic action potentials in patients immediately after cardioversion
of AF. These results were confirmed by Cotoi et al41 who also noted a
correlation between the duration of the monophasic action potential and
the risk of AF recurrence. These results were not expanded upon till about
20 years later when Kumagai showed atrial refractory periods to be shorter
following cardioversion of persistent AF.42 Abnormalities of atrial
refractoriness were also found in patients with a history of paroxysmal AF,
with some authors finding shorter atrial refractory periods43 and others a
shorter atrial fibrillation cycle length during AF.44
Experimental work has shown that with rapid atrial pacing rates there is
shortening of atrial refractoriness34'45'46 and an increase in atrial
vulnerability to AF. Vagal stimulation,45'47'48 acetylcholine49'50 and
51 52adenosine ' are all known to have profibrillatory effects on the atria,
which are thought to be mediated via shortening of atrial refractoriness.
The most important study linking changes in atrial refractoriness with AF
was that published by Wijffels in 1995.35 Using a conscious goat model
implanted with epicardial electrodes these authors continually reinduced
AF using a personal computer capable of detecting sinus rhythm and
delivering a 1-second 50Hz burst of atrial pacing. Over the first few days
of AF reinduction they noted shortening of atrial refractoriness and loss of
its normal adaptation to rate followed by an increase in the stability of
induced AF episodes. They described this domestication of AF as 'AF
begets AF'. The shortening of atrial refractoriness leading to a shortening
of the atrial wavelength made good theoretical sense as a process whereby
AF could promote its own sustenance. The process was termed atrial
electrical remodelling. This introduced the concept that AF itself could
alter atrial electrophysiology to promote its own maintenance.
Abnormalities in atrial refractoriness that predispose to AF are not
confined to shortening of the atrial refractory period. Nearly 20 years ago
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Attuel and coworkers measured the atrial refractory period in patients at
cycle lengths of 280-1500ms. They showed that loss of the normal
physiological rate adaptation of atrial refractoriness was associated with an
increased vulnerability to AF. Boutjdir54 also found impaired rate
adaptation of atrial refractoriness in his microelectrode studies of isolated
strips of human atrium from patients with AF. The finding that loss of rate
adaptation of atrial refractory periods is an integral part of atrial electrical
remodelling supports the importance of these early findings.
(ii) Atrial Conduction Velocity
(a) Interatrial conduction velocity - a link between reduced atrial
conduction velocity and AF is well established. Atrial conduction velocity
is reduced in patients following DC cardioversion of persistent AF.42'55'56
These patients also show a prolonged P-wave duration.42'56 Patients with
paroxysmal AF appear to show conduction abnormalities intermediate
between control patients and patients with persistent AF suggesting some
progression of conduction velocity abnormalities in the transition from
paroxysmal to persistent AF.55 The recovery of changes in atrial
conduction velocity following cardioversion of persistent AF is
significantly longer than the time course for recovery of atrial
refractoriness.56'57
Canine models of AF using sustained rapid atrial pacing have shown
slowing of atrial conduction velocity, suggesting an AF-induced reduction
in conduction velocity may contribute to the self-perpetuating process.58"60
The underlying mechanism for the slowing of conduction velocity may be
a reduction in the fast Na current.61 Goats studies, however, using the
fibrillation pacemaker have not shown significant changes in conduction
velocity in association with the onset of AF.35'2
Studies of patients in sinus rhythm have demonstrated reduced atrial
conduction velocity at rapid pacing rates,63 which in combination with the
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shorter atrial refractoriness induced by rapid pacing, results in a
significantly shorter atrial wavelength and an increased vulnerability to
AF. Reduced conduction velocity at rapid atrial pacing rates has also been
shown in isolated rabbit atria43 and in conscious dogs.34 The introduction
of premature atrial extrastimuli results in conduction velocity delay which
is more pronounced in patients with a history of atrial arrhythmias
compared to controls and may create an electrophysiological substrate for
the onset of AF.43,64
(b) Local conduction abnormalities - Local conduction disturbances in the
atria also appear to be important in AF. A recognised manifestation of
local conduction delay is fragmentation of local electrograms.65 Delayed
atrial conduction66 and fragmented electrograms67 have been demonstrated
in patients with atrial flutter. In addition fractionation of ventricular
electrograms has been linked to an increased risk of primary ventricular
fibrillation68 and ventricular fibrillation in association with hypertrophic
cardiomyopathy.69 Increased fragmentation of local atrial electrograms has
been demonstrated following cardioversion of persistent AF 42 and in
70 72
patients with paroxysmal AF. " ~ More recently fragmentation of atrial
electrograms has been shown in several areas of the right atrium in
patients with AF and atrial flutter.73 There is also some evidence that local
conduction delays, as shown by marked broadening of the posterior
triangle of Koch electrogram, are dependent on the site of stimulation and
are more prominent in pacing from the high right atrium than the coronary
sinus.74 The mechanism by which biatrial pacing prevents AF may be by
reducing such local conduction delays.75
Local conduction disturbances can also be produced by vagal
stimulation,76 rapid atrial pacing77 and hypoxia78 all of which have been
shown experimentally to promote AF. In addition to primary
electrophysiological changes in the atria, it has been postulated that
progressive atrial fibrosis with increasing age is associated with
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inhomogeneity of atrial conduction and may be responsible for the
observed increase in the incidence of AF in the elderly.79'80
Increased Atrial Size
The recognition that fibrillation was more stable in larger masses of tissue
was first made by Garrey in 1914.25 He recognised that reducing the size
of the tissue mass (turtle ventricle) eventually led to abolition of
fibrillation. It took many years for any advances to this piece of work. In
the early 1960's West et al81 repeatedly divided segments of rabbit atria to
determine the minimum tissue mass required to maintain AF. In vivo the
82induction of experimental AF is easier in larger dogs, and spontaneous
83chronic AF is more common in the larger breeds than smaller ones.
Experimentally induced AF is significantly more stable in animals with
larger atria,84 with AF durations in some adult cattle persisting for up to 8
weeks whereas in calves and goats AF durations were generally less than a
minute.
We understand from Moe's multiple wavelet hypothesis21 that the stability
of AF is related to the number of wavelets that can be present
simultaneously in the atrial wall. A short wavelength, as already discussed,
will allow more wavelets in a defined area, but an increase in atrial size
will also result in an increase in the number of wavelets (Figure 2.2). The
increase in atrial refractory period and conduction velocity in larger
animals is relatively small compared to the increase in atrial area thus
explaining their increased propensity to AF. Rensma34'85 calculated the
number of wavelets that might coexist in different species according to
atrial wavelength and the atrial surface area. The shortest atrial wavelength
obtained by extrastimuli in rabbits is about 3.5cm, 8cm in dog, 12cm in
man, 30cm in horse and 45cm in whale. The comparable atrial surface
areas show a much larger increase from 3cm in the rabbit increasing to
2 2 2 235cm in dogs, 60cm in man, 300cm in horses and 3000cm in whales.
This means that in rabbit atria a maximum of 3 wavelets may coexist, not
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enough to sustain AF. In dog and in man this increases to 5-6, to 10 in
horses and 19 in whales. Allessie22 suggested that a minimum of 4-6
wavelets are required for sustained AF. These findings relate closely to
observed practice where AF is short and non-sustained in rabbit atria86 but
83 80
can occur spontaneously and persist in both dog and man. AF is also
87 88 89
seen frequently in larger animals such as cattle ' and horses.
There is a clear relationship between atrial dilatation and AF, but there has
been debate about whether the observed atrial dilatation in patients with
AF is a cause or a consequence of the AF.19'90"94 Data from the
Framingham study showing a strong association between left atrial
dilatation and the subsequent onset of AF (with a risk factor of 8.3 in men
and of 15.3 in women).79 Patients with mitral valve disease can remain in
sinus rhythm despite left atrial dilatation but most eventually develop AF
strongly suggesting that left atrial dilatation is a significant risk factor for
Q9 . . ....
development of AF. Cardioversion of persistent AF in patients with atrial
dilatation is less successful and relapse into AF more common.19'95'96 The
induction of AF in the experimental setting is enhanced by atrial dilatation
(induced by volume expansion or mitral insufficiency) in otherwise normal
hearts.33'97"99
There is also evidence that atrial fibrillation itself causes atrial dilatation.
Induction of experimental AF by rapid atrial pacing leads to atrial
dilatation in dogs.100 Patients with Tone' AF when followed by
echocardiography have been shown to develop progressive atrial
dilatation.101 Further evidence for AF itself as a cause of atrial dilatation is
the reduction in left atrial size observed following cardioversion of
persistent AF,102 and also in the reduction in left atrial size noted in
patients using the implantable atrial defibrillator.103 The relationship
between AF and atrial dilatation appears to be reciprocal - both promote
each other.
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It has been proposed that atrial dilatation may promote AF by mechanisms
other than simply providing a larger atrial surface area for the multiple
wavelets. Although there is some discrepancy in the literature most studies
have suggested that atrial dilatation alters atrial electrophysiology. Acute
atrial stretch induced by an intra-atrial balloon,97 simultaneous atrial and
ventricular pacing104 or by increased afterload105 have all been shown to
shorten atrial refractoriness. Experimental work using atrial muscle
specimens obtained at the time of cardiac surgery106 has found the action
potential duration in chronically dilated atria to be shorter than in non-
dilated atria. Voltage clamp studies showed the likely mechanism to be a
reduction in L-type calcium current density. Other work has suggested that
atrial dilatation may promote AF through an increase in dispersion of atrial
QO
refractoriness. Thus atrial dilatation may not act solely as a physical
promoter of AF but may also have an electrophysiological action.
Increased Dispersion of Atrial Refractoriness
Inhomogeneity of atrial electrical properties is important both to the
induction and maintenance of AF. Conduction block, as occurs when
excitation reaches an area of the atrium with a longer refractory period, is
important in the division of wavelets of excitation into daughter
wavelets,36 the formation of which are essential in the induction and
stability of AF.
Figure 2.8 Schematic diagram of the formation of daughter wavelets when a
single wave of excitation encounters islands of refractory tissue (black ovals).
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The importance of areas of conduction block in the initiation of atrial
arrhythmias has been shown experimentally. Using isolated canine atria
perfused with acetylcholine Schuessler et al107 showed that initiation of
reentry was dependent on the block of premature impulses at areas of
functional block that occurred as a result of the cholinergically induced
dispersion of atrial refractoriness. Dispersion of atrial refractoriness is also
increased at higher heart rates,108'109 by high vagal tone,48'110'111 by atrial
98 • • • 78stretch and by atrial ischaemia. These are all factors recognised as
being important risk factors for AF in patients.
Experimental data on changes in dispersion of atrial refractoriness
associated with AF have been variable. Studies in the goat model35'112
found no change in dispersion of atrial ERP. Short durations of rapid
113
pacing in anaesthetised dogs do not alter dispersion of atrial ERP, but
longer durations of atrial pacing associated with persistent AF in the
• ... S8
canine model result in an increase in dispersion of AF cycle length and
an increase in dispersion of atrial ERP.59'114 There does appear to be a
genuine inter-species difference between the goat and dog.
An increase in dispersion of atrial ERP in patients with paroxysmal AF has
been recognized for a number of years.44'115 Increased dispersion of atrial
ERP has also been noted in patients with sinoatrial node disease116 and to
117be associated with increasing age both of which are strong risk factors
118for AF. Ramanna et al have shown that patients with paroxysmal AF
have an increase in dispersion of AF cycle length during AF compared to
control patients and have suggested that this may be the substrate for the
enhanced inducibility and vulnerability to AF observed in these patients.
Patients with persistent AF have been shown to have an altered spatial
distribution of atrial refractoriness55'119 compared to controls, but there
have not been any studies showing an increase in dispersion of atrial
refractoriness. In fact, dispersion of atrial refractoriness has been found to
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be lower in patients with chronic AF compared to both patients with
paroxysmal AF120 and patients in sinus rhythm.119 It may be that loss of
the 'normal' spatial dispersion of atrial refractoriness (where atrial
refractoriness is longer in the high right atrium near to the sinus node and
191 1 99
shorter further away ' ) is important in the maintenance of AF.
Our group has found dispersion of atrial fibrillation cycle length to be
increased at the time of DC cardioversion in patients who subsequently
have recurrence of AF compared to non-recurrers (Dr SP Fynn, MD
Thesis). Following a period in sinus rhythm dispersion of atrial fibrillation
cycle length has been shown to fall suggesting dispersion of atrial
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fibrillation cycle length may be linked to atrial electrical remodelling.
The Autonomic Nervous System
There are strong links between the autonomic nervous system and AF.
Clinical forms of both vagal and adrenergic paroxysmal AF have been
described, the first often occurring at rest or after meals and the latter more
often associated with stress or exercise.124'125 Vagal activity has been used
99 90 1 9a 1 9r
to induce and maintain AF experimentally for many years ' ' " and is
known to shorten atrial refractoriness34'45'129'130 and thus the atrial
wavelength due to a increase in the outward potassium current by
activation of the Ikaci, channel. Vagal stimulation may also promote AF by
increasing dispersion of atrial refractoriness.48'131
The effects of the sympathetic nervous system are less clear. Although
several studies have reported shortening of atrial refractoriness/action
potential duration, 49-50>131>132 with sympathetic stimulation or
administration of adrenaline/ noradrenaline, others have reported no
change,48'133 or even a prolongation of atrial refractoriness.45'134 The
differing effects seen in these studies may relate to the concentrations of
adrenaline/noradrenaline used and/or the differential effects of alpha and
1 9^
beta-adrenergic receptors. There is evidence from studies on ventricular
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muscle preparations that the effect of adrenergic stimulation on
refractoriness is dependent on the concentration of noradrenaline.136'137
More recently interest in the role of the sympathetic nervous system in
1
sustained AF has increased. Olgin and co-workers have shown that
heterogeneous atrial sympathetic denervation, resulting in an increase in
dispersion of atrial refractoriness, increases the stability of induced
episodes of AF in dogs. Further work by the same authors139 has shown
that induction of sustained AF by 6-weeks of rapid atrial pacing in dogs
results in a heterogeneous increase in atrial sympathetic innervation, as
measured by positon emission tomography (PET) scanning and tissue
concentrations of norepinephrine. Other authors have also found
significant nerve sprouting and sympathetic hyperinnervation in a canine
model of sustained AF produced by prolonged right atrial pacing.140
Bilateral stellectomy, with resultant homogeneous atrial sympathetic
denervation, prevents the induction of sustained AF by rapid atrial pacing
suggesting a key role for the sympathetic nervous system in promoting the
onset of persistent AF.141 So despite the lack of a consistent effect of the
sympathetic nervous system on atrial electrophysiology the sympathetic
nervous system may well have an important role in persistent AF.
Atrial Ischaemia
Ischaemic heart disease (IHD) is known to be associated with AF. In the
Framingham study IF1D was present in 25% of men and 14% of women
who developed AF.79 AF is observed frequently (~ 10%)142,143 in the
setting of acute myocardial infarction. However, in this setting ischaemia
may not be the only factor promoting AF with other factors such as
changes in autonomic tone, atrial dilatation due to pump failure or
pericarditis also being important. The most compelling evidence for atrial
ischaemia / infarction in the onset of AF is suggested by the increased risk
of AF associated with myocardial infarction due to occlusion of the
proximal circumflex artery compared to more distal circumflex artery
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occlusion or occlusion of other arteries at the time of myocardial
infarction.144 In addition, there is an increased risk of perioperative AF at
the time of CABG in patients with disease of the sinoatrial or
atrioventricular nodal arteries.145 The exact mechanism whereby atrial
ischaemia promotes AF is not understood but ischaemia can cause a
shortening of the action potential duration by promoting movement of
potassium out of cells,146 local adenosine release147 or by increasing local
78
atrial conduction abnormalities. Experimental AF also results in an
148increase of 2-3 fold in atrial blood flow and oxygen consumption raising
the possibility that AF itself may cause atrial ischaemia and so promote its
own maintenance.
Conclusions
The induction and maintenance of AF is the result of interplay between a
number of factors. Some such as atrial dilatation are likely to have an
independent role, whereas others such as the autonomic nervous system
and atrial ischaemia are likely to promote AF by altering atrial
electrophysiology. The final common pathway for the maintenance of
stable AF is likely to be a reduction in atrial wavelength achieved by
shortening of atrial refractoriness or a reduction in atrial conduction
velocity. The relative importance of each varies from patient to patient
illustrating the heterogeneous nature of AF. Therapeutic approaches can
vary according to the predominant factors in each patient.
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3.1 Atrial Electrical Remodelling
The Experimental Work
In a landmark experiment Wijffels et al1 showed that repeated induction of
AF in a conscious goat model resulted in the development of persistent AF
with time, demonstrating the self-perpetuating nature of AF, and coining the
phrase 'AF begets AF'. The induction of AF was accompanied by changes in
atrial electrophysiology: a shortening of the atrial effective refractory period
(AERP), loss of its normal adaptation to rate and an increased vulnerability
of the atria to induction of AF, the combination of which was termed 'atrial
electrical remodelling'.
In their study Wijffels et al secured multielectrode patches to the atrial
epicardial surface (see Figure 3.1) and tunnelled the wires from these patches
to the skin surface. Following a recovery period of 2-3 weeks, the wires
were connected to an external pacemaker and AF induction was commenced.
The fibrillation pacemaker monitors atrial electrograms and during sinus
rhythm detects a period of atrial electrical quiescence. On detection of atrial
electrical quiescence (sinus rhythm) a 1-second burst of 50Hz pacing is
delivered to the atrium inducing AF (Figure 3.2). During AF the pacemaker
detects constant atrial electrical activity and is inhibited. Thus AF can be











Figure 3.1 Position of atrial epicardial Figure 3.2 Illustration of the fibrillation
electrodes. LA-left atrium, RA-right atrium, pacemaker. LA-left atrium, SR-sinus
PV-pulmonary veins, SCV-superior vena cava, rhythm, AF-atrial fibrillation.
ICV-inferior vena cava, BB-Bachmann's From Wijffels et al, Circulation 1995; 92;
bundle. From Wijffels et al, Circulation 1995; 1954-1968
92; 1954-1968
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Using the fibrillation pacemaker Wijffels demonstrated changes in atrial
behaviour with repeated episodes of burst pacing. With increasing durations
of burst pacing episodes of induced AF lasted for longer periods, finally
resulting in the induction of persistent AF (Figure 1.2, P9). Atrial
electrophysiology also changed over this time with a reduction in atrial ERP
and loss or reversal of its normal rate adaptation (Figure 1.3, P10).
The key features of atrial electrical remodelling:
• Reduction in the atrial effective refractory period.
• Loss/reversal of the normal rate adaptation of the refractory period.
• Increased vulnerability to induction of AF.
The Underlying Mechanism of Atrial Electrical Remodelling
Wijffels et al then proceeded to attempt to define the underlying
mechanism(s)2 of atrial electrical remodelling. Using the same goat model
they examined the effects of the autonomic nervous system, atrial ischaemia,
atrial stretch and the high rate of atrial electrical activation per se that occurs
in AF.
In order to determine whether the autonomic nervous system was responsible
for the observed changes in atrial electrophysiology propranolol and atropine
were used to block the sympathetic and parasympathetic arms of the
autonomic nervous system respectively. No difference in atrial electrical
remodelling was found with full autonomic blockade implying that the
changes observed were not due to the autonomic nervous system.
Previous work had shown that induction of AF in anaesthetised dogs resulted
in a 2-3 fold increase in atrial perfusion and an increase in oxygen
consumption of the atrial myocardium.3 It was postulated that during AF the
atria could become ischaemic resulting in opening of ATP-regulated
potassium channels, which might lead to a reduction in the action potential
duration and so a shortening of the atrial refractory period. In order to test
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this hypothesis the ATP-regulated potassium channels were blocked by
intravenous administration of glibenclamide. Glibenclamide resulted in an
increase in the R-R interval during AF and slightly prolonged the atrial
fibrillation cycle length (AFCL), but the mean AFCL was still markedly
reduced compared to the non-remodelled goat. It should be noted that the
glibenclamide infusion was only commenced following induction of AF and
in the presence of established atrial electrical remodelling. Glibenclamide
was also administered to 3 goats following DC cardioversion ofpersistent
AF. It had no significant effect on AERP.
In order to simulate the effect of atrial dilatation and/or the increase in atrial
pressure that occurs in AF, 0.5-1 litre of colloid was infused into goats under
general anaesthesia. The fluid load did not result in change in the atrial
refractory period.
To model the high rate of atrial electrical activation that the atria experience
in AF the atria were paced at a cycle length of 180ms. This rapid atrial
pacing resulted in almost identical changes to the fibrillation pacemaker with
shortening of the atrial refractory period and increased inducibility of AF.
Wijffels also found that the cycle length of the atrial pacing was important.
Pacing the atrium at a cycle length of 360ms did not result in significant
changes in atrial refractory period compared to pacing at a cycle length of
180ms. It was therefore concluded that the observed changes in atrial
refractoriness are a consequence of the high rate of atrial electrical activation
that occurs in AF.
Wijffels also observed changes in the nature of the electrogram during AF
with increasing durations of atrial electrical remodelling. Initially the atrial
electrograms in AF were organised, but later they became more fragmented
and disorganised (Figure 3.3). This coincided with a shortening of the AF
cycle length and the atrial refractory period. The greater fragmentation of the
atrial electrograms may be due to activation at a single point coming from
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more than one direction, which might occur if there is an increased number
of wavelets (as could occur with shortening of the atrial refractory period
and therefore the atrial wavelength). The persistence of AF was also linked
to a reduction in the atrial fibrillation cycle length, especially when this fell
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Figure 3.3 Changes in atrial fibrillation cycle length and the organisation of the atrial electrograms
over increasing durations of AF. From Wijffels et al, Circulation 1995; 92; 1954-1968
Wijffels noted in his initial work that there was a discrepancy between the
time course of the onset of stable AF and atrial electrical remodelling. Atrial
electrical remodelling occurred quickly following the activation of the
fibrillation pacemaker but stable AF often took a further 2-3 days to become
established. This observation coupled with the observation that animals with
a similar degree of atrial electrical remodelling (as measured by changes in
atrial refractory period and the AF interval, Figure 3.4), showed considerable
variation in the time to onset of persistent AF (Figure 3.5), suggested the
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Figure 3.4 Changes in AF cycle length
over time. Most reduction occurs in the
first 2 days. Note the similarity of all 4
curves. From Wijffels et al, Circulation
1995; 92; 1954-1968
Figure 3.5 Data from the same 4 goats in
Figure 3.6. Note the variation in durations
of induced episodes of AF, despite the
similar changes in AF interval seen in
Figure 3.6. Also note the delay in onset of
sustained AF. From Wijffels et al,
Circulation 1995; 92; 1954-1968
Subsequent to the work undertaken in Allessie's laboratory by Wijffels and
colleagues there was interest elsewhere in developing an animal model of
AF. Morillo et al4 developed a dog model of AF using rapid atrial pacing
(400 beats/min). Using this model persistent AF could be induced in 82% of
animals over a period of 6 weeks. In association with the ability to induce
persistent AF there was a reduction in atrial refractory period, an increase in
atrial vulnerability and enlargement of both atria (Figure 3.6). Nattel's group
5 also developed a rapid pacing dog model of atrial fibrillation. They were
interested in assessing the underlying mechanisms that lead to the induction
of sustained AF using rapid atrial pacing. They noted that the majority of the
change in atrial ERP occurs before AF becomes sustained5 and that changes
in atrial conduction velocity, which occur more gradually, were also
important in AF stability with longer periods of rapid atrial pacing.
Figure 3.6 Two-dimensional echocardiogram of the dog heart. There is an increase in left
(A - 6.85cm2) and right (C - 3.99cm2) atrial areas from baseline to after 6 weeks pacing
(B-LA 11.7cm2 and D-RA 9.5cm2). LV - left ventricle, RV - right ventricle. From Morillo
et al, Circulation 1995; 91; 1588-1595
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Morillo and coworkers went on to analyse the structural changes occurring in
the atria using electron microscopy. They found changes compatible with a
significant perturbation of metabolic activity, with enlarged and disarrayed
myocardial fibres and giant mitochondria. Work in Allessie's lab also
confirmed these changes in cellular substructure in association with atrial
electrical remodelling.6 Following longer durations of induced AF in the goat
model6 (>9 weeks) the majority of atrial myocytes have marked changes in
their cellular substructures, such as loss of myofibrils, accumulation of
glycogen, changes in mitochondrial shape and size, fragmentation of
sarcoplasmic reticulum, and dispersion of nuclear chromatin. These changes
were accompanied by an increase in size of the myocytes (up to 195%).
There were virtually no signs of cellular degeneration, and the interstitial
space remained unaltered. Many of the changes observed are similar to the
changes that occur in the ventricle due to chronic ischaemia causing
'hibernating myocardium'.7'8 These cellular and structural changes were felt
to be important in the atrial contractile dysfunction observed during and soon
after atrial fibrillation.
The Role of Calcium
The cellular changes seen to occur with atrial electrical remodelling implied
a major disruption to cellular processes was occurring. The importance of
calcium influx into atrial myocardial cells as a mechanism for these changes
was proposed and several further important studies took place. The role of
calcium in atrial electrical remodelling is reviewed in detail at the start of
Chapter 4.
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Atrial Electrical Remodelling - Evidence in Humans
As early as 1971 Olsson et al9 demonstrated short monophasic action
potentials in patients immediately after cardioversion of AF. These results
were confirmed by Cotoi et al10 who also noted a correlation between the
duration of the monophasic action potential and the risk of recurrence of AF.
Attuel et al11 demonstrated that in addition to a shortened duration of the
atrial refractory period there was loss of the normal rate adaptation of atrial
refractory periods in patients following cardioversion of AF. These early
findings illustrated that changes in atrial electrophysiology compatible with
atrial electrical remodelling occur in humans. Franz et al12 measured
monophasic action potential durations (MAPdso) in patients following
cardioversion of chronic AF and chronic atrial flutter and found shortening
ofMAPd.0 at longer pacing cycle lengths (>35 Oms). The finding that MAPdoo
was reduced in both AF and atrial flutter again suggested that the rapid rate
of atrial electrical activation was the underlying cause for atrial electrical
remodelling.
Daoud and colleagues13 first demonstrated the onset and recovery of atrial
electrical remodelling in humans. Subjects with no history of AF and without
structural heart disease undergoing electrophysiology testing or
radiofrequency ablation were studied. Baseline atrial refractory period
measurements were made at a drive cycle length of 350ms and 500ms. AF
was then induced and maintained for 5 minutes by burst pacing. After 5
minutes AF was allowed to revert spontaneously to sinus rhythm, and
measurements of atrial ERP were repeated at the same two cycle lengths.
The results showed that even this short duration of AF resulted in a reduction
in atrial ERP (Figure 3.7), with an increase in inducibility of AF evident
during measurement of the atrial ERP post-AF (Figure 3.8).
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Figure 3.7 Temporal recovery of atrial ERP shortening following 5 minutes
of AF. Drive cycle 500ms (A) and 350ms (□). Mean values with error bars
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Figure 3.8 Inverse relationship between time to induction of secondary episodes of
AF during ERP testing and the percentage of such measurements inducing AF (r =
0.94, pO.OOOl). The results from the 350ms and 500ms drive trains are combined.
From Daoud et al. Circulation 1996; 94; 1600-1606
Daoud and co-workers extended their findings by using the same protocol to
study the effects of verapamil and procainamide on atrial electrical
remodelling.14 Pretreatment with verapamil, but not procainamide, resulted
in attenuation of acute AF induced changes in atrial electrophysiology. Of
note these workers found that verapamil in addition to reducing the
shortening of atrial ERP also reduced the inducibility of AF during
extrastimulus testing.
Daoud's studies on patients without a history of AF showed that the process
of atrial electrical remodelling could occur in humans and that it caused the
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same spectrum of changes in atrial electrophysiology as in animals. The time
course involved (minutes) however, was quite different to the initial goat
studies (hours) suggesting that different mechanisms may be involved.
Studies on patients with AT were the next priority. Two important questions
required an answer:
1) Did the changes in atrial electrophysiology observed after
cardioversion9'10'12 represents a cause or a consequence of the AF?
2) and if the changes were a consequence of AF, were they reversible?
These questions were the basis for the serial cardioversion protocol used in
our patient study.15 The protocol is described in detail in Chapter 6. In
summary unselected patients with persistent AF were internally cardioverted.
Electrophysiological parameters including AF cycle length, atrial
refractoriness and the coupling interval of atrial premature beats occurring
immediately following cardioversion were measured. Patients with recurrent
AF were admitted as quickly as possible following detection of AF
recurrence for repeat internal cardioversion. The aforementioned
electrophysiological parameters were again measured. Comparison was
made between the electrophysiological parameters at the time of initial
cardioversion and at the time of the second cardioversion following a period
of sinus rhythm or 'reverse remodelling'.
3.2 Other AF induced changes in atrial electrophysiology
Dispersion of Atrial Refractoriness
In his initial studies, Wijffels1 found that changes in atrial refractoriness and
atrial fibrillation intervals were similar in both atria with no evidence of an
increase in dispersion of atrial refractoriness. This has been verified in
subsequent work on atrial electrical remodelling in the goat model.16'17
Results from canine models of AF have shown an increase in dispersion of
atrial refractoriness in association with atrial electrical remodelling.18'19
Following 24 hours of rapid atrial pacing (400/min), epicardial mapping
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using multiple electrodes (mean of 66 per dog) was used to determine the
regional variability in atrial ERP.19 Rapid pacing for 24 hours resulted in a
reduction of atrial ERP and an increased dispersion. In addition to the major
regional differences observed variability of atrial ERP within each area was
also increased. In this dog model of AF rapid atrial pacing causes a
nonuniform shortening of the atrial ERP both between and within different
atrial regions. Fareh and colleagues19 also assessed atrial vulnerability to AF
in their model. They found that atrial vulnerability was most strongly linked
to ERP heterogeneity, rather than the shortening of atrial ERP or atrial
wavelength.
An increase in dispersion of atrial ERP in patients with paroxysmal AF was
first recognized a number of years ago.20 Dispersion of atrial refractoriness
was also found to be increased in atrial tissue obtained at the time of cardiac
21
surgery from patients with AF. Increased dispersion of atrial ERP has also
22been noted in patients with sinoatrial node disease and to be associated
. . . 9T
with increasing age, a possible mechanism for the increasing incidence of
AF with age. More recently Ramanna et al24 have shown that patients with
paroxysmal AF have an increase in dispersion of AF cycle length compared
to controls and have suggested that this represents a mechanism of increased
atrial vulnerability in these patients. Paradoxically recent studies of
dispersion of atrial ERP in patients with chronic AF have given different
results to those above, with either no increase in dispersion25 or lower
dispersion in AF patients than controls.26 Although Pandozi27 noted a
significant dispersion of right atrial ERP following cardioversion of
persistent AF he did not compare these findings to control patients. Our own
group has found that dispersion of AF cycle length is higher in patients with
recurrent AF following DC cardioversion, and that following a period of
sinus rhythm dispersion of atrial refractoriness is reduced.28
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Conduction Velocity
Having found significant changes in atrial refractoriness associated with
maintained AF Wijffels1 went on to study the effects of maintained AF on
atrial conduction velocity. Conduction velocity was measured along
Bachmann's bundle (the epicardial area of the atrium between the left and
right atria - see Figure 3.1). No significant change in conduction velocity
was found during the first 4-days of maintained AF although the authors did
find that following cardioversion of chronic AF there was a slight slowing of
conduction velocity along Bachmann's bundle. Although conduction
velocity does not appear to change during maintained AF subsequent
preliminary data has reported a link between baseline intra-atrial conduction
9Q . • ...
velocity and the onset of stable AF. Changes in connexin40 distribution
have been found in goats with persistent AF,30 but these do not result in
significant changes in conduction velocity. The time course of change in
connexin40 distribution has been shown to run in parallel with the
development of persistent AF, but the exact electrophysiological mechanism
of this effect has not been elucidated.31
Unlike the goat model, most studies using the rapid atrial pacing canine
1 8 99 99
model of AF ' ' have shown a significant decrease in conduction velocity,
although one group19 found conduction velocity to increase. The time course
of changes in conduction velocity in the dog model of AF is also of interest.
18 °2
Changes in conduction velocity are not apparent during the first week 'J of
rapid pacing in the canine model but following 6-weeks of rapid atrial pacing
. .... i o2?
conduction velocity is significantly slowed. ' This slower time course of
onset of changes in conduction velocity is mirrored by a slower recovery
following return to sinus rhythm.32
Reduced atrial conduction velocity25'34'35 and an increased P-wave
duration34'35 have been demonstrated in patients with chronic AF
immediately post-cardioversion. The time course of onset of changes in
conduction velocity is unknown in man but the recovery of the slow atrial
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conduction velocity and prolonged p-wave duration associated with chronic
AF is known to take longer than recovery of atrial refractoriness with no
change noted in the initial 4-days following cardioversion.35 Full recovery of
p-wave duration to equal that of control patients does occur by 1-month post-
cardioversion.36
Figure 3.9 Rhythm strips (lead II) from immediately post-cardioversion (top) and
following a 6-week period of sinus rhythm (bottom) from a single patient. The mean P-
wave duration has decreased from approximately 160ms to 120ms during the 6-weeks.
Conclusions
Atrial fibrillation results in a number of electrophysiological changes that
might promote its own maintenance. Atrial electrical remodelling occurs in
both animal and human models of AF. There is also evidence that atrial
electrical remodelling occurs in patients with AF but it is not clear whether it
is a cause or consequence of AF. Changes in atrial conduction velocity occur
in the rapid atrial pacing dog model of AF and slowing of the atrial
conduction velocity has been demonstrated in humans following
cardioversion of persistent AF. The role of changes in dispersion of atrial
refractoriness in humans is not clear and further work in this area will be of
interest.
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3.3 Cellular Aspects of Atrial Electrical Remodelling
The most prominent electrical change associated with atrial electrical
remodelling is a reduction in action potential duration. A schematic diagram
of the cardiac action potential is shown below. The reduced action potential
duration (APD) is due to an imbalance between the inward Ca2+ current and
the outward K+ currents. A reduced inward Ca2+ current, an increase in the
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Figure 3.10 Schematic diagram showing pattern of ionic currents in the atrial
action potential. Adaptedfrom Priori SG et al. Eur Heart J 1999;20:P174-95
Abnormalities ofmembrane currents in diseased human atrial fibres were
37
first reported in 1976 by Hordof et al. Cells from dilated atria were
compared to cells from non-dilated atria and found to have differences in
action potential responses. Verapamil was noted to blunt APD only in the
cells from non-dilated atria raising the possibility that the cells from the
dilated atria already had down-regulation of Ca2+ currents. Abnormalities of
the Ca2+ current in dilated atria were later confirmed by Le Grand and
38 2+coworkers who found the APD to be reduced and the Ca current lower in
myocytes from dilated compared to non-dilated atria. These findings
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predated the description of atrial electrical remodelling. Following the
description of AF-induced atrial electrical remodelling by Wijffels1 interest
intensified in the alterations of ion channel function responsible for the
observed changes in atrial electrophysiology.
Animal Data
Various animal models of AF have been used to study the changes in cellular
electrophysiology associated with AF. There are important differences in the
results of the studies, which probably relate to the different species used and
the mechanism by which atrial electrical remodelling is induced (AF v rapid
TQ
atrial pacing). Nattel's group published the first study of the changes in
ionic channels associated with atrial electrical remodelling in 1997. This
group uses a rapid atrial pacing (400bpm) dog model of AF to induce atrial
electrical remodelling, and have gone on to publish widely on the ionic and
molecular changes involved in atrial electrical remodelling. The study
protocol involved pacing dogs for 1-day, 7-days or 42-days and comparing
them to sham dogs, which have a pacemaker inserted but no rapid atrial
TQ •
pacing. In the study of Yue et al each dog underwent electrophysiological
study prior to sacrifice, during which atrial effective refractory period
(AERP) and AF inducibility (by 10 Hz burst pacing) were measured.
Following the study the animals were sacrificed and single cells were
isolated for voltage clamp studies. The electrophysiological study prior to
sacrifice showed typical features of atrial electrical remodelling. The
inducibility of AF increased with longer durations of rapid atrial pacing.
AERP was reduced in all the rapidly paced dogs and also showed reduced
rate adaptation. The cellular studies showed the resting membrane potential
to be unchanged in the paced dogs. Action potential duration (APD) was
reduced for both APDso and APD95 in the paced dogs. The associated changes
in ion channel function were a progressive decrease in the Ca2+-independent
transient outward current (k) and the L-type Ca2+ current (Icax) density by
about 70%.39 In the same study the authors noted a number of other currents
were unaffected by the 6-weeks of atrial tachycardia including: the inward
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rectifier current (La), the ultrarapid (Wd), rapid (Ik.) and slow (Ls) delayed
rectifiers, T-type Ca2+ current (Ic«.t) and the Ca2+-dependent chloride current.
7+
Having demonstrated a reduction in the Ca -independent transient outward
current (Lo) and L-type Ca2+ current (Icax) the authors went on to study the
effects of drugs on these currents. In order to determine the role of Ica L the
authors looked at the effects of nifedipine and Bay K 8644 on action
potential duration. Nifedipine, a calcium channel blocker, significantly
reduced APD in sham dogs, but had little effect on the APD in dogs paced
for 6-weeks. The use of Bay K 8644, a calcium agonist, restored a plateau
phase to the action potential in cells from paced dogs. These results suggest
that changes in the L-type Ca2+ current are responsible for the shortening of
the APD. To study the effects of L the authors studied the effect of 4-
aminopyridine (4-AP) on the APD of non-remodelled atrial myocytes. Low
doses of 4-AP result in inhibition of the Lur.d current but not the L> current. At
low doses 4-AP (inhibition of W d only) raised the plateau of the action
potential but did not alter APD. Higher concentrations of 4-AP (inhibition of
Ikur aand Lo) resulted in a reduction in APD, due to an accelerated phase-3
repolarisation. A reduction in APD with reduced L, was not expected and
therefore the effect of 4-AP on APD in the presence of nifedipine (to mimic
the effect of the combined reduction in ion currents as occurs in remodelled
atria) was tested. In this setting 4-AP caused only a mild prolongation of
APD, suggesting that the reduction in L is much less important than the
reduction in IcaL as the mechanism underlying the reduced APD in AF. In
addition to the experimental evidence above, mathematical models40 of the
action potential suggest that changes in Ica l are important in the reduction of
APD and AERP observed in the setting of atrial electrical remodelling.
The rapid atrial pacing dog model of AF has consistently been shown to
• • • 18
result in a reduction of atrial conduction velocity. This would support the
maintenance of AF by reducing the atrial wavelength that would favour
multiple circuit reentry. To study the underlying cellular and ionic
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mechanisms of the reduction in atrial conduction velocity Gaspo et al used
whole-cell patch-clamp techniques to study atrial myocytes isolated from
control dogs and dogs subjected to rapid atrial pacing for 7 or 42 days.41
They specifically studied the rapid inward (phase 0 of the action potential)
Na current (W), which is an important determinant of conduction velocity in
atrial tissue. The protocol they used was similar to previous work by the
same group. Dogs were rapid atrially paced (400 bpm) for periods between 7
and 42 days. An electrophysiological study was performed prior to sacrifice.
Conduction velocity was measured using a silicon sheet with an array of 40
bipolar electrodes sutured onto the right atrial epicardial surface. Following
the study single atrial myocytes were prepared for voltage-clamp studies.
The results showed that AF durations and AF inducibility increased with
longer durations of rapid atrial pacing. Conduction velocity was significantly
reduced in the dogs subjected to rapid atrial pacing for 7 or 42 days. The
voltage-clamp study showed that Da was also significantly reduced in the
paced dogs. There was a strong correlation between the changes in In3, the
logarithm of AF duration and conduction velocity. The underlying
mechanism of the reduction in Da was not determined but a rise in
2"b 2T-intracellular Ca [Ca ]i can lead to down regulation of Na channel
expression.42 It is also possible that other factors such as connexin
expression may be important in changes of conduction velocity.
Following their work showing decreases in the ionic current density of the L-
type Ca2+ current (Icax), the transient outward current (D) and the Na current
(Da), Nattel's group went on to look at the molecular mechanisms underlying
these changes.43 Using a competitive reverse transcriptase-polymerase chain
reaction, mRNA concentrations were quantified in control dogs and in dogs
subjected to 7 days (P7) and 42 days (P42) of rapid atrial pacing. Changes in
mRNA levels for the alphas subunit of the L-type Ca2+ channel, for Kv 4.3
(the putative gene for L>) and for the alpha subunit of the cardiac Na channel
were all significantly reduced in both P7 and P42 dogs. The level of
reduction was similar to the observed changes in atrial ionic current densities
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and the reductions were more marked in P42 than P7 dogs. The authors then
studied the levels ofprotein expression for Kv 4.3 and the alpha subunit of
the Na channel using western blot analysis and found these to be similarly
reduced. The levels of mRNA and protein expression for other currents
previously identified as not being involved in atrial electrical remodelling
were not altered. The same group had already shown that rapid atrial pacing
reduces the number of dihydropyridine receptors (L-type Ca2+ channels) as
assessed by radioligand binding and that longer durations of rapid atrial
pacing resulted in greater reductions.44 On the basis of these findings the
authors concluded that there is an underlying molecular basis for the self-
perpetuating nature of AF.
The ionic and molecular changes in dogs have been well illustrated by
Nattel's group, however important differences between the manifestations of
atrial electrical remodelling in the goat and dog model have previously been
noted. For instance in the dog model various groups have noted changes in
conduction velocity associated with atrial electrical remodelling, ' but
previous work on the Allessie goat model has failed to show any significant
changes in conduction velocity1 despite changes in connexin distribution.30
Van der Velden and co-workers45 explored the molecular changes underlying
atrial electrical remodelling in the original Allessie goat model of AF. They
measured monophasic action potential (MAP) durations at the time of the
initial surgery to implant the epicardial patches and again following a mean
of 135 days ofmaintained AF. AERP was also determined at baseline and
again following a mean of 11 days of AF. Following sacrifice mRNA levels
were determined using the reverse transcriptase-polymerase chain reaction.
The results showed that following cardioversion of AF the MAP was
significantly reduced compared to control measurements and showed a
marked reversal of rate adaptation. AERP was also markedly reduced when
measured. The mRNA analysis showed a significant reduction in expression
of the alphas subunit of the L-type Ca channel and the Kv 1.5 potassium
channel gene that underlies Iku,. No significant changes were found in the
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mRNA levels encoding for the rapid Na channel, the Na / Ca2+ exchanger or
the Kv 4.2/4.3 channels responsible for L. The results correspond with the
findings of Yue et al43 for the alphas subunit of the L-type Ca2+ channel but
differ significantly for the potassium channels Kv 1.5 and Kv 4.3, and for the
fast Na channel. These differences, especially the lack of a change in Na
current mRNA in the goat model, may explain the different findings in terms
of conduction velocity changes in association with atrial electrical
remodelling.
Following this work using models of persistent AF, other workers have
studied the changes in ion channel function and mRNA expression that occur
with short durations (<8 hours) of rapid atrial pacing in an anaesthetised rat
model.46 A total of 9 genes encoding for voltage-dependent K+ channels
were studied, but the authors did not study the L-type Ca2+ channel. No
change in the expression and function was found for 6 of the genes studied.
An increase in Kv 1.5 mRNA and protein and a progressive decrease of the
mRNA levels of the Kv 4.2 and Kv 4.3 and their proteins was found. To
determine whether the changes in Kv 1.5 mRNA and channel expression
were significant the authors recorded monophasic action potentials (MAP)
from the atrium after 4 hours of rapid pacing (when changes in Kv 1.5 were
maximal). The rapidly paced atria showed a significant shortening of the
MAPdso compared to sham operated atria. This change in MAPd% was almost
abolished by a low concentration of 4-aminopyridine (a relatively specific
Kv 1.5 blocker). The Kv 1.5 gene is thought to encode the ultrarapid delayed
rectifier current (Lur d). This finding is different to that of previous
workers.39'45 The changes in Kv 4.2 and Kv 4.3 mRNA (which encodes for I.o
in rats) would be compatible with previous findings of a reduction in Lwith
longer durations of rapid atrial pacing in dogs.39
The ionic mechanisms underlying regional action potential heterogeneity
have also been investigated. Feng and co-workers47 studied action potential
heterogeneity in non-remodelled atria from dogs. There was a tendency to a
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longer action potential duration in cells from the crista terminalis compared
to other regions in the right atrium confirming previous data gathered using
48
standard microelectrode techniques. The longer action potential durations
2_p
were associated with a larger L-type Ca current in the crista cells. Cells
from the right atrial appendage showed a reduced Lo current. Li and
coworkers found left atrial ERP to be shorter than right atrial ERP in isolated
canine atrial myocytes. Whole cell patch clamping showed an increased kr in
the left atrial myocytes.59
Human Data
Although animal work is crucial in developing an understanding of the likely
mechanisms underlying atrial cellular and ionic physiology, complementary
human data to back up the animal work is important. Studies on human atrial
tissue, however, have a number of methodological problems. The
contributions of the underlying heart disease, drugs and varying durations of
AF should all be considered. In addition the harvesting of human atrial tissue
is limited to the time of cardiac surgery and handling conditions can often be
suboptimal. These factors may explain the considerable variation of the
findings in the literature.
Abnormalities of trans-membrane currents in dilated human atria were
TO
recognized several years ago. Using standard microelectrodes Le Grand et
al found that in trabeculae taken from dilated atria (at the time of cardiac
surgery) the action potential was shortened and the plateau was markedly
depressed compared to trabeculae taken from non-dilated atria. The most
significant change in ionic current to explain this shortening of the action
potential duration was a marked reduction in the calcium current density in
the cells from dilated atria.
The first study of the ionic changes in human AF using isolated atrial
myocytes and patch clamp techniques focused on changes in K+ currents and
the K+ channel alpha-subunit proteins (Kv 1.5 and Kv 2.1).49 Van Wagoner
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et al used atrial tissue samples taken at the time of cardiac surgery from
patients in chronic AF (undergoing mitral valve repair and/or the Maze
procedure) and compared them to control patients in sinus rhythm at the time
of bypass surgery or cardiac transplantation. The results showed that outward
K+ sup currents are reduced in patients with AF. The most significant
reductions (~ 60%) were noted in the L and the Lsus currents. Western blot
analysis was performed to determine whether there was a corresponding
reduction in voltage-gated K+ sup channel alpha-subunit proteins. The
Western blots showed a reduction in Kvl.5 but not Kv2.1 expression in the
membranes of myocytes from patients in AF. A reduction in K+ currents
results in prolongation of the APD and was the opposite of the expected
result.
In view of the findings of his first study Van Wagoner et al then went on to
study the atrial L-type Ca2+ currents in patients with AF.50 Again they used
atrial tissue from patients undergoing cardiac surgery to isolate atrial
myocytes for patch clamp and voltage clamp recordings. Patients with AF
2+
were found to have a significant reduction (~ 60%) in L-type Ca current
(La).
Other authors have also found changes in gene expression and proteins
involved in calcium transport.51 Using right atrial appendage tissue collected
at the time of cardiac surgery from patients with paroxysmal and persistent
AF and control patients in sinus rhythm mRNA levels were assessed using a
semi-quantitative reverse transcription polymerase chain reaction. Protein
expression was analysed using slot-blot analysis. The results showed a
significant reduction in both the mRNA and protein expression of the L-type
Ca2+ channel ai-subunit and sarcoplasmic reticulum Ca2+-ATPase in patients
with persistent AF (>8 months) compared to controls and patients with
paroxysmal AF. It is also of note that no changes were found in patients with
paroxysmal AF, despite this group representing the severe end of the
spectrum with daily long-lasting bouts of AF. In similar previous work this
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group had noted changes in the L-type Ca2+ channel ai-subunit mRNA were
related to the duration of AF, with the most significant changes in patients
with AF of >6 months duration.
C-3
Other authors have also found similar changes in mRNA levels. In a study
using atrial tissue collected from right and left atrial appendages and free
walls of both atria at the time of cardiac surgery, patients with persistent AF
were noted to have reduced levels of mRNA for the a-subunit of the L-type
Ca2+ channel and the sarcoplasmic reticulum Ca2+-ATPase. There was no
spatial dispersion of gene expression from the 4 sites studied. The same
group then went on to study changes in potassium channel mRNA
expression using the same atrial tissues.54 They found a reduction in the
mRNA encoding Kv 1.5, HERG and KVLQT1 in patients with persistent
atrial fibrillation for more than 3 months. In contrast, the mRNA level of
minK was significantly increased in patients with persistent atrial fibrillation
for more than 3 months. These changes, however, would not account for the
shortening of action potential duration.
Bosch and co-workers studied the relationship between action potentials and
ionic currents in human AF.55 Using right atrial appendage tissue obtained at
the time of cardiac surgery single atrial myocytes were studied by patch
clamping. The action potential duration was reduced in cells from patients
with chronic AF compared to control patients (sinus rhythm). Associated
with the change in APD there was a reduction of about 70% in the inward
Ca2+ current (W). There was also a marked reduction in L> currents but no
change in the Lsus current (different from Van Wagoner). No change was
found for the rapid Na+ current.
Other workers have also assessed the effects of persistent AF on potassium
currents. Grammer and colleagues56 studied the effects of remodelling on the
gene expression of Kv 4.3 and Kv 1.4 (pore-forming subunits for Lo), and Kv
1.5 (pore-forming subunit for kus, kur) Changes in function of the Kv 4.3
potassium channel, which putatively encodes for k have previously been
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described by Yue et al39 in their dog model of AF. Atrial tissue obtained at
the time of cardiac surgery from patients in chronic AF was compared to
atrial tissue from patients in sinus rhythm. Ion currents were studied in single
atrial myocytes using the patch-clamp technique and mRNA expression was
assessed using a semi-quantitative reverse transcription-polymerase chain
reaction. The atrial myocytes from patients in AF showed a marked
reduction in L but little change in IkSUS. Associated with the reduction in L>
there was a reduction of 61% in mRNA encoding for Kv 4.3. There was no
significant change in the second subunit involved with L, Kv 1.4, or in the
level of Kv 1.5. The results for L, are similar to those of Yue et al39 in the
dog model, but the lack of change in L** and Kv 1.5 is different to the
findings of van Wagoner et al49 who found a reduction in Kv 1.5 protein
expression in patients with AF. The parallel changes in L and Kv 4.3 suggest
transcriptional regulation as the underlying mechanism for changes in
current densities.
Further work incorporating measurement of atrial effective refractory period
(AERP) with quantitative analysis of mRNA and protein expression of ion
channels has more recently been published.57 Patients undergoing cardiac
surgery with paroxysmal or persistent AF and controls in sinus rhythm were
studied. The AERP was determined at both the left and right atrial
appendages during surgery. Following this the atrial appendages were
removed, RNA was isolated and using this cDNA synthesized. This was then
amplified using a single polymerase chain reaction. Protein analysis was
performed by quantitative slot-blotting. The results showed that patients with
paroxysmal and persistent AF had significantly lower AERPs than patients
in sinus rhythm. The mRNA analysis showed a reduction in mRNA content
9+
for L-type Ca channels and for 5 potassium channels (Kv 4.3, Kv 1.5,
HERG, mink, and Kir3.1) in patients with persistent but not paroxysmal AF.
The protein analysis showed a correlation between the protein levels of all
the ion channels studied with both the AERP and the rate adaptation of the
AERP. The changes in protein level were noted in both paroxysmal and
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persistent AF, unlike the mRNA changes that were noted only in persistent
AF. This is the first study to show a discrepancy between mRNA changes
and protein expression. It suggests that short paroxysms of AF may result in
changes in protein expression independent of changes in mRNA. The authors
suggest a possible proteolytic control system (the calpain system).
Most recently the issue of whether down-regulation of ion channels is
expressed exclusively through modulation of the pore-forming a-subunit has
been raised. Grammer and colleagues58 have found that the reduction of
certain isoforms of the a-subunit of the L-type Ca channel is greater than the
P-subunit.
Conclusions
2_|_Both human and animal data show a downregulation in L-type Ca channel
function is the principal ionic abnormality underlying the shortening of the
atrial action potential duration seen in AF.39'43"45'50"53'55'57 There is
2"b
downregulation of L-type Ca channel mRNA and channel protein
synthesis, suggesting a strong role for transcriptional down-regulation.
Decreases in t<= are also consistently found although the importance of this
abnormality for action potential changes and arrhythmia promotion is less
clear.39'43'46,55"57 Again this seems to be principally controlled by
transcriptional down-regulation. No clear patterns of change have been
observed for other currents with some authors finding a reduction in Kv 1.5
mRNA levels45'49'54'57 others finding no change,55'56 and one group even an
increase.46 Changes in Na channel activity in association with slowing of
conduction velocity have been described in dogs41 but despite the
recognition of changes in conduction velocity in human AF no changes in
Na channel mRNA or ionic activity have yet been described. The
interpretation of the data is clouded by the various species of animal model
used and the variety of clinical backgrounds from which human AF samples
are taken.
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Experimental Authors Duration of Changes
Model Pacing/AF Ionic mRNA Protein
Dog RAP Yue et al (39) up to 6-weeks ^ 1.0 (-70%)
1 Ica..(~70%)
Dog RAP Gaspo et al (41) up to 6-weeks "I' Da





Dog RAP Gaspo et al (44) •I L-type Ca
Goat AF Van der





no change Da or Kv 4.3
Rat RAP Yamashita
et al (46)
up to 8-hours 4- Kv 4.2 / 4.3 and 4 proteins
T Kv 1.5
Table 3.1 Summary of the changes in ionic currents, mRNA and proteins reported
in the literature in animal studies. The numbers in parentheses indicate reference
numbers. RAP - rapid atrial pacing.
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Authors Type of AF Changes
Ionic mRNA Protein
Van Wagoner (49) Persistent
Van Wagoner (50) Persistent
Brundel(51) Persistent



















4- Kv 1.5 (Iksus)
-I IcaL 4- a-subunit









no change in Lsus or La
J' Ito
no change in Lsus
4" Ica.l J' Ica.l
1 Kv 4.3 4 Kv 4.3
4- Kv 1.5 4Kv 1.5
Iherg 4herg
4- min K 4 min K





Table 3.2 Summary of the changes in ionic currents, mRNA and proteins reported in
the literature in human studies. The numbers in parentheses indicate reference numbers.
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3.4 A New Fully Implantable Goat Model Of Atrial Fibrillation
Background
Currently available fully implantable animal models of atrial fibrillation
(AF) use rapid atrial pacing (Figure 3.11) rather than AF to induce atrial
electrical remodelling. As a consequence the effect of the remodelling
process on AF stability (duration of individual episodes of AF) and AF
inducibility cannot be determined. In contrast, the original Allessie goat
model (Figure 3.2) allowed measurements of these two variables
continuously, but until now has not been incorporated into a fully
implantable system.
The key components of the fully implantable goat model of AF are the
ability to induce AF, to record durations of induced AF episodes and to be
able to measure atrial refractory periods by extrastimulus pacing. The new
model used two pacemakers, two right atrial leads and one right ventricular
lead. The first pacemaker was dual chamber and incorporated specially
designed software for the induction of AF. The atrial electrogram was
continually analysed and when atrial electrical quiescence was detected (as
occurs in the periods between P-waves in sinus rhythm) a 2-second burst of
64 Hz pacing was delivered at four times diastolic threshold (Figure 3.15).
During AF when continuous atrial activity was sensed the burst-pacing
algorithm in the pacemaker was inhibited. The pacemaker stored a log of all
burst pacing allowing assessment of AF durations. The ventricular lead was
required to ensure that appropriate atrial sensing was occurring (at least
100ms separate from sensed ventricular activity), as atrial lead dislodgement
and inappropriate burst pacing in the ventricle would be catastrophic. The
second pacemaker was a single chamber device used for extrastimulus
pacing to determine atrial refractory periods. During measurement of atrial
refractory periods the burst-pacing algorithm was inhibited by programming
the dual chamber pacemaker to single chamber mode. The atrial lead in the
dual chamber pacemaker was used to record atrial capture (by telemetry
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from the pacemaker interrogation wand) during extrastimulus pacing thus
allowing accurate assessment of atrial capture (Figure 3.12).
Methods
Using 14 goats we developed a fully implantable pacemaker-based model of
AF. The experiments were conducted in accordance with the project license
issued by the United Kingdom Home Office under the Animals (Scientific
Procedures) Act 1986. The animals were allowed free access to food and
water and were unrestrained in their pens throughout the experiments. The
new model is a modified pacemaker-based model of AF in which the
original Allessie burst pacing protocol is incorporated, thereby allowing
continuous monitoring /recording of the self perpetuating process in addition
to measurements of atrial refractoriness and AF inducibility.
Figure 3.11 Surface ECG illustrating
rapid atrial pacing. Atrioventricular node
ablation has been performed and the
ventricles are paced at 75/min.
Pacemaker implant
Anaesthesia was induced and maintained using 3% Isoflurane and a 2:1
mixture of O2 and N2O. The animals were placed in the left lateral position
and 1 gram of flucloxacillin was given intravenously. Using aseptic surgical
technique an incision was made in the lateral aspect of the neck exposing the
right internal jugular vein. The vein was mobilised and ligated and three
active-fixation bipolar steroid eluting leads introduced via a small venotomy
and positioned on the septal portion of the right atrium (2 leads) and right
ventricular apex (1 lead). Sensing and threshold characteristics were
determined before connecting one atrial lead to an Intermedics pacemaker
and the remaining leads to the atrial and ventricular channels of a Medtronic
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Thera® pacemaker. The leads were secured and pacemakers buried
subcutaneously prior to wound closure. An ECG telemetry unit (Data
Sciences Inc) was buried subcutaneously in the right flank through a further
small incision.
400/120
Day 2 AERP = 140ms
Day 1 AFCL = 167ms
Day 4 AERP = 120ms
Figure 3.12 The upper part of the figure illustrates measurement of refractory periods. The left
panel (A) is taken from Day-2. Following a drive train of 8 cycles at 400ms an extrastimulus
with a coupling interval of 150ms results in atrial capture. The lower trace shows that the
extrastimulus at 140ms does not result in capture. The right hand panel (B) shows refractory
period measurement from the same goat on day-4. The upper trace shows atrial capture with an
extrastimulus at 130ms associated with 2 repetitive atrial responses. The lower trace shows that
an extrastimulus at 120ms does not result in atrial capture. The lower part of the figure (C)
shows atrial fibrillation cycle length (AFCL) measurements from day-1 and day-5. Each cycle is
marked with an arrow. The AFCL shortens from 167ms on day-1 to 123ms on day-5.
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Figure 3.13 Lateral radiograph of positions of
pacemaker leads. Two leads can be seen in the
right atrium and one in the right ventricle. The
cardiac silhouette can also be seen. The
ventricular lead and one atrial lead were
connected to a Medtronic Thera pacemaker
responsible for burst pacing. The second atrial
lead was connected to an Intermedics pacemaker
and was used to determine atrial effective
refractory periods using non-invasive
programmed stimulation (NIPS).
Methodological Problems
The initial validation protocol was hampered by several problems.
1. Atrial lead displacement - following pacemaker implant atrial lead
displacement occurred in several goats. This was more of a problem initially.
Particular issues that contributed to lead displacement included how active
the goat was on recovery from general anaesthesia and good stability of the
leads during robust testing at the time of implant. In one goat atrial lead
displacement was not detected during post-implant testing. Burst pacing
through this lead resulted in a fatal ventricular arrhythmia.
2. Ability to programme pacemakers independently - in creating the
pacemaker pocket for the two pacemakers, care had to be taken to separate
the pacemakers in the pocket in order to allow effective individual
programming and telemetry from each pacemaker.
3. Left atrial measurements - we also implanted coronary sinus leads in a
number of goats in order to measure left atrial refractory periods. Although
good positions were found in a number of animals long term stability was
not adequate and therefore we abandoned this part of the protocol.
4. DC cardioversion - cardioversion of the goats was greatly facilitated by
the use of adhesive electrodes. Conventional DC cardioversion using
'paddles' was unsuccessful in most cases.
5. Spare equipment was essential as the goats frequently chewed the cables
involved in pacemaker programming.
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Validation protocol
Previous work by Garratt et al17 using the original Allessie goat model had
shown that changes in atrial refractoriness and the onset of AF stability were
reproducible over two consecutive 5-day periods. The validation protocol
was designed to assess the reproducibility of these variables over two
consecutive 5-day periods in the new fully implantable model. A schematic
diagram of the validation protocol is shown in Figure 3.14. If changes in
atrial refractoriness and AF stability were reproducible in the new model we
would be able to test the effect of drugs on atrial electrical remodelling and
AF stability using 5-day protocols. The important elements of reproducibility
were considered to be changes in atrial refractoriness and the onset of AF
stability, as our first prospective drug study was to assess the relationship
between these factors in the presence of verapamil.
After pacemaker implant the animals were allowed to recover for at least 5-
days. The animals then commenced repetitive reinduction of AF for the first
5-day period (remodelling 1). Specifically designed software in the
Medtronic pacemaker was used to deliver burst pacing during sinus rhythm
via the right atrial lead in a manner similar to that in the originally described
Allessie goat model. Whenever sinus rhythm was detected the pacemaker
delivered a 2-second burst of pacing at 64 Hz. Burst pacing was inhibited
whenever AF was detected. During the 5-day period measurements were
made of AERP, inducibility of AF by extrastimulus pacing, AF stability, AF
cycle length and ventricular cycle length at t = 0, 4, 8, 12, and 24 hours, then
twice daily until the 5th day. At the end of the 5-days the goats were DC
cardioverted under general anaesthesia. Thereafter AERP was measured
daily until it recovered to baseline. Following a mean period of 10-days
repetitive reinduction of AF was commenced for the second 5-day period
(remodelling 2). At the end of the second 5-day period the goat was again
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Figure 3.14 Illustration of the validation protocol
Measurement of refractory periods and AF cycle length
The Intermedics pacemaker was used to deliver extra stimulus pacing via the
external programmer to determine atrial effective refractory periods (AERJP)
during a basic pacing drive of 400ms. A standard drive train of 8 extrastimuli
(Sj) was followed by a single S2, all at four times diastolic threshold. The
initial S1-S2 coupling interval was commenced at a shorter interval than the
expected AERP and increased incrementally until atrial capture was
achieved. The AERP was recorded as the mean of the two longest S1-S2 that
failed to capture the atrium (Figure 3.12). To determine AFCL we recorded
10-second segments of bipolar atrial electrogram at 100 mm/s via telemetry
from the atrial lead in the Thera pacemaker (Figure 3.12). Two independent
observers then calculated mean AFCL and these two values were averaged.
. .......
: 1:::: :::: ;[F 1 | iiiiliiiilj:;
:p :::: : ^ 4: :Tif:::
3.5 nVi 'mo T1 /m i :::::::
























































e. a™. iiil vs iMB V5 us
Figure 3.15 Illustration of an intracardiac recording of the burst pacing algorithm in action.
The ECG is telemetered from the Thera pacemaker and shows atrial fibrillation (AF) on the
left, reverting to sinus rhythm, and upon detection of sinus rhythm (2 beat detection
programmed) a 2-second 64Hz burst of atrial pacing that successfully reinduces AF. The
episodes of AF are short lived typical of the findings in the early stages of remodelling.
Burst pacing
^ ^ Remodelling 1 ^
012345 012345
Time (days) Time (days)
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Duration of induced AF
The duration of induced episodes of AF was determined using 1) direct
telemetry of the endocardial atrial signal via the pacemaker programmer and
from 2) the surface ECG telemetered via the Datasciences implant (Figure
3.16) which was continuously displayed and recorded on a computer. In
addition the Thera software recorded a log of time and cumulative number of
bursts delivered.
Burst Pacing - 64Hz for 2 seconds
SR SR llllllilllllllil ilJiilllllllllllilllllllillllillillllilil
-0.5
Figure 3.16 Surface ECG transmitted from the Datasciences implant. SR indicate the sinus
beats prior to a 2-second burst at 64Hz of atrial pacing that reinduces AF. (mV - millivolts)
The time course of changes in atrial refractory periods (AERP) were
reproducible with a mean AERP at baseline of 165±15ms for remodelling 1
and 165±20ms for remodelling 2, 141±19ms v 136±20ms after 24-hours of
repeated reinduction of AF, 135±23ms v 123±21ms at 48-hours, 122±19ms v
116±9ms at 72-hours and 118±21ms v 118±17ms at 120-hours (all P=NS).
The inducibility and stability of AF were also reproducible. The time periods
of repeated induction of AF required to induce AF of duration 1 -hour, 6-
hours and 24-hours were 84±31hrs v 62±28hrs, 95±27hrs v 92±31hrs,
104±28hrs v 104±28hrs respectively (all P=NS). The time course of changes
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Figure 3.17 The stability of induced AF. The graphs show similar
durations of burst pacing required to induce each of the prespecified
durations of AF in remodelling 1 and 2.
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Figure 3.18 Changes in atrial effective refractory period (AERP). The
graphs show that changes in AERP were similar in remodelling 1 and 2.
Conclusions
A new fully implantable equivalent of the original Allessie goat model of AF
has been developed. Changes in atrial refractoriness and the onset of AF
stability are reproducible over consecutive 5-day periods of maintained AF
similar to the original Allessie model.17 The new model has the advantage of
being fully implantable and allows assessment of the stability of AF in
addition to atrial refractoriness.
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The description of atrial electrical remodelling1 and the understanding that
' AF begets AF' led immediately to interest in how this process might be
prevented or attenuated. The goal of being able to modify the natural
history of AF seemed to be in sight. Wijffels then went on to show that the
stimulus for atrial electrical remodelling was the rapid rate of atrial
electrical activation that occurs in AF2 and this was confirmed by the
description of models of AF based on rapid atrial pacing.3'4 Morillo et al3
showed that in conjunction with atrial electrical remodelling rapid atrial
pacing resulted in biatrial enlargement and cellular structural changes
which might result in a reduction in contractile function. There was an
obvious parallel between the experimental model and the changes found in
patients with AF such as atrial enlargement and loss of contractile
function,5'6 which are thought to be important in promoting left atrial
thrombus and the risk of cerebrovascular accidents.
The coexistence of atrial electrical remodelling and atrial contractile
dysfunction in the rapid atrial pacing model of AF suggested the
possibility of a common underlying aetiology and mechanism. Previous
work had shown that rapid pacing increases cell cytosolic calcium levels7'8
and that intracellular calcium overload causes cardiac contractile
dysfunction.9'10 This led to the suggestion that an increase in intracellular
calcium could be the mechanism for the observed electrical and structural
changes in AF.
The potential role of intracellular calcium overload as the underlying
mechanism of atrial electrical remodelling and atrial contractile
dysfunction in AF led to interest in the use of calcium-channel blocking
drugs to prevent these deleterious effects of AF. Interest focused on the L-
type calcium-channel blocker verapamil, which has been used to control
11 12the ventricular rate in AF for many years. ' Although there had been
reports of verapamil being of some use in converting AF of short duration
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to sinus rhythm either alone12 or in combination with quinidine13 most of
the data on the use of verapamil in AF did not suggest a useful potential
antiarrhythmic action of verapamil in AF. For instance, verapamil exerts
unfavourable effects in patients with WPW and pre-excited AF by
shortening the refractory period of the accessory pathway so promoting
conduction to the ventricle14 which can result in ventricular fibrillation.15
In the controlled setting of the electrophysiology laboratory verapamil and
diltiazem were found to increase durations of AF induced by programmed
electrical stimulation in patients with paroxysmal AF.16 The effects of
verapamil on atrial electrophysiology in patients with paroxysmal AF are
1 7
also not favourable. Verapamil slows atrial conduction velocity and
results in an increase in fragmented atrial electrical activity17'18 both of
which have the potential to promote AF.
Verapamil, however, was shown to exert favourable effects on AF-induced
atrial contractile dysfunction. Using an open-chest pig model Leistad and
coworkers19 induced AF for short periods in the presence ofboth
verapamil and Bay K8644 (which increases calcium entry via L-type
calcium channels). Following conversion from AF to sinus rhythm the
authors assessed the degree and duration of atrial contractile dysfunction
using echo. They found that while verapamil attenuated atrial contractile
dysfunction Bay K8644 increased the dysfunction strongly suggesting that
intracellular calcium overload was responsible.
Studies of the effects of verapamil on atrial electrical remodelling
followed shortly after. Using an anaethetised rapid atrial pacing dog model
20Goette showed that electrical remodelling could be induced despite
autonomic blockade and without any changes in right atrial pressure.
Verapamil blocked atrial electrical remodelling and calcium overload
accentuated it. This beneficial effect of verapamil on atrial electrical
remodelling was confirmed in experiments on humans. Daoud and
colleagues induced AF for 5-10 minutes using rapid atrial pacing. This
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short period of AF was shown to be adequate to develop changes in atrial
refractoriness.21 Pretreatment with verapamil, but not procainamide,
resulted in attenuation of the acute AF-induced changes in atrial
refractoriness and a reduction in the number of secondary episodes of AF
22induced during determination of the atrial refractory period. Similar
results for verapamil were found by others using 10-minute periods of
• 9^
pacing induced AF in humans. In the same study conventional
antiarrhythmic drugs such as procainamide, propafenone, sotalol and
9 9
amiodarone had no effect on atrial electrical remodelling.
In addition to preventing short-term atrial electrical remodelling (minutes)
verapamil was shown to reduce atrial electrical remodelling induced by
24-hours of rapid atrial pacing in the goat model.24 Lee et al25 also found
verapamil to prevent atrial electrical remodelling at 24-hours in their rapid
atrial pacing dog model but that this effect did not persist for longer
durations of atrial electrical remodelling (1-week and 6-weeks). In
addition, verapamil increased the durations of episodes of AF induced at
electrophysiological study (performed in full autonomic blockade) in the
dogs paced for 1-week and 6-weeks. Despite the lack of effect of
verapamil in preventing atrial electrical remodelling induced by longer
durations of AF or rapid atrial pacing the T-type calcium channel blocker,
mibefradil, has been found to be effective at preventing atrial electrical
remodelling induced by rapid atrial pacing of up to one-week in
duration.26'27
In association with evidence showing the beneficial effects of verapamil
on atrial electrical remodelling clinical reports of the effects of verapamil
in patients undergoing cardioversion of persistent AF were published.
Tieleman and colleagues28 evaluated the time of recurrence of AF
following DC cardioversion using daily trans-telephonic monitoring. The
highest incidence of recurrence was in the first 5-days following
cardioversion. The authors suggested this might be due to persistence of
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atrial electrical remodelling during this time. On further analysis of the
data the use of calcium-lowering drugs during AF was the only
independent predictor of maintaining sinus rhythm, suggesting that
calcium-lowering drugs had modified the substrate (atrial electrical
9Q
remodelling) for recurrence. De Simone et al found that pretreatment
with verapamil and propafenone for 3 days before cardioversion of
persistent AF resulted in a reduced rate of recurrence compared to
pretreatment with propafenone alone. Verapamil has also been shown to
reduce the incidence of recurrent ERAF (early recurrence of AF)
following cardioversion.30
The available data suggested that verapamil exerted beneficial effects on
atrial electrical remodelling and also on AF recurrence following
cardioversion. However, none of the studies had addressed the issue of
whether verapamil's action in attenuating atrial electrical remodelling led
to any reduction in the stability of AF. In order to study the relationship
between the effects of verapamil on atrial electrical remodelling and AF
stability an animal model based on the original Allessie goat model with
continuous reinduction of AF, allowing measurement of AF durations and
atrial refractoriness, rather than rapid atrial pacing alone would be
required. The development of our fully implantable version of the Allessie
goat model allowed us to study the inter-relationship of these effects.
Following the development of our model I collaborated with Dr Julian
Hobbs in studying the effects of verapamil on the stability of AF. This
work is reported in his MD thesis and was presented at The British Cardiac
Society in May 2000. In summary we found that verapamil promoted the
stability of AF, requiring less burst pacing to induce the prespecified
durations of induced AF (Figure 4.1), despite attenuation of atrial
electrical remodelling. The features of attenuation of atrial electrical
remodelling are a reduction in the fall of atrial refractoriness and
preservation of its rate adaptation (Figure 4.2). Atrial fibrillation cycle
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Figure 4.1 Increase in the stability of atrial fibrillation (AF) with verapamil
compared to placebo and baseline remodelling. The duration of burst pacing
required to induce AF durations of 1 -hour, 6-hours and 24-hours is significantly
reduced by verapamil. (**p=0.007, * p=0.001) With permission Dr JHobbs.
Figure 4.2 Atrial effective refractory period (AERP) at basic cycle lengths
(BCL) from 200ms-400ms. Times from 0 hours (t=0) to 120 hours (t=l20).
Verapamil attenuates the reduction in atrial refractoriness and loss of rate
adaptation. With permission from Dr J Hobbs.
In addition to our findings of an increase in stability of AF with verapamil
other authors have found verapamil to exert a profibrillatory effect. Data
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from Maastricht using the original Allessie goat model31 showed that
verapamil promotes AF stability in both the non-remodelled and
remodelled atria, but that this effect was more prominent in the remodelled
atrium. Verapamil had no effect on atrial refractoriness at longer (300-
500ms) pacing cycle lengths but resulted in a shortening of AF cycle
length and the atrial refractory period during AF (105-135ms) by
approximately 15%, and caused an increase in fragmentation from type I
to type II and type III AF.32
Friedman and coworkers also found that verapamil prolonged durations of
induced AF in anaethetised dogs. Using single extrastimuli to induce AF
in non-remodelled atria these authors found an increase in the mean
duration of induced AF from 19±6 sees in control dogs to 130±24 sees in
dogs treated with verapamil. Verapamil did not significantly alter atrial
refractoriness or atrial conduction velocity when measured in sinus
rhythm, but induced AF tended to be faster and more disorganised in
animals treated with verapamil compared to control animals.
Haemodynamic monitoring showed that verapamil reduced arterial blood
pressure and systemic vascular resistance but did not change cardiac
output. In association with the increase in AF duration and altered
haemodynamics an increase in plasma catecholamines was observed. A
strong correlation between the increased duration of AF episodes and
plasma catecholamine levels was noted. A small group of animals were
studied with the combination of verapamil and beta-blocker (metoprolol).
The pro-fibrillatory effect of verapamil was prevented by the beta-blocker,
despite a more exaggerated haemodynamic effect due to the combination
of drugs. The authors suggested that the profibrillatory action of verapamil
is mediated by increased catecholamines. Against this hypothesis previous
work has shown that sympathetic stimulation, by graded bilateral stellate
ansa stimulation, does not promote sustained AF in the dog.34
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Bernadcau and coworkers studied the effect of verapamil using
multielectrode epicardial mapping in order to determine the underlying
electrophysiological reasons for its profibrillatory action. Using an
anaethetised dog model and induction of AF by burst pacing verapamil
was found to exhibit a dose-dependent promotion of AF stability. Contrary
to the findings of Friedman et al33 verapamil was found to alter atrial
electrophysiology at baseline. There was a slight reduction in atrial
refractoriness at a cycle length of 300ms, reduced dispersion of atrial
refractoriness, and a heterogeneous increase in atrial conduction velocity.
During AF the AF cycle length was reduced from 94±4ms to 84±3ms.
Epicardial mapping indicated that verapamil increased the number of
separate zones of reactivation per cycle suggesting an increase in the
number of functional reentry circuits. This is a possible mechanism
whereby verapamil might promote multiple circuit reentry. Autonomic
blockade prevented the profibrillatory action of verapamil and the
epicardial mapping showed that autonomic blockade reduced the number
of zones of reactivation (functional reentry) to control conditions.
Data from studies on patients also show that verapamil shortens the mean
fibrillatory interval during AF.36 Atrial fibrillation cycle length was
measured before and after administration of verapamil in a group of
patients with chronic AF. Verapamil resulted in a reduction in the mean
fibrillatory interval in the right atrial appendage, the right atrial free wall
and the coronary sinus. The monophasic action potential duration (MAPdw)
was also reduced following verapamil suggesting that verapamil shortened
atrial refractoriness in AF. There was no alteration in the relationship
between fibrillation interval and MAPiwo, suggesting that verapamil does
not influence the excitable gap during AF. The authors point out that
verapamil was given slowly over 10 minutes with no significant change in
blood pressure or right atrial pressure.
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Conclusions
The studies suggest that despite beneficial effects on short-term atrial
electrical remodelling,20'22"24 longer term atrial electrical remodelling
25 27
cannot be prevented by L-type calcium channel blockade. ' The
maximum duration of effective attenuation of atrial electrical remodelling
by L-type calcium channel blockers is 5-days as shown in our study.(Dr
WJ Hobbs, MD thesis) Despite the advantageous effect of verapamil on
atrial electrical remodelling AF stability is increased, ' (Dr WJ Hobbs,
MD thesis) probably by reducing atrial refractoriness in AF31 and
increasing functional reentry.35 A potential role for catecholamines in the
profibrillatory action of verapamil is suggested by the finding by some
workers that beta-blockers prevent this effect.33'35 It should be noted




4.2 The Verapamil / Propafenone Combination
Verapamil has beneficial effects on atrial electrical remodelling but this
does not translate into a reduced stability of AF. We postulated that the
combination of verapamil with an antiarrhythmic drug might produce a
beneficial effect. Propafenone was chosen to test for two reasons. First
there are theoretical reasons to believe that propafenone would be effective
in preventing the profibrillatory action of verapamil. Propafenone is
known to cause a use-dependent prolongation of atrial refractoriness,37
which should counteract the verapamil induced reduction in atrial
refractoriness during AF.31'35 Second recent clinical data has shown good
efficacy for the combination of verapamil and propafenone in preventing
29
recurrent AF following cardioversion. In addition propafenone has no
role in preventing atrial electrical remodelling23 but is effective at
preventing secondary episodes of AF during refractory period testing.
Propafenone is a Class Ic antiarrhythmic drug with electrophysiologic
38actions of sodium-channel blockade and beta-blocking activity. The
sodium channel blockade is both rate (increases at faster rates) and
voltage-dependent (increases at less negative membrane potentials).39
Although not recognised in its classification as a Class Ic agent,
propafenone is known to prolong atrial refractoriness and action potential
... . . 3"7duration in atrial myocardium with marked use-dependence. The beta-
blocking potency is 1/20 to 1/80 than that ofpropranolol on a molar basis,
but as plasma concentrations of propafenone may be 50x higher these
effects may be relevant. 40'41 In addition to its effects on fast Na channels
and its beta-blocking activity propafenone also blocks K+ currents
including kr, Iki , and L ,42'43 but the clinical relevance of this action is not
well defined.
The mechanism of action of propafenone in terminating atrial arrhythmias
has been studied in some detail. Termination of reentrant atrial excitation
(atrial flutter) by propafenone correlates with prolongation of the atrial
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conduction velocity,44'45 but not with wavelength prolongation. In a
cholinergic dog model of AF propafenone has been shown to increase
atrial refractoriness in a use-dependent manner and terminate AF by
reducing the number and size of reentry circuits.41 Although propafenone
was also shown to slow conduction velocity in this model its net effect on
atrial wavelength was prolongation and this was felt to mediate its anti-
fibrillatory action.
Clinically, propafenone is well known to be effective in suppressing
episodes of paroxysmal AF46"48 and in cardioverting AF of recent onset.49
Propafenone has also been shown to prevent the induction of AF,50 and to
terminate acute AF in patients with WPW51 by prolongation of the atrial
fibrillation cycle length. In view of the previous findings of a possible
catecholamine mediated profibrillatory action of verapamil it is important
to note that propafenone retains its ability to prolong AF cycle length and
to cardiovert AF in the presence of adrenergic stimulation.52
Propafenone has a combination of favourable actions that suggest it may
prevent the profibrillatory action of verapamil including prolongation of
atrial refractoriness, an ability to prolong AF cycle length (even in the
presence of adrenergic stimulation) and beta-blocking activity.
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4.3 The Profibrillatory Effect of Verapamil is not
Prevented by Propafenone
Methods
The study was performed using the new pacemaker based version of the
Allessie goat model (see Chapter 3 for details). Eleven adult female goats
(mean weight 58±7 kg) were used in the study. The experiments were
conducted in accordance with a project license issued by the United
Kingdom Home Office under the Animals (Scientific Procedures) Act
1986. The animals were allowed free access to food and water and were
unrestrained in their pens throughout the experiments.
Pacemaker implantation, measurement of duration of induced AF,
refractory periods and AF cycle length was performed as outlined in
Chapter 3.
Study protocol
Following pacemaker implant the animals were allowed to recover for at
least 5 days. Atrial refractoriness was measured on a daily basis to ensure
its stability. When a baseline AERP had been determined the animals then
underwent a 5-day protocol of repeated reinduction of AF followed by a
recovery period of at least 5 days duration. During this period
measurements were made of AERP, AF stability, AF cycle length, and
ventricular cycle length at t = -4, 0, 4, 8, 12, 24, 32, 48, 56, 72, 80, 96,
104, 120 hours (Figure 4.3). The t= -4 hours measurement was taken as the
baseline AERP. At t = 120 hours burst pacing was discontinued and the
animals DC cardioverted under general anaesthetic. Anaesthesia was
induced and maintained using 3% Isoflurane and a 2:1 mixture of 02 and
N20. The AERP was measured at time intervals of t = 4, 8, 12, 24, 32, 48,
56, 72, 80, 96, 104, 120 hours following cardioversion. In all animals
AERP returned to baseline by 120-hours. Animals (n = 7) in the first part
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(PI) of the study were then randomised to placebo, verapamil or
verapamil/propafenone infusion in random order (Figure 4.3) and in
second part (P2) of the study (n = 4) to placebo or propafenone infusions
in random order. The second part of the study was cut short due to the
onset of foot and mouth disease in the UK in the year 2000.
Recovery Recovery Recovery Recove
Infusion
4HHHV"
Burst pacing Burst pacing
ttttttt tt tt ft tttt ft
Infusion Infusion
Burst pacing Burst pacing
// // //
012345 012345 012345 012345
Time (days) Time (days) Time (days) Time (days)
Figure 4.3 Schematic diagram of study protocol, t- indicates time of measurements.
Infusion protocol
We inserted 6F sheaths (Cordis®) into the left internal jugular vein under
local anaesthetic and secured them with a single suture and a collar
fashioned from a sphygmomanometer cuff. Each animal wore a harness to
which an infusion pump (Graseby Medical MS 16A®) was secured. A
Portex® infusion line with an in-line bacterial filter was used to connect
the pump and central line. Loading doses followed by infusions were
commenced 4 hours before burst pacing to allow a steady state to develop
with electrophysiological measurements both prior to the start of the
infusions (baseline) and immediately prior to the start of burst pacing (t =
0). Verapamil was given as an initial bolus of O.lmg/kg over 10 minutes
followed by a continuous infusion of 5mcg/kg/min during the rest of the
experiment. Propafenone was given as an initial bolus of lmg/kg followed
by a continuous infusion of 333pg/kg/hr, up to a maximum of 480mg per
day (maximum dose to goats of 60kg and above). The dose used was
based on the manufacturers (Knoll Pharmaceuticals) recommended dose
for intravenous use humans and was the maximum human dose in 9 of the
11 goats. A higher dose was used in 2 further animals but was
discontinued due to side effects. The results for these animals are not
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included. During the verapamil/ propafenone infusion the bolus doses
were separated by 30 minutes to prevent side effects. During the placebo
infusion the same volume of normal saline was infused. The central lines
were removed immediately following each 5-day infusion and new lines
re-inserted at the beginning of the next infusion.
Statistical analysis
Data analysis was performed using the statistical package SPSS version
8.0. Analysis of serial measures was performed by converting the data to a
single measure using the area under the curve technique.53 The logarithm
of non-parametric data was used to transform the data to a normal
distribution for statistical analysis. A two tailed p value of less than or
equal to 0.05 was taken as significant.
Results
Effect of the drug infusions on baseline AERP and electrical remodelling
The protocol was successfully completed by 10 of the 11 goats. Due to
problems with venous access one goat completed only two of the three
infusions (placebo and verapamil/propafenone) in PI of the study protocol.
Measurements of AERP were obtained in all 11 goats. Neither placebo nor
verapamil had any effect on baseline AERP prior to the onset of the pacing
protocol. The verapamil/ propafenone infusion resulted in a significant
increase in AERP from a baseline of 164±20ms to 179±19ms (p < 0.01,
Figure 4.4). Propafenone alone also resulted in a significant increase in
AERP from a baseline of 148±36ms to 163±45ms (p - 0.02, Figure 4.5).
During placebo infusion and burst pacing AERP fell by a mean of
32±15ms at 24-hours, 46±18ms at 48-hours and by 48±23ms at 120-hours.
The fall in atrial refractoriness was greatly attenuated by both the
verapamil and the verapamil /propafenone infusions. During the verapamil
infusion and burst pacing AERP fell by a mean of 13+19ms at 24-hours,
7±22ms at 48-hours and by 17±10ms at 120-hours (p < 0.01 v placebo).
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During the verapamil/propafenone infusion and burst pacing AERP fell by
a mean of l±6ms at 24-hours, 8±14ms at 48-hours and by 16±17ms at
120-hours (p < 0.01 v placebo, Figure 4.4). During propafenone alone and
burst pacing AERP fell by a mean of 0±37ms at 24-hours, 23±48ms at 48-
hours and by 48±10ms at 120-hours (p = 0.26 v placebo). The initial
increase in atrial refractoriness secondary to propafenone was abolished
following 120-hours of atrial electrical remodelling (Figure 4.5). The
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Figure 4.4 Changes in atrial refractoriness (AERP) at a drive
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Figure 4.5 Changes in atrial refractoriness (AERP) at a drive
train of 400 milliseconds (ms) for n = 4 goats, P2 of the study.
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Table 1 : PI of study. Mean atrial effective refractory periods
Infusion Placebo Verapamil Verap/Prop
-4 hrs 180+40ms 175±33ms 164±20ms
Ohrs 180±38ms 177±28ms 179±19ms
24hrs 147±36ms 162±31ms 163±21ms
72 hrs 130±42ms 165±32ms 157±28ms
120 hrs 131±42ms 158±33ms 147±32ms
Table 2 : P2 of study. Mean atrial effective refractory periods
Infusion Placebo Propafenone
-4 hrs 155+33ms 148±44ms
0 hrs 158±36ms 163±55ms
24hrs 125±34ms 148±66ms
72 hrs 110±29ms 123±73ms
120 hrs 108±30ms 105±51ms
Overall effect of drug infusions on the stability of induced AF
In agreement with previous findings, despite attenuation of atrial electrical
remodelling verapamil accelerated the self-perpetuation of AF in the goat
model. The profibrillatory action of verapamil was not prevented by
propafenone (Figure 4.6). Durations of burst pacing with the verapamil
and verapamil/propafenone infusions required to induce individual
durations of AF 1-second (11 hours and 7 hours), 1-minute (12 hours and
10 hours), 1-hour (39 hours and 29 hours), 6-hours (44 hours and 62
hours) and 24-hours (70 hours and 78 hours) were broadly similar.
Propafenone alone resulted in a reduction in AF stability compared to
placebo (Figure 4.7).
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Effect of drug infusions on AF cycle length
There was a high correlation (r = 0.96) between measurements of mean
AF cycle lengths made by the 2 observers. In agreement with previous
findings AF cycle length was lower with both the verapamil and the
verapamil/propafenone infusions than placebo in the first 24-hours (p =
0.02). In contrast to previous findings the AF cycle length remained on
average lower than placebo with both the verapamil and verapamil/
propafenone infusions for the entire 120-hour period of burst pacing
(Figure 4.8). Propafenone alone caused a non-significant increase in AF
cycle length compared to placebo over the 120-hour period (Figure 4.9).
The effectiveness of propafenone on the non-remodelled atrium
Further analysis of the data shows that the effects of propafenone are more
noticeable on the non-remodelled atria. Over the full 5-day period there
are no significant differences in atrial refractoriness or AF cycle length for
the infusions containing propafenone either alone or in combination with
verapamil. However, atrial refractoriness shows a trend to being longer
prior to commencing burst pacing with verapamil/ propafenone infusion
compared with verapamil alone (p = 0.08). With propafenone alone
compared to placebo atrial refractoriness is not only shows this trend at
baseline prior to commencing burst pacing but also shows a trend to
remains longer than placebo (p = 0.068) over the initial 48-hours of
infusions. Atrial refractoriness could not be measured during AF so AF
cycle length was used as a surrogate for atrial refractoriness. AF cycle
length showed a similar pattern with a significant prolongation of AF cycle
length in the first 72-hours of the verapamil/ propafenone infusion
compared to verapamil alone (p = 0.043). In fact in the first 72-hours AF
cycle length is not significantly different between the placebo and
verapamil/ propafenone infusions (p = 0.34, Figure 4.8). This analysis of
AF cycle length was not possible for propafenone compared to placebo as
one goat had no AF and the numbers were too small. It is worth noting that
despite the favourable early effects of propafenone on atrial refractoriness
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and AF cycle length there was no difference in the durations of induced
episodes of AF with the verapamil/propafenone infusion compared to
verapamil alone during the initial 24-48 hours of burst pacing.
Propafenone alone resulted in a trend to less AF than with placebo, but due

















0 24 48 72 96 120
Duration of burst pacing (hours)
Figure 4.6 Duration of induced episodes of AF plotted
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Figure 4.7 Duration of induced episodes of AF plotted
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Figure 4.8 Changes in atrial fibrillation cycle length (AFCL) with burst
pacing. The mean AFCL with the verapamil infusion is significantly less
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Figure 4.9 Changes in atrial fibrillation cycle length (AFCL) with burst
pacing. The mean AFCL with the propafenone infusion is not significantly
different from placebo over the 120-hour period (P = NS). ms- milliseconds
Effect of verapamil on ventricular cycle length during AF
Ventricular cycle length during AF was longer in the
verapamil/propafenone arm (685±72ms) than in the verapamil arm
(615±53ms) and both were significantly longer than the ventricular cycle
length in the placebo arm (413±86ms, p < 0.01) throughout the 5-day
pacing period, confirming the effects of the drugs on AV nodal conduction




Main findings of the study
The main finding of this study is that propafenone does not prevent the
profibrillatory action of verapamil. Propafenone, in the absence of
verapamil, reduced the durations of induced episodes of AF compared to
placebo. Changes in atrial refractoriness at baseline confirm a significant
electrophysiological action of propafenone at the dosage studied. The
results also confirm previous findings that verapamil inhibits the reduction
in atrial refractoriness (atrial electrical remodelling) associated with a 5-
day period of AF, but that the effects on remodelling are outweighed by its
profibrillatory actions with the net effect of an increase in the self-
perpetuation of AF in the goat model. Verapamil causes a reduction in AF
cycle length that is not prevented by propafenone.
Why did propafenone not prevent the profibrillatory action of verapamil?
Duytschaever and colleagues found that during episodes of induced AF in
the goat verapamil caused a reduction in atrial refractoriness resulting in a
reduction in the atrial wavelength.31 Verapamil has also been shown to
cause a reduction in AF cycle length and action potential duration in
patients with chronic AF.36 Propafenone might be expected to be effective
in preventing or reducing this profibrillatory action of verapamil as it
exerts a marked use-dependent prolongation of atrial refractoriness, and
can cardiovert AF by prolongation of the atrial wavelength.41'51 In our
study there was evidence for an initial propafenone-mediated prolongation
of atrial refractoriness at a pacing cycle length of 400ms. However,
following a period of atrial electrical remodelling (24-48 hours) the
refractory period lengthening effect of propafenone was lost (Figure 4.4
and 4.5). This was also evident for the effect of propafenone on AF cycle
length, which was significantly longer with the combination of
verapamil/propafenone in the first 72-hours of burst pacing than with
verapamil alone. However, despite effects on atrial refractoriness, both at
400ms and during AF, propafenone did not prevent AF when used in
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combination with verapamil even early in the protocol. On its own
propafenone had some antifibrillatory effect, which would likely have
been significant with an increased number of animals.
This raises two issues. Firstly propafenone loses its effect on atrial
electrophysiology as remodelling progresses. It is possible that
remodelling induced changes in ion channels occur altering the effect of
propafenone. For instance, a reduction in sodium channels during atrial
electrical remodelling has been described.54 A possible explanation for the
absence of a significant effect of propafenone on AF stability is the lack of
a significant electrophysiological effect on the remodelled goat atrium.
**** Although there is no previous data on the use of propafenone in
goats, the electrophysiological effects of flecainide55 on remodelled goat
atria have been previously examined. Flecainide had no effect on the
refractory period during AF and because of a reduction in conduction
velocity the wavelength in AF was in fact reduced. Despite this flecainide
was effective in converting AF to sinus rhythm. Propafenone also reduces
atrial conduction velocity during AF and it is possible that any beneficial
effects of a prolongation in atrial refractoriness during AF (if this occurs)
may have been negated by a reduction in atrial conduction velocity.
Second, propafenone alone has an antifibrillatory action but not in
combination with verapamil. This suggests that the profibrillatory action
of verapamil is not mediated via changes in atrial electrophysiology that
can be influenced by propafenone e.g. atrial refractoriness during AF. An
alternative mechanism for the profibrillatory action of verapamil may be
the creation of local conduction disturbances, promoting re-entry.
Evidence for this hypothesis is the marked increase in fragmentation of
atrial electrograms that have been noted with verapamil both in sinus
rhythm17 and in AF.31 Changes in local conduction with increased
fragmentation of wavefronts may underlie the epicardial mapping findings
of AF in the presence of verapamil, which show an increase in the number
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of zones of reactivation suggesting an increase in multiple wavelet
reentry.35
The relevance of propafenone's beta-blocking action
11
Friedman et al suggested that verapamil promoted AF stability by
causing a significant sympathetic response that could be prevented by
metoprolol. However, unopposed sympathetic stimulation has not
previously been shown to promote AF stability in dogs.34 Propafenone has
beta-blocking activity that may have resulted in a reduction of AF stability
but this was not found. The longer ventricular cycle length with verapamil
and propafenone combination compared to verapamil alone (685±72ms v
615±53ms) suggests the presence of some beta-blocking effect in the
study.
Possible explanations of the clinical benefit of verapamil and propafenone
The beneficial clinical effect of the verapamil and propafenone in
preventing recurrence of AF following cardioversion found by De Simone
et al29 may have been secondary to an effect of verapamil on atrial ectopy
(triggers) rather than atrial electrical remodelling (substrate). Increased
intracellular calcium levels increase spontaneous tachyarrhythmias in
cardiac muscle56 and by blocking calcium entry into cells verapamil
reduces atrial ectopy following cardioversion of persistent AF.30 During
our study protocol the trigger for AF remained constant as AF was
continually reinduced by burst pacing. This would have negated any
beneficial effects of verapamil on AF triggers.
Limitations of the study
The assessment of the ongoing electrophysiological processes involved in
the profibrillatory action of verapamil and the lack of effect of
propafenone are limited to measurement of AERP, AF cycle length and
AF duration. Insights into possible mechanisms underlying the findings of
this study may have been possible with measurements of conduction
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velocity or of atrial refractoriness during AF itself. Mapping of atrial
activation was not performed and consequently the effect of the drugs on
the number and organisation of reentrant wavelets could not be
determined.
Novel aspects and clinical implications.
The results indicate that the combination of verapamil and propafenone is
not likely to be of any value in halting the clinical progression of
paroxysmal to persistent AF and may in fact accelerate this process.
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Repetitive Four-Week Periods of Atrial
Electrical Remodelling Promote Stability
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Evidence for a second factor independent of atrial
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Background Episodes of atrial fibrillation (AF) are known to cause both
a rapid reduction in atrial refractoriness (atrial electrical remodelling) and
a more delayed increase in AF stability in the chronic goat model. The
aims of this study were to examine (1) the hypothesis that an AF-induced
increase in AF stability might be due to a mechanism with a longer onset
and offset than changes in atrial refractoriness and (2) the possibility that
repeated periods of maintained AF might cause a cumulative increase in
AF stability independent of changes in atrial refractoriness.
Methods and Results AF was maintained in six goats by burst atrial
pacing for three consecutive 4-week periods, each separated from each
other by a mean of 6±2.1 days of sinus rhythm. Six days of sinus rhythm
was just sufficient for refractoriness changes to fully reverse in all goats.
Assessments of atrial effective refractory period (AERP), AF cycle length,
AF inducibility and duration of individual episodes of AF were made at
regular intervals. The mean duration of burst pacing required to induce
individual episodes ofAF of 60-seconds, 1-hour and 24-hours duration
decreased progressively from month 1 to month 2 to month 3 (178 hours,
110 hours and 21 hours; 229 hours, 136 hours and 68 hours; 277 hours,
192 hours and 102 hours respectively, p < 0.03). The frequency with
which AF was induced during extrastimulus pacing increased
progressively from 16.7% in month 1, to 31.7% in month 2 and 46.9% in
month 3 (p < 0.001).
Conclusions Sequential 4-week periods of atrial fibrillation result in an
increase in AF stability independent of baseline atrial refractory period.
This suggests the presence of a 'second factor' in the self-perpetuation of
AF with a longer time course than changes in atrial refractoriness.
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Introduction
Atrial fibrillation has a tendency to become more persistent with time and
a large percentage of patients with paroxysmal AF develop persistent
AF.1'2 In an experimental study3 Wijffels and coworkers demonstrated, in
a chronically instrumented conscious goat model, that episodes of AF are
self-perpetuating ("AF begets AF"). This self-perpetuating process is
accompanied by a reduction in atrial refractoriness (termed atrial electrical
remodelling), and there are good theoretical reasons to believe that such an
electrophysiological change would lead to the stabilisation of AF.4 The
concept of atrial electrical remodelling has since become widely accepted
and its presence has been confirmed in different models by a number of
groups.5"7
Changes in atrial refractoriness, however, may not be the only factor
responsible for the onset of stable AF.8 Wijffels and others3'9 have found
that changes in atrial refractoriness do not run in parallel with the time
course of onset of stable AF. Atrial refractoriness falls rapidly in the first
few days of AF reinduction and maximal changes in atrial refractoriness
often precede the onset of stable AF by several days. A role for factors
other than atrial electrical remodelling in the recurrence of AF following
cardioversion in patients has also been suggested. Some patients with
previous prolonged episodes of AF continue to show persistently increased
vulnerability to AF despite long periods of sinus rhythm between
episodes.10
Using the original Allessie chronically instrumented goat model Garratt
and coworkers11 studied repetitive 5-day periods of AF reinduction to
examine the hypothesis that an AF-induced increase in AF stability might
be due to a mechanism (a so-called second factor) with a longer time
course than that of changes in atrial refractoriness. If this were the case,
then it would be expected that the increase in AF vulnerability and
stability that is evident following a period of AF would remain for a longer
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time than that required for atrial refractoriness to return to normal. A
second aim of the study was to examine the possibility that repeated
episodes of AF result in a cumulative increase in AF inducibility or
stability independent of changes in atrial refractoriness. This would
provide a potential means whereby recurrent paroxysms of AF might
progress to persistent AF despite full reversal of refractoriness changes
between successive paroxysms. No progressive increase in AF
inducibility, vulnerability or stability was demonstrable in this study,
indicating either that a second factor did not exist or had a longer onset
than the 5 days selected in the protocol.12 The aim of the current study was
to retest the above hypotheses using 4-week periods of AF. This duration
of AF was chosen because it has been shown that AF of this duration leads
to ultrastructural changes in atrial myocardium.13
Methods
Six adult female goats (mean weight 60.5 ± 10 kg) were used in the study.
The experiments were conducted in accordance with the project license
issued by the United Kingdom Home Office under the Animals (Scientific
Procedures) Act 1986. The animals were allowed free access to food and
water and were unrestrained in their pens throughout the experiments.
A fully implantable burst pacing model of AF
Currently available implantable pacemaker-based animal models of AF
use rapid atrial pacing rather than continuous reinduction of AF to induce
atrial electrical remodeling. As a consequence the effect of the remodeling
process on AF stability (duration of individual episodes of AF) cannot be
measured continuously. We developed a modified pacemaker-based model
of AF in which the original Allessie burst pacing protocol is incorporated,
thereby allowing continuous monitoring/recording of the self perpetuating




Anaesthesia was induced and maintained using 3% Isoflurane and a 2:1
mixture of O2 and N2O. The animals were placed in the left lateral position
and 1 gram of flucloxacillin was given intravenously. Using aseptic
surgical technique an incision was made in the lateral aspect of the neck
exposing the right internal jugular vein. The vein was mobilised and
ligated and three active-fixation bipolar steroid eluting leads introduced
via a small venotomy and positioned on the septal portion of the right
atrium (2 leads) and right ventricular apex (1 lead). Sensing and threshold
characteristics were determined before connecting one atrial lead to an
Intermedics pacemaker and the remaining leads to the atrial and ventricular
channels of a Medtronic Thera® pacemaker. The leads were secured and
pacemakers buried subcutaneously prior to wound closure. An ECG
telemetry unit (Data Sciences Inc) was buried subcutaneously in the right
flank through a further small incision.
Study protocol
After pacemaker implant the animals were allowed to recover for at least 5
days. The animals then commenced repetitive reinduction of AF for the
first 4-week period. Specifically designed software in the Medtronic
pacemaker was used to deliver burst pacing during sinus rhythm via the
right atrial lead in a manner similar to that in the originally described
Allessie goat model. Whenever sinus rhythm was detected the pacemaker
delivered a 2 second burst of pacing at 64 Hz. Burst pacing was inhibited
whenever AF was detected. During this period measurements were made
of AERP, inducibility of AF by extrastimulus pacing, AF stability, AF
cycle length and ventricular cycle length at t = 0, 4, 8, 12, and 24 hours,
then twice daily until 120 hours and then every 24 hours until the end of
the 4-week protocol. At the end of the 4-weeks the goats were DC
cardioverted under general anaesthesia. Thereafter AERP was measured
daily until it recovered to baseline. When AERP reached baseline
repetitive reinduction of AF was commenced for the second 4-week
130
period. At the end of the second 4-week period the goat was again DC
cardioverted and AERP measured daily until recovery, prior to
commencing the third period of AF reinduction. After the third 4-week
period the goat was DC cardioverted and AERP measured daily until
recovery (Figure 5.1).






4-weeks maintained AF SR 4-weeks maintained AF SR 4-weeks maintained AF SR
Figure 5.1 The Study Protocol. AF - atrial fibrillation, SR - sinus rhythm
Measurement of refractory periods and AF cycle length
The Intermedics pacemaker was used to deliver extra stimulus pacing via
the external programmer to determine atrial effective refractory periods
(AERP) during a basic pacing drive of 400ms. A standard drive train of 8
extrastimuli (Si) was followed by a single S2, all at four times diastolic
threshold. The initial S1-S2 coupling interval was commenced at a shorter
interval than the expected AERP and increased incrementally until atrial
capture was achieved. The AERP was recorded as the mean of the two
longest S1-S2 that failed to capture the atrium. The time course of
remodelling was calculated using the logarithmic function x = (AERP. -
AERPt-o) / ln(t), where t is time, In is natural logarithm, and x is the time
constant of remodelling.14 To determine AFCL we recorded 10-second
segments ofbipolar atrial electrogram at 100 mm/s via telemetry from the
atrial lead in the Thera pacemaker. Two independent observers then
calculated mean AFCL and these two values were averaged.
Inducibility of AF
At the time of measurement of AERP, the presence or absence of AF
induced as a response to the earliest extrastimulus was recorded at each
pacing rate. AF was considered to be induced if the single premature
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response was followed by rapid irregular atrial activity lasting > 1 second
on at least 2 of 3 attempts.
Duration of induced AF
The duration of induced episodes of AF was determined using 1) direct
telemetry of the endocardial atrial signal via the pacemaker programmer
and from 2) the surface ECG telemetered via the Datasciences implant
which was continuously displayed and recorded on a personnel computer.
In addition the Thera software recorded a log of time and cumulative
number of bursts delivered.
Statistical analysis
Data analysis was performed using the statistical package SPSS version
8.0. Data were expressed as mean ± standard deviation. Paired data were
analysed using a paired t-test for parametric data and Wilcoxon Log Rank
test for non-parametric data. Analysis of serial measures was performed by
converting the data to a single measure (area under the curve).15 The
logarithm of non-normally distributed data was used to transform data to a
normal distribution for analysis by ANOVA. A two tailed p value of less
than or equal to 0.05 was taken as significant.
Results
Stability of AF
All 6 goats successfully completed the protocol. The stability of AF
increased with time over each 4-week period of burst pacing in each goat.
Despite a wide variation in the onset of AF stability in individual goats
there was evidence of a progressive increase in AF stability from month 1
to month 2 to month 3 in all the goats (Figure 5.2). There was a
progressive reduction from month 1 to month 2 to month 3 in the mean
duration of burst pacing required to induce individual episodes of AF of 1-
second (65 hours, 23 hours and 1.5 hours), 10-seconds (103 hours, 83
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hours and 4 hours), 60-seconds (178 hours, 110 hours and 21 hours), 1-
hour (229 hours, 136 hours and 68 hours), 6-hours (258 hours, 176 hours
and 87 hours) and 24-hours duration (277 hours, 192 hours and 102 hours,
p < 0.03). There was considerable inter-goat variability in the onset of AF
stability as illustrated in Figure 5.3.
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Figure 5.2 Changes in mean duration of burst pacing required to induce atrial
fibrillation (AF) episodes. Results are expressed as mean of values obtained in all
goats. From month-1 to month-3 there is a progressive decrease in the duration of
burst pacing required to induce all of the pre-specified AF durations (indicated
on the y-axis). The P value refers to ANOVA of area under each curve.15
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Figure 5.3 Variability in the onset of AF stability in the 6 goats.
Note the different scales on the x-axis on for each goat.
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Inducibility of AF
AF inducibility was assessed during extrastimulus pacing at the time of
measurement of atrial effective refractory period. The frequency with
which AF was induced during extrastimulus pacing increased
progressively from 16.7% in month 1, to 31.7% in month 2 and 46.9% in
month 3 (p < 0.001). Episodes of AF of greater than 1-second duration
were inducible by burst pacing at baseline at the start of month 3, in
contrast to months 1 and 2.
Atrial Refractoriness
Atrial electrical remodelling (defined as a reduction in atrial refractoriness
measured during a 400ms drive) occurred in all 6 goats in the study.
Measurement of atrial refractoriness was possible in all the goats during
the first 12 hours ofmaintained AF. As the duration of AF episodes
became more sustained over time the opportunity to measure atrial
refractory periods became fewer. In month 1 this was possible in 6/6 goats
at 24 hours, 6/6 goats at 32 hours, 6/6 goats at 72 hours, 4/6 at 120 hours
and 2/6 at 10 days. In month 2 in 6/6 goats at 24 hours, 6/6 goats at 32
hours, 4/6 goats at 72 hours, 3/6 at 120 hours and 1/6 at 10 days. In month
3 in 5/6 goats at 24 hours, 5/6 goats at 32 hours, 2/6 goats at 72 hours, 1/6
at 120 hours and 0/6 at 10 days. Refractory period measurements during
the three successive 4-week periods of maintained AF are shown in Figure
5.4. There was a trend to more rapid time course of remodelling (t) during
the first 32 hours of burst pacing from a mean of 5.3 in month-1, to 9.1 in
month-2 and 14.9 in month-3 (p = 0.07). Following both the first and
second periods of AF atrial refractoriness had returned to baseline values
(± 5%) after 6 days of sinus rhythm in all 6 goats. The mean time required
for AERP to return to baseline was 144 ± 55 hours. The mean time
required for AERP to return to normal did not change over the three one-
month periods (month-1 144 hours, month-2 156 hours and month-3 132
hours, p = 0.78). The variability between goats of changes in AERP is
shown in Figure 5.5.
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Atrial Fibrillation Cycle Length
The shortening of atrial refractoriness was accompanied by a reduction in
mean AF cycle length in all goats (Figure 5.6). There was no evidence of a
cumulative effect of the episodes of maintained AF on the AF cycle length
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Figure 5.4 Changes in right atrial refractoriness measured during a basic pacing cycle length
of 400ms at pre-specified time points throughout the protocol. Results are expressed as mean
of values obtained in all goats. The P value refers to ANOVA of x (the time constant of
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Figure 5.5 Variability in the onset of AERP changes in the 6 goats.
The individual goat numbers are the same as in Figure 5.3. Note the
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Figure 5.6 Changes in atrial fibrillation cycle length (AFCL) at pre-specified time
points throughout the protocol. Results are expressed as mean of values obtained in
all goats, ms - milliseconds.
Mean ventricular rate in AF
The mean ventricular rate in AF remained stable from month 1 to month 3
(393±65ms, 436±50ms, 373±23ms, p = 0.1). The mean sinus cycle length
measured at 24-hours post-cardioversion also remained stable from month




The principal findings of the study are that repetitive periods of maintained
atrial fibrillation have a cumulative effect on AF stability and AF
inducibility independent of changes in baseline atrial refractoriness i.e.
there is a second factor independent of atrial refractoriness involved in the
self-perpetuation of AF. The time course of the onset and offset of action
of this second factor is longer than that of changes in atrial refractoriness.
In this study care was taken to avoid repeated cardiac instrumentation
and/or tissue biopsy, as such procedures would have complicated
interpretation of the sequential measurements of AF stability. As a
consequence of this study design, the question of the precise nature of this
'second factor' remains unresolved.
What is the second factor?
There are several possible candidates for a second factor including
structural changes in the atria such as atrial dilatation, changes in
conduction properties of the atria and changes in the spatial dispersion of
atrial refractoriness.
Structural Changes
Patients with longstanding AF often have dilated atria16 and an increase in
atrial 'area' would be expected to increase AF stability in accordance with
Moe's multiple wavelet hypothesis.17 Although previous experimental
work in dogs has shown biatrial enlargement following a 6-week period of
rapid atrial pacing,6 patients with brief (<2 weeks) or moderate (2-6
weeks) durations of AF do not have a measurable increase in left atrial
size.18 Several weeks of AF in the goat model causes structural changes in
atrial myocytes that may predispose to atrial dilatation including loss of
myofibrils and fragmentation of the sarcoplasmic reticulum.19 These
13
myolytic cell changes increase between weeks 1 and 8 of maintained AF
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and have been shown to correlate with the stabilisation of AF.20 Following
a 16-week period of AF structural changes are still present 8-weeks
following return to sinus rhythm,21 and in association with the persistence
of these structural changes the atria remain vulnerable to AF. Structural
changes resulting in increased atrial vulnerability to AF have also been
shown in other models. Using a combined rapid atrial pacing / mitral
regurgitation model of AF Everett and coworkers22 have shown a
differential time course of reversal of electrophysiological remodelling and
structural remodelling in the dog.
Interstitial changes promoting vulnerability to AF have also been shown in
the canine pacing-induced heart failure model of AF. In this model AF
• • • • •
vulnerability is increased without alterations in atrial electrophysiology,
the likely underlying mechanism being the presence of extensive
interstitial fibrosis resulting in discrete areas of slow atrial conduction. The
difference between the original findings of Garratt and coworkers11 using
repetitive 5-day periods of maintained AF compared to the 4-weeks used
in our study may be due to an increase in structural changes associated
with the longer duration of maintained AF.
Dispersion of Atrial Refractoriness
The increased stability of AF during months 2 and 3 of maintained AF
may have occurred due to a persistent increase in dispersion of atrial
refractoriness. Regional variability of atrial refractoriness was
demonstrated to be essential for the generation of AF in the classic
computer model of Moe et al.4 Previous studies in the goat, however, have
not found any AF-induced changes in dispersion of atrial refractoriness.3
In addition, following restoration of sinus rhythm recovery of atrial
refractoriness occurs at the same rate in the left and right atria,11 and
dispersion of atrial refractoriness has even shown a trend to decrease
following 24-hours of rapid atrial pacing in the goat model.24
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The findings in dog models have been somewhat different. Chronic atrial
pacing results in an increase in dispersion of AF cycle length9 and an
increase in dispersion of atrial refractoriness.25'26 This increase in
• • 25refractoriness heterogeneity increases vulnerability to AF. Following
restoration of sinus rhythm recovery of dispersion of atrial refractoriness is
27
relatively rapid returning to control values within 20 hours.
Significant dispersion of right atrial refractoriness is present following
cardioversion ofpersistent AF in humans, and an increased dispersion of
atrial fibrillation cycle length at the time of cardioversion of persistent AF
29has been shown to be associated with an increased risk of recurrent AF.
Patients with lone paroxysmal AF have an enhanced vulnerability to AF,
despite long periods of sinus rhythm, and this has been linked to an
increased dispersion of atrial refractoriness, as determined by
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measurement of local atrial fibrillation cycle length. Despite variable
evidence from animal models dispersion of atrial refractoriness does
appear to be an important factor in the onset of stable AF in patients with
both paroxysmal and persistent AF.
Conduction Velocity
A reduction in atrial refractoriness promotes stability of AF by reducing
atrial wavelength. Similarly a reduction in conduction velocity would
result in a reduction in atrial wavelength so increasing AF stability.17
Patients with chronic AF have been shown to have a reduced atrial
conduction velocity31,32 and an increased P-wave duration31'32 immediately
post-cardioversion. However, no changes in conduction velocity have been
noted in the goat model of AF.3'11 Studies in dog models of AF have
shown a reduction in conduction velocity,9'26'33 and an associated decrease
in sodium current (Da) in atrial myocytes, with AF duration being related
to Da density in each dog.34 Changes in conduction velocity have been
Q 9 f\
shown to have a longer time course of onset ' than changes in atrial
refractoriness, and a link between the onset of AF stability and changes in
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conduction velocity has previously been suggested.9 The recovery of
conduction velocity to control values following conversion of AF to sinus
rhythm also appears to be more prolonged than recovery of atrial
refractoriness both in dogs26 and in humans.32
Cellular Mechanisms
The time course of onset and offset of atrial electrical remodelling (i.e.
days) suggests that processes involving altered gene expression of ion
channel proteins may be involved. Several recent studies have shown
changes in atrial ionic currents, protein expression and mRNA. There is
good evidence from both animals and humans that the reduction in atrial
refractoriness associated with atrial electrical remodelling is associated
with a reduced L-type Ca2+ current (Ic3 l) density of about 70% and a
reduction in the Ca2+-independent transient outward current (L).35'36
Changes in mRNA levels for the alphas subunit of the L-type Ca2+ channel
for Kv 4.3 (the putative gene for L>) and in the expression of the channel
proteins have also been described. ' It is possible that despite recovery
of atrial refractoriness to control values, mRNA and protein levels of the
2+
L-type Ca channel remain lower than in the control situation so
promoting a more rapid onset of atrial electrical remodelling when AF is
again maintained. The earlier fall in atrial refractoriness during the second
and third periods ofmaintained AF in the current study might suggest this
as a possible explanation.
Connexins
Changes in intercellular conduction caused by altered expression or
distribution of connexins and the resultant possible microheterogeneities in
atrial conduction could promote AF stability. Expression of connexin 43
• • 7 39
(Cx43) has variably been reported to be increased or unchanged in
animal models of AF. Changes in connexin 40 (Cx40) distribution39 and
reduced levels of Cx40 protein expression20 have consistently been shown
in the goat model of AF. An important role for Cx40 is suggested by the
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finding that Cx40 deficient mice have reduced atrial conduction velocity
and are prone to atrial tachyarrhythmias.40 A period of 2-4 weeks of
maintained AF is required to generate significant inhomogeneities of Cx40
distribution in the goat model and these changes are correlated with the
onset of stable AF.20 Gap junction remodelling has a slower onset than
changes in atrial refractoriness but no data are yet available on recovery of
gap junction remodelling.
Clinical evidence for the efficacy of early DC cardioversion of AF
The findings from our study suggest that a longer duration of AF prior to
cardioversion (4-weeks rather than 5-days as studied by Garratt et aln)
results in changes in the atria that promote the stability of AF. There have
been no clinical studies designed specifically to assess the merits of early
DC cardioversion from an electrophysiological standpoint, but there have
been studies looking at the safety of early cardioversion of AF using
transoesophageal echocardiography (TOE). The advent of TOE to reliably
exclude atrial thrombus has created interest in an alternative policy of
immediate cardioversion of AF persisting for >48 hours without the need
for the 3-week period of anticoagulation as currently recommended by the
American College of Chest Physicians.41 The studies performed have
primarily focused on the safety of such a regime but have also provided
some insight into the issue of whether earlier cardioversion using this
rationale results in improved maintenance of sinus rhythm. Olsson's group
found a clear benefit in the maintenance of sinus rhythm from a TOE
guided early cardioversion approach 42 In this study TOE was used to
select patients for immediate cardioversion when atrial thrombus was
excluded, there was no spontaneous echo contrast and the left atrial
appendage outflow velocity was > 0.25ms"1. Patients with atrial thrombus,
spontaneous echo contrast or a reduced left atrial appendage outflow
velocity were commenced on warfarin and had cardioversion performed
following 3-weeks of anticoagulation. The majority of patients (162 of
242, 66%) had immediate cardioversion. This group of patients had an
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improved rate of sinus rhythm at 1-month post-cardioversion compared to
the 80 patients with conventional anticoagulation for 3-weeks followed by
cardioversion (75% v 45%, p < 0.01). However, the patients with
immediate cardioversion had significant clinical differences to the delayed
cardioversion group, with a lower age (62 v 67 years, p < 0.05) and less
structural heart disease (31% v 45%, p < 0.05). Specifically left atrial size
was lower (44 v 47mm, p < 0.01) and ejection fraction higher in the
immediate cardioversion group. The arrhythmia pattern was also
significantly different between the groups with more atrial flutter and first
presentation AF in the immediate cardioversion group. Although providing
encouraging results for the policy of TOE guided cardioversion in
maintaining sinus rhythm the significant differences in clinical variables
between the two groups does not allow any firm conclusions to be drawn.
The recently published ACUTE study (The Assessment of Cardioversion
Using Transoesophageal Echocardiography)43 has given us further insights
into the role of early TOE guided cardioversion in AF. The most
significant finding was that TOE guided cardioversion was as safe as
cardioversion preceded by 3-weeks of oral anticoagulation in terms of the
risk of thrombo-embolism and death. An important aspect of the study is
that all patients had therapeutic anticoagulation with heparin at the time of
the TOE guided cardioversion and this was followed by a month of oral
anticoagulation. In this study the maintenance of sinus rhythm 8-weeks
post-randomisation was similar in both groups (52.7% v 50.4%, p = 0.43)
and the two groups were well matched for all clinical variables. This result
suggests that the findings of Olsson's group42 of higher rates of sinus
rhythm may well have been due to the difference in clinical variables
between the two groups rather than any meaningful effect of early
cardioversion.
It is worth questioning why the ACUTE study43 failed to show any benefit
in maintenance of sinus rhythm from the TOE guided cardioversion
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approach. In looking more closely at the results, the randomization of
patients did not create a group with exclusively short durations of AF (i.e.
< 3-weeks). In fact a large number of patients in the immediate TOE
guided arm had relatively long durations of AF prior to cardioversion. The
median duration of AF at the time of enrollment into the study was 13-
days (range 4-48 days), and the mean duration of anticoagulation prior to
TOE guided cardioversion was 2.3-days for in-patients and 4.3-days for
outpatients. These durations of AF may well have been too long to show
any clear benefit in the maintenance of sinus rhythm. Further analysis of
this data would be of interest.
The most compelling evidence for the efficacy of early cardioversion in
maintaining sinus rhythm comes from Weigner et al.44 In a two centre
study patients with AF >48 hours or of unknown duration underwent TOE
guided cardioversion over a 9-year period. Of 539 eligible patients a total
of 413 were cardioverted as per protocol (70, 13.1%, were excluded due to
left atrial thrombi). In those patients for whom the preceding duration of
AF was <3-weeks there was a significantly higher rate of sinus rhythm at
1-year compared to patients with AF durations >3-weeks (65.8% v 44.7%,
p < 0.01). There was also a significant reduction in recurrent AF (49.2% v
66.3%, p = 0.01). Patients with AF of unknown duration were excluded
from this analysis. The two groups were well matched for clinical
variables including age, left atrial size and left ventricular function. The
mean durations of AF prior to cardioversion were significantly different at
1.1±1.1 weeks v 4.7±6.9 weeks, p < 0.001. As can be seen from the graph
on the following page the majority of the advantage in maintenance of
sinus rhythm was in a reduction in recurrent AF in the first 4-weeks
following cardioversion. This reduction in AF recurrence is clinically
meaningful as over 60% of the patients in this study had an AF duration of
< 3-weeks.
143
0 "i 1 1 1 p 1 1 i 1 r 1 1 i
4 8 12 16 20 24 28 32 36 40 44 48 52
Weeks post-CV
Figure 5.7 Freedom of atrial fibrillation recurrence following cardioversion was
significantly (P <0.01) greater among patients who were in atrial fibrillation for
<3 weeks. From Weigner et al. Am J Med 2001; 1J0:694-702.
Clinical Implications
The sustained increase in AF stability and vulnerability following a 4-
week period of maintained AF as distinct from a 5-day period of
maintained AF suggests that early DC cardioversion of persistent AF may
be beneficial in suppressing AF recurrence post cardioversion. These
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6.1 Atrial Ectopy as a Trigger for Atrial Fibrillation
- a review
6.2 The Coupling Interval of Atrial Premature Beats
Following DC Cardioversion of Persistent AF
Predicts Subsequent Recurrence of AF
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Atrial Ectopy as a Trigger for Atrial Fibrillation
The first ECG recording showing an atrial premature beat (APB)
triggering the onset of AF was published in 1918.1 Widespread acceptance
that episodes of AF were triggered by APBs was gained in the 1970s
following the surface ECG recordings made by Killip et al illustrating the
mechanism of recurrence of AF following DC cardioversion and the
intracardiac recordings of Bennett and Pentecost3 from patients with atrial
arrhythmias following myocardial infarction.
Flolter recordings from healthy volunteers indicate that APBs occur in
slightly more than 50% of people but that frequent APBs (>100/hr) occur
in only a small subset of the population.4'5 Even long distance runners have
APBs, but again frequent APBs (>100/hr) were found infrequently.6
Factors which promote atrial ectopy are little understood but of particular
interest to the medical profession is that the number of APBs is increased
in physicians working in the emergency department overnight,7 suggesting
that changes in autonomic tone or sleep deprivation may have a role in
their genesis.
Paroxysmal AF
The frequency of APBs is quite variable between patients and even within
an individual patient. Despite this large variability, an increase in the
numbers of APBs does appear to be associated with AF. Analysis of
Holter data from patients with paroxysmal AF has shown that APB
frequency is increased in the minute prior to the onset of AF.8 Using a 12-
lead Holter system other authors have found that in addition to an increase
in APB frequency in the minute prior to the onset of paroxysmal AF, the
APBs resulting in AF initiation were consistently monomorphic in about
70% of patients and predominately (77%) from the left atrium.9 Prior to
coronary artery bypass grafting (CABG) an increased burden of APBs
(>10/hr) on a pre-operative Holter is associated with a higher likelihood of
developing AF following bypass surgery11 and data following CABG has
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shown an increase in the frequency of APBs and episodes of non-sustained
AF in the hours preceding the onset of sustained AF.10
The frequency of APBs is clearly important in AF initiation but what
particular features of one APB result in AF initiation? The more closely
coupled an APB is to the previous sinus beat, the more likely it will be to
encounter areas of atrial refractoriness resulting in wavefront splitting and
the initiation of AF. Bennett and Pentecost3 showed that APBs resulting in
initiation of AF had a significantly shorter coupling interval than those that
did not. The role of APBs with a short coupling interval in AF initiation
was also highlighted by Capucci et al12 in the initiation of paroxysmal AF
and by Frost et al13 in the initiation of AF in patients following bypass
surgery. More recently the average coupling interval of APBs in the
minute prior to the onset of paroxysmal AF has been shown to be shorter
than at times of sinus rhythm remote from AF onset.14 A subset of the
patients in this study exhibited large numbers of APBs with similar
coupling intervals in the immediate period prior to the onset of AF,
suggesting a common underlying (focal) source.
Persistent AF
One of the most important clinical problems related to APBs is their role
as a trigger responsible for the recurrence of persistent AF following DC
cardioversion. Even with the best medical treatment and serial
cardioversions only 42% of patients remain in sinus rhythm a year
following cardioversion, and this falls to 17% at 4 years.15 The timing of
AF recurrence can be grouped into 3 important stages. First is the initial
few minutes following cardioversion when the atria are especially
vulnerable to AF. Second is the period of several days to a week during
which the atria are recovering from atrial electrical remodelling when they
remain vulnerable to a critically timed APB. Third is the period of late
recurrence (> 1-week) and factors important in AF recurrence at this stage
are less well understood.
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Several studies from the electrophysiology laboratory have shown that
APBs with a short coupling interval are responsible for the immediate
(within 2-minutes) reinitiation of AF following cardioversion.16"19 There is
much less data, however, on the importance of short-coupled APBs
occurring immediately after cardioversion in recurrences of AF after
leaving the catheter laboratory. One study found the timing of AF
recurrence in the month following cardioversion to be linked to the
shortest coupling interval of APBs recorded by a continuous 12-lead
20surface ECG in the first 2-minutes following cardioversion. This study
showed that patients with short-coupled APBs tended to have earlier
recurrence than those with longer coupled APBs, however the likelihood
of AF recurrence was not predicted by either the coupling intervals of
APBs or the number of APBs.20 In general the number of APBs following
cardioversion has not been found to be a strong predictor of AF
recurrence, although one study did find a relationship between APB
frequency and an increased risk of AF recurrence. In this study Holter
monitoring in the first 24-hours following cardioversion of a broad cross-
section of AF patients, similar to that found in the UK, found an APB
frequency of >10/hour to be associated with an increased risk of AF
21
recurrence over the subsequent year.
Evidence from drug treatment
Although traditionally used to alter the substrate for AF recurrence,
antiarrhythmic drugs in the peri-cardioversion period also reduce the
frequency of APBs (triggers) and the incidence of early relapse into
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AF. ' ' " A range of agents have been used including procainamide,
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propafenone, sotalol, ' and amiodarone. The calcium channel blocker
verapamil has also been shown to reduce the frequency of APBs following
cardioversion of AF25 and both it and propranolol suppress ectopic beats
originating from the pulmonary veins. The ability of antiarrhythmic
drugs to suppress APBs or pulmonary vein ectopy does not seem to be
Vaughan-Williams class dependent. It is possible that the different drugs
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suppress ectopy in various ways. For instance, Class I and III agents may
increase atrial refractoriness resulting in short coupled APBs being unable
to capture the atrium. Beta-blockers and calcium channel blockers may
reduce cellular early afterdepolarisations, by reducing inward calcium
currents. Interestingly, sotalol not only reduces the frequency of APBs
following cardioversion but also increases the coupling interval18
suggesting an effect on both trigger and substrate, perhaps as a result of a
combination of its beta-blocking and Class III antiarrhythmic effects.
Focal sources
In some patients a common origin for the APBs occurring early after DC
cardioversion and resulting in immediate reinitiation of AF (IRAF) has
been suggested. Frequent APBs with a similar P wave morphology and a
consistent cycle length with less than 10ms variability have been observed
in some patients with ERAF.18 However, other authors have noted the
origin of AF-inducing ectopy to be more variable.26 The difference in
findings may relate to differences in AF aetiology between the studies, the
18
first study including a large number of patients with idiopathic AF and
the second study included only patients with structural heart disease, and
26therefore theoretically more diffuse atrial disease.
The fact that the trigger for recurrent AF might have a 'focal' origin in
some patients led to interest in the use of radiofrequency ablation to reduce
APB frequency and prevent recurrence of AF. Natale and coworkers
published the results of ablation of APBs in patients with persistent AF.27
Patients were selected on the basis of persistent AF, left atrial size <4.5cm,
ejection fraction >45%, and early recurrence of AF (<10 days) clearly
precipitated by frequent APBs following electrical cardioversion. Mapping
and ablation were performed in 48 patients. The origin of the APBs was
the left atrium in 62.5% and the right atrium in 37.5%. After a mean
follow-up of 12 months, 40 of the 48 (83%) patients were in sinus rhythm.
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Targeting triggers of recurrent persistent AF for treatment by
radiofrequency ablation has also been performed by analyzing the pattern
of immediate reinitiation ofAF (IRAF) following DC cardioversion in
patients with lone AF. Lau and colleagues28 located and ablated a focal
source underlying IRAF in 4 of 32 patients (12%) with persistent AF and 5
of 12 patients (42%) with paroxysmal AF. The Bordeaux group have also
reported on the use of radiofrequency ablation to target the reinitiating
triggers for persistent AF.29 Following cardioversion ofpersistent AF,
patients with 'P on T' ectopy had mapping and ablation. A total of 32
pulmonary veins and 2 atrial foci were ablated in 15 patients. At 1-year of
follow-up 60% of patients were in sinus rhythm without drugs. Other
authors have found the electrogram-guided approach disappointing for
patients with persistent AF with only 22% of patients free from AF
following pulmonary vein ablation.30 More recently the success of an
anatomic approach involving isolation of at least 3 of the 4 pulmonary
veins in preventing AF has been reported.31 A total of 251 patients with
paroxysmal (179) and persistent (72) AF were treated by circumferential
radiofrequency ablation around pulmonary venous ostia. Of these, 152
(85%) patients with paroxysmal AF and 49 (68%) with persistent AF were
free from AF at a mean follow-up of 10±5 months. The anatomic approach
appears to be more favourable than electrical mapping of ectopy in
patients with persistent AF, suggesting a more diffuse abnormality of atrial
physiology in persistent AF.
Trigger / Substrate Interplay
The presence of APBs is almost universal yet AF does not occur in
everyone. Insights into the reasons why some people develop AF, and the
mechanism by which some APBs trigger AF is available from previous
experimental work. Premature atrial extrastimuli result in delayed atrial
conduction in normal hearts. The introduction of premature atrial stimuli
in patients with documented previous AF results in significantly more
intra-atrial conduction delay than in control patients.32 An increase in
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dispersion of atrial refractoriness may also promote AF and this has been
shown to occur in association with APBs in patients with a history of AF.
The introduction of extrastimuli during right atrial pacing causes an
increase in dispersion of refractoriness in patients with a history of AF, but
... . . . 33
a reduction in dispersion of refractoriness in control patients. Both
conduction delay and an increase in dispersion of atrial refractoriness
increase the chance of developing AF and these underlying
electrophysiological abnormalities may be the reason for AF onset with
suitable triggers in susceptible patients.
There is also evidence that atrial refractoriness has an important
relationship with triggers in AF onset. Short periods of pacing-induced AF
in patients with normal hearts result in a shortened atrial effective
refractory period (AERP), which is associated with increased AF
inducibility during AERP measurement.34 Inducibility of AF (by atrial
extrastimulus pacing) in animal models of AF is also associated with short
refractory periods. " The use of verapamil to attenuate AF-induced
shortening of the AERP results in a reduction in AF inducibility during
AERP measurement.38'39 The above studies provide evidence of a key
interplay between atrial refractoriness and triggers in the onset of AF, but
all relied on experimentally induced AF to alter substrate and atrial pacing
to act as a trigger.
There is some evidence for a relationship between the timing of
spontaneously occurring APBs and AF onset in patients. Tieleman et al
reported the timing of AF recurrence following DC cardioversion of
persistent AF. The majority of recurrences occurred in the first week
following cardioversion. This was attributed to the persistence of atrial
electrical remodelling at this time.20 In addition these authors reported a
relationship between the shortest coupled APB recorded in the first 2-
minutes following cardioversion and the timing of AF recurrence. They
hypothesised that the reason for this finding was that early following
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cardioversion only short-coupled APBs meet areas of atrial refractoriness,
resulting in wavefront splitting and the genesis of AF, whereas longer
coupled APBs can uniformly excite the atria. Following a period of sinus
rhythm, with associated reversal of atrial electrical remodelling and
prolongation of atrial refractoriness, longer coupled APBs, which initially
met only excitable (remodelled) atrial tissue, now encounter areas of atrial
refractoriness, resulting in AF. It should be emphasised that this link is
only hypothesis.
The onset of AF in clinical practice appears to rely on the presence ofboth
APBs and a suitable substrate. The relationship between APBs and
substrate has not yet been determined, but there is some evidence from
clinical practice that repetitive firing of focal AF sources can, in time,
result in atrial electrical remodelling and the onset ofpersistent AF.40 AF
in turn may also result in an increase in firing from the pulmonary veins as
recently demonstrated experimentally.41 The links between trigger and
substrate continue to be defined and further elucidation of their interplay
may allow greater insight into the mechanism of AF.
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6.2 The Coupling Interval of Atrial Premature Beats Following
DC Cardioversion of Persistent AF Predicts Subsequent
Recurrence of AF
Introduction
Atrial premature beats (APBs) with a critical coupling interval are
important in the recurrence of AF following DC cardioversion of
persistent AF. '27 Internal DC cardioversion42 affords a unique opportunity
to measure the frequency and coupling intervals of APBs following
cardioversion by recording intracardiac electrograms from the right atrium
and coronary sinus. By discontinuing all antiarrhythmic drugs 3-days prior
to cardioversion and performing internal DC cardioversion without general
anaesthesia we were able to study atrial electrophysiology in the
immediate post-cardioversion period without the influence of drugs. We
analysed the frequency and coupling intervals of APBs in the immediate
post-cardioversion period.
Patients with successful cardioversion were classified into two groups
based on duration of sinus rhythm greater than or less than 7-days. The
duration of 7-days was chosen because the majority of AF recurrences
• • • 70
occur during this time period, probably due to the persistence of atrial
70
electrical remodelling, which recovers within a few days following
restoration of sinus rhythm.37'43'44 Because of the persistence of atrial
electrical remodelling in the initial few days following cardioversion it is
more likely that a single critically timed APB, the focus of this study,
would be responsible for AF recurrence. It has been suggested that AF





Sixty-five consecutive patients (mean age 60±10 years, 41 male / 24
female) with chronic atrial fibrillation (n = 62) and atrial flutter (n = 3)
were drawn from a waiting list for transthoracic cardioversion and new
referrals to a tertiary referral clinic for atrial fibrillation. Assessment was
by clinical history, physical examination, routine laboratory and thyroid
function tests, 12 lead ECG, and transthoracic echocardiography. Patients
who met any of the following criteria were excluded from the study:
contraindication to anticoagulation; paroxysmal atrial fibrillation; atrial
fibrillation due to a reversible cause; a history of myocardial infarction or
revascularisation in the previous 6 months. All patients received at least 4
weeks of anticoagulation with warfarin to establish an INR between 2 and
3, and anticoagulation was continued through the time of the procedure.
In those with an INR below 2 at any time in the 4 weeks prior to
cardioversion we performed omniplane transoesophageal
echocardiography under sedation to exclude left atrial thrombus before
cardioversion and the patient received intravenous heparin until the INR
was greater than 2. All anti-arrhythmic medication was discontinued three
days prior to admission, except amiodarone, which was continued in five
patients. Once anti-arrhythmic medication was discontinued it was not
recommenced for the duration of the study. The study protocol was
approved by the local Medical Ethics Committee, and written informed
consent was obtained from all patients.
Internal Cardioversion Protocol
A TADcath model 8010 temporary transvenous defibrillation catheter (110
cm, Cournand Curve, ProCath Corp) was inserted into the coronary sinus
through the right internal jugular vein. This is an 11-electrode catheter, 2
electrodes being used for bipolar pacing/sensing and 9 comprising the
defibrillation electrode. A second defibrillation catheter was placed in the
right atrium through the right femoral vein, with the tip in the right atrial
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appendage and positioned so that the majority of the catheter electrodes
had contact with the right atrial free wall. A 6-French quadripolar catheter
(Daig Corp., MN, USA) was positioned at the right ventricular apex to
allow synchronisation of the defibrillation shock, appropriate
synchronisation being confirmed with a Defibrillation Systems Analyser
(DSA, InControl). Immediately before shock delivery, 2 to 12 mg of
midazolam was administered intravenously to ensure adequate sedation.
Defibrillation DC shocks were delivered between the right atrial and
coronary sinus electrodes at an output of 400 V with a 6/6 ms biphasic
truncated exponential waveform. If the first shock was unsuccessful, the
right atrial defibrillation catheter was repositioned and the procedure
repeated.
Post-cardioversion Measurements
The endocardial signals were monitored continuously and stored using the
Pruka CardioLab® 4.0 EPS system. Atrial premature beats (APB) were
analysed for the immediate 120-seconds following internal DC
cardioversion. The coupling interval of each APB was calculated as the
shortest A-A interval in either the right atrial appendage or distal coronary
sinus lead, and was measured with the on screen calipers at a screen speed
of lOOmm/sec. Only APBs occurring after sinus beats were counted. Atrial
ectopic beats clearly not originating from the sinus node area, with
coupling intervals greater than the previous sinus beat were not classified
as APBs. If a patient had an early recurrence of atrial fibrillation (i.e.
before leaving the catheterisation lab) only the APBs from the first
successful cardioversion were analysed. Holter monitors were fitted to all
patients in sinus rhythm within 1-hour of leaving the catheterisation lab.
Statistics
Statistical comparisons were performed by student's t-test for normally
distributed data and the Mann-Whitney rank sum test when a normal
distribution could not be assumed. Categorical variables were compared by
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the Chi-squared test. Continuous data are expressed as mean ± SD, and a
value ofP<0.05 was considered statistically significant. Statistical analysis
was performed using SPSS 9.0.
Results
Internal cardioversion was successful (sinus rhythm > 2 seconds) in 61 of
the 65 patients. There were no serious complications but 2 patients
developed haematomas in the neck (at the site of cannulation of the right
internal jugular vein) and one patient developed a pericardial effusion,
which caused discomfort but did not require drainage. A total of 34
patients (56%) experienced AF recurrence in the first week following
cardioversion. The 4 patients in whom internal cardioversion was not
successful had similar clinical characteristics to the 61 successfully
cardioverted patients other than a larger mean left atrial size at 4.9±0.4cm
v 4.1±0.6cm (p = 0.02). The clinical characteristics of the patients divided
according to duration of sinus rhythm (> or < 7-days) are shown in Table
6.1. The most notable differences between recurrers and non-recurrers was
that patients experiencing recurrent AF at < 7-days tended to have a longer
previous duration of AF (P - 0.06) and were more likely to have lone AF
(P = 0.04).
Atrial Premature Beats
The details of the atrial ectopy in the first 2-minutes following
cardioversion are shown in Table 6.2. Patients with AF recurrence at <7-
days had APBs with significantly shorter coupling intervals than non-
recurrers. Multivariate logistic regression (variables - age, sex, duration of
AF, diagnosis of lone AF, presence of structural heart disease, left atrial
size, number of APBs and average coupling interval of APBs) showed the
average coupling interval of APBs in the first 2-minutes following
cardioversion to be the strongest predictor of AF recurrence before 7-days
(p < 0.01). Immediate reinitiation of AF (IRAF) occurred in 15 patients
and 12 of these patients left the lab in AF. Because IRAF is known to be
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associated with short coupled APBs reanalysis of the data following
exclusion of these 12 patients was performed. This showed that patients
with recurrent AF still had significantly shorter mean and shortest
coupling interval APBs than non-recurrers (376±77ms v 574±114ms, P <
0.01; 328±69ms v 447±137ms, P < 0.01).
In addition to an association with AF recurrence the coupling intervals of
APBs were related to the timing of AF recurrence. The duration of sinus
rhythm (for all patients) was significantly correlated with both the mean (r
= 0.62, p < 0.01) and shortest (r = 0.49, p < 0.01) coupling interval of
APBs. The correlations between the shortest and mean coupling interval of
APBs and duration of sinus rhythm for patients with AF recurrence at <7-
days are shown in Figure 6.1.
The relationship between shorter coupled APBs and AF recurrence can
also be used to determine the likelihood of recurrent AF following
cardioversion. A mean APB coupling interval of <500ms is 67% sensitive
and 92% specific in predicting recurrent AF before 7-days. A shortest
coupling interval of <490ms is 88% sensitive but only 71% specific for





Coupling Interval of Shortest APB (ms)
Figure 6.1 Duration of sinus
rhythm compared to shortest (upper
graph) and mean (lower graph)
coupling interval of atrial premature
beats (APBs). The correlations are
both significant (p < 0.01). The
dashed lines at 490ms (shortest
coupling interval) and 500ms
(average coupling interval)
represent the values used for
assessing the likelihood of AF
recurrence before 7-days (see text).
Average Coupling Interval of APBs (ms)
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Table 6.1
Clinical and Echocardiographic Characteristics of Patients
With and Without AF Recurrence at 7-days Post Internal Cardioversion
Recurrers Non-Recurrers P
(n = 34) (n = 27)
Male / Female 25/9 20/7
Age (years)
Mean ± S.D. 60 ±9 62 ± 10
Range 45 -75 37 - 77
Duration of Chronic
AF (months)
Mean ± S.D. 30 ±35 16 ± 18









Mean ± S.D. 4.1 ±0.6 4.0 ± 0.6
Range 3.2-5.9 3.2-5.5
LV Function
EF >50% 27 21
EF <50% 7 6
P = 0.06
P - 0.04
SR - sinus rhythm; AF - atrial fibrillation; LA - left atrium; LV - left
ventricular; EF - ejection fraction; S.D. - standard deviation.
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Table 6.2
Atrial Premature Beats in the Initial 2-minutes Following Cardioversion
Recurrers Non-Recurrers P
(n = 34) (n = 27)
Number of APBs 6 ± 6 5 ± 6 P = 0.27
Average Coupling Interval (ms) 457 ±112 615 ±117 P<0.01
Shortest Coupling Interval (ms) 365 ± 99 489 ±144 P<0.01
Average SCL pre-APB (ms) 959 ±214 946 ± 243 P = 0.6
All values are mean ± SD. APBs - atrial premature beats;
ms - milliseconds; SCL - sinus cycle length.
The number of APBs in the first 2-minutes following cardioversion was
not related to recurrence. There was a significant correlation between the
number of APBs in the first 2-minutes and the total number of APBs in the
first 24-hours on Holter (r = 0.58, p < 0.01). The frequency of APBs on
Holter monitoring was also not associated with AF recurrence (recurrers
3375±4505 v non-recurrers 3761±6378, p = 0.45).
Discussion
Shorter coupled atrial premature beats in the initial 2-minutes following
cardioversion of persistent AF are associated with an increased risk of
subsequent AF recurrence. Patients with AF recurrence have shorter
coupled atrial premature beats than those who maintain sinus rhythm and
the patients with the shortest coupled atrial premature beats have earlier
recurrences. In agreement with the previous findings of Tieleman et al20
the frequency of APBs does not appear to be related to AF recurrence.
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Several clinical variables such as longer durations of AF prior to
cardioversion,46'47 increased age46'47 and left atrial enlargement,46'48 are
known to be associated with an increased risk of AF recurrence following
cardioversion. The predictive nature of clinical variables in determining an
individual patient's risk of AF recurrence has been studied,49 but
unfortunately combining clinical variables into a predictive risk score is
complicated and not easily applied in clinical practice.
The coupling interval of APBs is an easily measured electrophysiological
variable important in AF recurrence. Following the description of atrial
electrical remodelling37 there has been considerable interest in defining an
electrophysiological variable that relates to AF recurrence. Prior to the
description of atrial electrical remodelling a small early study had
suggested that shorter monophasic action potential durations50 were linked
with an increased risk of recurrent AF following cardioversion. Despite the
increased use of internal DC cardioversion (which allows assessment of
atrial electrophysiology following DC cardioversion) there has been little
further data linking atrial electrophysiology with AF recurrence. Further
data from our own group did not find atrial refractoriness following DC
cardioversion to be a predictor of subsequent AF recurrence,51 although we
did find an increased dispersion of AF cycle length in patients with
recurrent AF. Data from a subgroup of patients with measurement of both
atrial refractory period and the coupling interval of APBs (19 patients)
showed a correlation between the shortest coupling interval APB in the
first 2-minutes following cardioversion and the atrial refractoriness post-
cardioversion (r = 0.48, p = 0.038).
The lack of association between atrial refractory period and the risk of AF
recurrence following cardioversion is in agreement with the findings of
other authors.52 One group has reported an association between recurrent
AF and shorter atrial refractory periods post-cardioversion.53 The
association, however, was relatively weak with an odds ratio of only 1.04
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for AF recurrence in patients with lower refractory periods, which has
little clinical utility.53
Limitations
The sensitivity and specificity calculations were performed retrospectively
on the data and should be validated prospectively. As most DC
cardioversions are performed externally validation of the findings using
surface ECG recordings is important.
Clinical Relevance
Measurement of the coupling interval of APBs following internal DC
cardioversion is a simple method for determining a patient's risk of AF
recurrence and also in predicting the timing of this event. The coupling
interval of APBs is more difficult to measure following external DC
cardioversion, but is also possible with good quality surface ECG
recordings.20 Analysis of APBs following internal DC cardioversion can
identify a group ofpatients at increased risk of early AF recurrence post-
cardioversion who may benefit from more intensive antiarrhythmic
strategies. Further studies following external DC cardioversion and in
patients taking antiarrhythmic medication at the time of cardioversion
would be of interest.
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7.1 Lengthening of the Coupling Interval of Atrial
Premature Beats Following Repeated Early Internal
Cardioversions for Persistent Atrial Fibrillation:
Evidence for Reversal of Atrial Electrical Remodelling
in Man
Introduction
Atrial fibrillation (AF) has a tendency to become more persistent with
time. A large percentage of patients with paroxysmal AF eventually
• 1 2
develop chronic AF. Recently Wijffels and coworkers have
demonstrated, in a chronically instrumented conscious goat model, that
episodes of AF may be self-perpetuating ("AF begets AF") and have
suggested that there may be a purely electrophysiological explanation for
the increased persistence of AF with time. The self-perpetuating process in
this animal model is associated with a marked shortening of atrial
refractoriness and loss of the normal adaptation of atrial refractoriness to
heart rate (termed atrial electrical remodelling) that is reproducible in other
animal models.3"5 These authors suggested that the refractoriness changes
would stabilise episodes of AF by decreasing atrial wavelength
(wavelength=refractory period x conduction velocity), leading to an
increase in the potential number of electrical reentrant wavelets in the atria
and thereby increase AF stability as predicted by Moe's multiple wavelet
hypothesis.6
In the animal model described above, the remodelling process is
reversible and atrial refractoriness returns completely to normal within 1-
week of cessation of burst pacing (or DC cardioversion) and resumption of
sinus rhythm. During this "remodelling reversal" phase the atria are in a
state of increased vulnerability, which has been suggested as the
mechanism for the markedly increased risk of AF recurrence seen in
patients with chronic AF in the first week after cardioversion.7 A logical
extension of this suggestion is that if such a patient could be kept in sinus
rhythm over this short period, then subsequent likelihood of recurrence
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would be dramatically lowered. This possibility forms an attractive
theoretical basis for the use of repeated early cardioversions in such
patients. Alternatively, if atrial remodelling were found to be irreversible in
humans, then it would be difficult to support such a strategy in this patient
group, at least on the basis of the atrial electrical remodelling hypothesis.
The aim of this study was to examine the hypothesis that atrial electrical
remodelling is reversible after DC cardioversion in patients with persistent
AF. The coupling intervals of APBs (as an index of atrial refractoriness)
recorded in the first 2-minutes following the time of cardioversion of
persistent AF were compared with those recorded following cardioversion
of subsequent spontaneous AF recurrences in the same patient group. We
postulated that reversal of atrial electrical remodelling resulting in an
increase in atrial refractoriness would prolong the coupling interval of
atrial premature beats that occur in the immediate post-cardioversion
period.
Tieleman7 reported that short-coupled atrial premature beats (APBs) were
associated with earlier AF recurrence, suggesting that short-coupled APBs
are an important cause of AF recurrence in the remodelled atria. If reversal
of remodelling occurs then changes in the coupling intervals of APBs
would also be expected. A lengthening of the coupling interval of APBs
may allow for an increase in duration of sinus rhythm.
This study was performed as part of a more detailed assessment of reversal
of atrial electrical remodelling in this patient population. Atrial fibrillation
cycle length was recorded in all patients prior to cardioversion and in a





Consecutive patients with persistent AF (minimum duration of 3-months)
documented by serial ECGs were considered for the study. Written
informed consent was obtained through the use of an information sheet and
consent form approved by the Central Manchester Research Ethics
Committee, which also approved the protocol. Planned exclusion criteria
for the study were a contraindication to anticoagulation, pregnancy, and a
lack of willingness to undergo repeated cardioversion at short notice in the
event of spontaneous AF recurrence. Only 2 patients under consideration
were actually excluded from entry into the study, both because of
difficulties in travelling rapidly from their homes to the hospital.
Internal Cardioversion
The methods for internal cardioversion and post-cardioversion
measurements are as described previously (Chapter 6).
Patient Follow-Up and Repeat Cardioversions
Patients were discharged the day after the procedure. Antiarrhythmic
therapy was not reinstituted after cardioversion (except for amiodarone,
which, if present before cardioversion was continued throughout), but
anticoagulation was continued for 6 weeks. We attempted to accurately
define the time of recurrence of atrial fibrillation by fitting Holter monitors
for the initial 72 hours following cardioversion, or ifAF recurred after this
period from the patient history. In addition, patients made transtelephonic
recordings of their cardiac rhythm to a central monitoring station on a daily
basis for 35 days after the procedure. Transtelephonic recordings were also
made in the event of symptoms suggestive of return of arrhythmia during
this period. In the event of a confirmed recurrence of AF, patients were
readmitted as rapidly as possible for repeat internal cardioversion (CV2).




Statistical comparisons were performed by student's t-test or Mann-
Whitney rank sum test when a normal distribution could not be assumed.
Serial measures were compared by ANOVA. Continuous data were




Internal cardioversion was successful (sinus rhythm > 2 seconds) in 34 of
the 39 patients. Five patients had repeated early recurrence of AF and left
the lab in AF. Of the remaining 29 patients, 17 suffered a recurrence of AF
and had a further internal DC cardioversion after a mean period of 129
hours (range 1 to 740) of sinus rhythm. The mean duration of AF from the
time of AF recurrence to CV2 was 17±14 hours. Of these 17 patients, 8
patients went on to have a second recurrence of atrial fibrillation
necessitating a third internal cardioversion, after a further mean period of
141 hours (range 5 to 480) of sinus rhythm. The mean duration of AF
following the second AF recurrence prior to CV3 was 13±5 hours. The
clinical details of the patients at each successive cardioversion are shown
in Table 7.2.
Sinus Rhythm* Sinus Rhvthm* Sinus Rhvthin
Chronic AF AF Recurrence AF Recurrence
I nternal Cardioversion Internal Caniioversion I nternal Cardioversion
(CV 1) (CV 2) (CV 3)
Figure 7.1 Schematic diagram of the study protocol. Following cardioversion daily
transtelephonic ECG recordings are made*. In the event of AF recurrence, patients
are admitted rapidly for repeat cardioversion(s) (CV 2 and CV 3).
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Coupling Interval of Atrial Premature Beats
Of the 17 patients undergoing repeat internal cardioversion (CV2) for AF
relapse, 16 had at least one APB in the initial 2-minutes following CV1
and 15 had at least one APB following CV2. Of the 8 patients undergoing
CV3 7 had at least one APB. The results for the shortest and average
coupling intervals for the atrial premature beats are shown in Table 7.1.
There is a significant lengthening of the shortest coupling interval of the
APBs from CV1 to CV3 (341 ± 83ms to 486 ± 137ms, p = 0.02). The
average coupling interval is also significantly prolonged from CV1 to CV3
(481±118ms to 605±191ms, p = 0.02). Sinus cycle length preceding atrial
premature beats does not change from CV1 to CV3 (907 ± 184ms to 997 ±
209ms, p = 0.92). In addition to the changes in coupling interval from CV1
to CV3 there is a reduction in the number of APBs in the 2-minutes
following cardioversion. The lengthening of the shortest coupling interval
APB in two patients is illustrated in Figure 7.2.
Table 7.1 Coupling Intervals of Atrial Premature Beats
ICV1 ICY 2 ICY 3
Shortest Coupling Interval (ms) 341 ±83 417±144 486±137*
Average Coupling Interval (ms) 481±118 506 ±156 605±191*
Sinus Cycle Length pre-APB (ms) 907 ±184 924 ±231 997 ± 209
Number of APBs in first 2 mins 8.3 ±8.2 5.0 ±7.3 3.2 ±3.3*
ms - milliseconds; APB - atrial premature beat. ICV - internal cardioversion
*




























Figure 7.2 Representative examples of the shortest coupled atrial premature beats after 3
successive cardioversions from 2 patients. There is a progressive increase in shortest
coupling interval with successive cardioversions. There is some variation in preceding cycle
length from one cardioversion to another, but no consistent effect on sinus rate was noted.
RA - right atrium; CS - coronary sinus; RV - right ventricle; ms - milliseconds
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Table 7.2
Clinical and Echocardiographic Characteristics of Patients
All patients 2nd Cardioversion 3,d Cardioversion
(n = 39) (n - 17) (n = 8)
Male / Female 30/9 11/6 5/3
Age (years)
Mean ± S.D. 61 ± 10 60 ±11 54 ±9
Range 37-81 37-77 37 - 65
Duration of Chronic
AF (months)
Mean ± S.D. 38 ±66 25 ±36 27 ±24
Range 3-384 6- 150 7 - 78
Aetiology of AF
Ischaemic 7 3 1
Valvular 4 2 1
Hypertensive 8 3 1
Alcohol 3 2 3
Lone 17 7 2
Amiodarone Therapy 4 3 2
LA Diameter (cm)
Mean ± S.D. 4.1 ±0.7 4.4 ±0.6 4.2 ±0.6
Range 3.2-5.9 3.2-5.4 3.5-5.4
LV Function
EF >50% 27 12 6
EF <50% 12 5 2
SR - sinus rhythm; AF - atrial fibrillation; LA - left atrium; LV - left
ventricular; EF - ejection fraction
181
Discussion
A policy of repeated early cardioversion for recurrent AF results in a
prolongation of the shortest and average coupling intervals of APBs in the
first 2-minutes following cardioversion. There is also a reduction in the
number of APBs in the 2-minutes following cardioversion. The changes in
APB coupling interval are likely to represent a manifestation of reversal of
atrial electrical remodelling.
The repeated early cardioversion protocol found a number of pieces of
evidence for reversal of atrial electrical remodelling. The AF cycle length
prior to CV1 and CV2 increased from a mean of 161±22ms to 167±26ms
(p = 0.05) in the right atrial appendage, and from 162±20ms to 168±22ms
(p = 0.01) in the distal coronary sinus.8(Dr W J Hobbs, MD thesis) In a
small group of patients atrial refractory periods at pacing cycle lengths
500-700ms also showed a significant prolongation between CV1 and
CV2.18 (Dr S P Fynn, MD thesis) These measurements indicate a reversal
of AF-induced atrial electrical remodelling following a period of sinus
rhythm, despite the period of recurrent AF prior to repeat cardioversion.
There is a change in atrial electrophysiology at the time of acute
recurrence of AF following cardioversion of persistent AF. The pattern of
change of the three measured variables indicates a prolongation of atrial
refractoriness i.e. reversal of atrial electrical remodelling. It is unlikely that
the changes are artefactual due to patient familiarity with the procedure or
repeated sedation as there is no evidence of changes in autonomic tone,
with similar ventricular rates in AF prior to each cardioversion and sinus
rates following each cardioversion.
Previous Evidence for the Reversibility of Atrial Electrical
Remodelling in Humans
Shortened atrial monophasic action potential durations and atrial refractory
periods have been demonstrated in patients following cardioversion of AF
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and atrial flutter.9"11 In addition, Franz et al showed a "flat" response of
atrial monophasic action potential duration to changes in heart rate, similar
to the flattened rate adaption curve seen in the goat model.2 These findings
have been interpreted as demonstrating the presence of atrial electrical
remodelling in humans as a consequence ofpersistent clinical AF.
Prior to our study there was only one study that examined reversibility of
atrial electrical remodelling in humans.12 In this study the atrial refractory
period response to very short episodes of induced AF was measured. Short
bursts of AF resulted in reduction of atrial refractory periods (measured at
350 and 500ms pacing cycle length) and which following a few minutes of
sinus rhythm returned to normal. The current study extends the findings of
these authors in that it demonstrates reversibility of atrial electrical
remodelling in patients with spontaneously occurring, persistent clinical
AF rather than in subjects with induced, short-lasting, "nonclinical"
episodes. The time course of the increase in refractoriness after AF
termination in these 2 studies is very different (being much slower in the
current study), which suggests that 2 distinct physiological or
pathophysiological processes are involved. The fact that in the current
study these changes are still demonstrable several hours after onset of AF
recurrence indicates that they have a time course similar to that described
in the goat model (i.e. hours rather than minutes).13 Following the
completion of our study several authors have documented reversal of atrial
electrical remodelling in patients who remain in sinus rhythm following
cardioversion.14"16 The body of evidence strongly suggests that atrial
electrical remodelling occurs in human AF, but as yet it is not clear that
reversal of atrial electrical remodelling reduces clinical AF recurrence.
Indeed atrial vulnerability can persist despite long durations of sinus
rhythm.17
The highest risk of recurrent AF is in the initial few days following
cardioversion7 and it is during this period of time that reversal of atrial
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electrical remodelling occurs.15'16 This study suggests that changes in the
'substrate' for recurrent AF may not be the only factor involved in the
reduced risk of AF recurrence following a period of sinus rhythm. The
'triggers' for recurrent AF i.e. atrial premature beats, are reduced in
number and prolonged in coupling interval following a period of sinus
rhythm. Fewer APBs with longer coupling intervals should represent a less
potent trigger for AF recurrence (Chapter 6). However, despite favourable
evidence for reversal of atrial electrical remodelling and a reduction in the
number of APBs early after cardioversion, the repeated early cardioversion
protocol was not successful at maintaining sinus rhythm in the majority of
patients.18 It is likely that the long duration of previous AF in our patients
increased the risk of subsequent AF recurrence.19'20 The fact that AF
recurred despite favourable evidence on the reversal of electrical
remodelling suggests the importance of other factors, such as atrial
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structural changes ' in rendering the atria vulnerable to recurrent AF.
Limitations of the study
It is possible that a number of electrophysiological variables other than
atrial refractoriness are "remodelled" during persistent AF. Studies in dog
models of atrial fibrillation have shown a decrease in atrial conduction
23
velocity. No attempts were made to assess other variables such as atrial
conduction velocity. The duration of recurrent AF prior to repeat
cardioversion may have attenuated the findings, but despite this all three
measures (APB coupling interval, AF cycle length and atrial
refractoriness) showed clear evidence of reversal of atrial electrical
remodelling.
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7.2 A Study Of 179,000 Atrial Premature Beats
Indicating Reversal Of Atrial Electrical Remodelling
In Man
Introduction
In tandem with the study of reversal of atrial electrical remodelling in the
patients undergoing serial cardioversions for recurrent AF, we also sought
to assess reversal of atrial electrical remodelling in patients without AF
recurrence. Patients without AF recurrence had no clinical indication for a
repeat invasive electrophysiological procedure limiting assessment of
reverse remodelling to non-invasive measurements. The lengthening of the
coupling interval of APBs in the serial cardioversion study prompted us to
assess the coupling intervals of atrial premature beats (as a measure of
atrial refractoriness) from Holters recorded on each of the first 3-days
following cardioversion.
Methods
Patients were drawn from the elective cardioversion waiting list as in
Section 7.1. The same inclusion and exclusion criteria applied. Following
successful cardioversion of persistent AF the patients were fitted with
Holter monitors for 72-hours. The tapes were analysed using the Reynolds
Pathfinder 700 system. Following automatic identification by the analyser
careful editing was performed to accurately classify all atrial premature
beats (APBs). The Holter data was then analysed using specially
developed software (Reynolds Medical Research Tools©) to determine the
coupling interval (R-R interval) of all atrial premature beats (APBs) with a
cycle length of less than 65% of the previous normal-normal interval. The
data generated was a series of numbers that were imported into a
spreadsheet. In order to reduce error due to artefact all coupling intervals
of less than 300ms and more than 65% of the mean sinus cycle length
were excluded (<10% of the data). The mean coupling interval during each
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24-hour period was calculated for each patient. The coupling interval of
the 10th percentile of the shortest coupled APBs for each 24-hour period
was classified as plO and used as a measure of the shortest coupling
interval.
Results
A total of 45 patients commenced Holter monitoring following
cardioversion and 23 patients (mean AF duration 14.5 ± 16 months, mean
age 60 ± 7 years, 16 male) completed 72 hours of Holter monitoring in
sinus rhythm. Analysis of the Holter tapes identified 179,814 APBs from
the 23 patients over 3 days. The number of APBs identified each day was
constant over the 3-day period: day-1 58,310; day-2 65,883; day-3 52,631.
The range of coupling intervals of APBs described a normal distribution
(Figure 7.3). There was a significant prolongation of both the mean
coupling interval and the coupling interval of the shortest 10% of APBs (p
10) from day-1 to day-3 post-cardioversion. (Table 7.3) This pattern for a
single patient is shown in Figure 7.4.
Mean CI (ms) plOCI(ms) Mean no. APBs
Day 1 547 ± 73 479 ± 67 2535 ± 4042
Day 2 559± 84 498 ± 83 2995 ± 3779
Day 3 577 ± 84* 512 ±76* 2288 ± 3529
Table 7.3 Mean and plO coupling intervals (CI) and numbers of
atrial premature beats from Day 1 to Day 3 post-cardioversion of
AF. *p <0.01 compared to day-1
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Patients were then divided into 2 groups based on the presence of recurrent
AF before 1-week. Recurrent AF prior to 1-week occurred in 12 of the 23
patients. Although the increase in plO and mean coupling intervals were
not statistically different between the two groups there was an interesting
trend towards a greater change of the coupling interval of APBs in the
patients with AF recurrence (Table 7.4). This was especially noticeable for
plO coupling intervals which increased 43±12ms for recurrers compared to
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Figure 7.3 Illustration of typical normal distribution of atrial premature
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Figure 7.4 Illustration of the increase in coupling interval of atrial premature beats
over a period of 3-days following cardioversion of persistent AF in a single patient.
Table 7.4 Changes in coupling intervals: recurrers v non-recurrers
Recurrers Non-Recurrers P
Mean CI Day-1 544±63ms 546±85ms
0.96
Mean CI Day-3 582±66ms 572±106ms
0.87






Difference day 1 to 3 43±12ms 26±29ms
0.07
CI - coupling interval; ms - milliseconds; plO - shortest coupling interval
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Further analysis of the data showed that there was no relationship between
APB coupling intervals and clinical variables such as duration of AF, left
atrial size, patient age or a diagnosis of lone AF. The number of APBs was
also not related to these variables.
Discussion
The coupling intervals of atrial premature beats increase in duration over
the first 72 hours following cardioversion of persistent AF. The level of
prolongation (30ms) is compatible with changes in atrial refractoriness
associated with reversal of atrial electrical remodelling over this period of
time. An increase in APB coupling interval is not associated with
maintenance of sinus rhythm.
Despite favourable changes in the coupling intervals of APBs on Holter
monitoring for the initial 72-hours following cardioversion, the degree of
prolongation of coupling interval does not relate to persistence of sinus
rhythm. In fact, the opposite trend is observed with a more pronounced
lengthening of the coupling interval of APBs in patients with recurrent AF.
A possible explanation for the lack of an association between reversal of
atrial electrical remodelling and maintenance of sinus rhythm is that
reversal of atrial electrical remodelling is not related to a reduction in AF
vulnerability. This would also be suggested by the data from the serial
cardioversion study, where reversal of atrial electrical remodelling was
demonstrated by lengthening of AF cycle length, an increase in atrial
refractoriness and prolongation of the coupling interval of APBs occurring
O 1 Q
shortly after cardioversion, but recurrent AF was very common. ' Other
factors may be more important than remodelling such as atrial structural
changes or focal initiators of AF (Chapter 8).
Another explanation is that reversal of atrial electrical remodelling in fact
promotes atrial vulnerability, at least for a short period of time. A possible
mechanism for increased atrial vulnerability might be an increase in
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dispersion of atrial refractoriness. Dispersion of atrial refractoriness has
been shown to be lower during persistent AF than sinus rhythm in man,24
and it is possible that a non-homogeneous reversal of atrial electrical
remodelling might result in an increased dispersion of refractoriness so
increasing the chances of AF recurrence. Our own group has shown that an
increased dispersion of atrial refractoriness, as assessed by AF cycle length
7 S
at the time of cardioversion, is associated with increased AF recurrence.
The numbers and coupling intervals of APBs were not related to longer
durations of AF, left atrial size, increased age or the absence of structural
heart disease. These results suggest that clinical variables that are
important in AF recurrence are not linked to changes in the triggers for AF
but exert their effect through influences on the substrate for recurrent AF.
Study limitations
A major drawback of this study was the measurement of APB coupling
intervals using RR intervals. In addition to being influenced by changes in
atrial coupling intervals the observed changes in APB coupling interval
may have reflected changes in AV nodal conduction properties in the first
few days following cardioversion. However, changes in AV nodal
conduction following DC cardioversion have not previously been
documented. It is possible the internal DC cardioversion itself may have
influenced AV nodal conduction, but it is more likely that the shock would
have prolonged AV nodal conduction so resulting in a shortening of APB
coupling interval in the initial few days following cardioversion. Of
particular note is that there were no changes in cardioactive medication
over the time of the study.
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Prevalence and Significance of Focal
Sources of Atrial Arrhythmia in Patients
Undergoing Cardioversion of Persistent
Atrial Fibrillation
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Background: Recent reports have highlighted the importance of focal
atrial arrhythmias as a curable cause for a group of patients with
frequently recurrent paroxysmal atrial fibrillation (AF). The importance of
this arrhythmia mechanism in the general population of patients with
persistent AF is unknown.
Methods: Following successful internal cardioversion of 50 consecutive
patients with persistent AF (mean age 60 years, mean duration of AF 26
months), endocardial activity in the immediate post-cardioversion period
was analysed for the presence of focal atrial activity. Post-cardioversion
atrial arrhythmias were considered to be focal if there was evidence of a
localised source of repetitive early atrial activation, either in the form of 1)
self-terminating monomorphic atrial tachycardia (at least 5 beats) or 2)
recurrences of atrial fibrillation with an initial atrial activation sequence
(first 5 beats) that was both monomorphic and reproducible with repeated
recurrences.
Results: Evidence for a focal atrial arrhythmia was present in 20 of the
total group of 50 patients (40%). Multivariate analysis of clinical
characteristics revealed the diagnosis of lone AF as the only independent
predictor of a focal source of AF (p=0.028). Thirty-nine patients were
discharged from hospital in sinus rhythm. At one month follow-up 25 of
these 39 (64%) had suffered AF recurrence. The only significant predictor
of AF recurrence was evidence of a focal source of atrial arrhythmia
immediately post-cardioversion, with a relative risk of 1.73 (1.1-2.7),
p=0.015.
Conclusions: Focal atrial arrhythmias are common in patients presenting
with "idiopathic" persistent AF, suggesting a possible causative role in the
generation of this common arrhythmia.
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Introduction
Atrial fibrillation (AF) is the cardiac arrhythmia most frequently
encountered in clinical practice and remains a considerable clinical
challenge, in part because of limitations in our understanding of the
electrophysiological mechanisms underlying the condition.
Conventionally, AF has been believed to result from the simultaneous
existence of multiple migratory wavelets of activation in both atria1 and a
site-specific or focal mechanism has not been supported by experimental
studies2 or mapping data obtained at the time of cardiac surgery.3'4
Recently, however, a focal form of clinical AF has been described in a
number of young patients with structurally nonnal hearts.5'6 These patients
have a characteristic clinical presentation with unifocal atrial premature
beats and frequent short runs ofAF. Electrophysiological studies in this
group have revealed that the atrial arrhythmias in a particular patient tend
to originate from an identifiable source firing intermittently and resulting
in a consistent pattern of atrial activation. This characteristic clinical
presentation of very frequent shorts runs of arrhythmia is rare amongst the
general patient population with AF however, most individuals having
more sporadic paroxysms (weeks or months between attacks) or recurrent
episodes that require electrical cardioversion for termination (persistent
AF). The aim of this study was to determine the prevalence and
significance of focal atrial arrhythmias in this latter group of patients as
assessed in the immediate post-cardioversion period. Focal atrial
arrhythmias were identified and characterised using endocardial signals
from intracardiac electrodes inserted for the purpose of internal
cardioversion7"10 of persistent AF.
Methods
Patient Selection
Consecutive patients presenting to the cardiac department of a general
hospital with persistent AF (minimum duration of presenting episode 3
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months) documented by serial electrocardiograms were considered for the
study. The study was designed to include as broad a cross section of
patients with persistent AF as possible and the only exclusion criteria were
a contraindication to anticoagulation or an unwillingness to enter the
study. Written informed consent was obtained using an information sheet
and consent form approved by the Central Manchester Research Ethics
Committee, which also approved the study protocol.
Study Protocol
Initial clinical assessment included history, physical examination, 12-lead
surface ECG, thyroid function tests and transthoracic echocardiography.
Patients were admitted to hospital for internal cardioversion of persistent
AF after at least 4-weeks of adequate anticoagulation. Blood was sampled
for measurement of International Normalised Ratio (INR) weekly and also
on the day prior to the planned procedure. Transoesophageal
echocardiography was performed to exclude left atrial thrombus
immediately prior to cardioversion in any patients with a measured INR
below 2.0 at any time in the 4 weeks prior to the procedure.
Anticoagulation was not stopped prior to cardioversion. Antiarrhythmic
medication was stopped 3 full days prior to the procedure in all patients
except those taking amiodarone, which was continued.
Internal Cardioversion
A TADcath model 8010 temporary transvenous defibrillation catheter
(110cm, Cournand curve, ProCath Corp) was inserted into the coronary
sinus via the right internal jugular vein. This is an 11 electrode catheter, 2
electrodes being used for bipolar pacing/sensing and 9 comprising the
defibrillation electrode. A second defibrillation catheter was placed in the
right atrium via the right femoral vein, with the tip in the right atrial
appendage and positioned so that the majority of the catheter electrodes
had contact with the right atrial free wall. A quadripolar catheter was
positioned at the right ventricular apex to allow for synchronisation of the
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defibrillation shock, appropriate synchronisation being confirmed using a
Defibrillation Systems Analyser (DSA, InControl). Immediately before
shock delivery, 2 to 12mg midazolam was administered intravenously to
ensure adequate sedation. Defibrillation DC shocks were delivered
between the right atrial and coronary sinus electrodes at an output of 400V
with a 6/6ms biphasic truncated exponential waveform. If the first shock
was unsuccessful the right atrial defibrillation catheter was repositioned
and the procedure repeated up to a maximum of 4 times. Following
successful cardioversion, continuous bipolar recordings were made from
the distal coronary sinus and right atrial electrodes and surface
electrocardiographic leads for at least 2 minutes post-cardioversion. If
there was recurrence of AF in the immediate post-cardioversion period the
procedure was repeated up to a maximum of 4 times.
Electrogram Analysis
Bipolar electrograms were recorded at a filter setting of 30 to 500 Hz at a
gain of 5 to 10 cm/mV. The endocardial signals were acquired using a
multichannel Cardiolab system (Pruka Engineering Inc.) and stored on
optical disc. Individual atrial electrograms were measured with the on¬
screen calipers at a screen speed of lOOmm/sec. Catheters were not
manipulated during the recording period in order to avoid mechanically
induced ectopic activity. Electrogram analysis was performed offline by 2
observers independently.
Definitions
Post-cardioversion atrial arrhythmias were considered to be focal if there
was evidence of a localised source of repetitive early atrial activation,
either in the form of 1) self-terminating monomorphic atrial tachycardia
(at least 5 beats) or 2) recurrences of atrial fibrillation with an initial atrial
activation sequence (at least first 5 beats) that was both monomorphic and
reproducible with repeated recurrences. Reproducibility was determined in
terms of electrogram morphology, activation sequence and tachycardia
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cycle length. Atrial fibrillation was defined on the basis of surface
electrocardiographic criteria: the absence of P waves and presence of f
waves that were irregular in timing at a rate of greater than 320 beats per
minute. Patients were classified as having lone or idiopathic AF in the
absence of a recognised cause as determined by the patient's history,
physical examination and 2-D echocardiogram.
Patient Follow-up
Patients were discharged the day following the procedure. Antiarrhythmic
therapy was not reinstituted following cardioversion (except amiodarone
which, if present precardioversion, was continued throughout) but
anticoagulation was continued for at least 6 weeks. Patients underwent
continuous Holter monitoring for 72 hours, daily transtelephonic
monitoring of cardiac rhythm for 30-35 days post-procedure and clinical
review with 12-lead electrocardiography at 1-month post-cardioversion.
Transtelephonic assessment of cardiac rhythm was also undertaken in the
event of symptoms suggestive of a recurrence of AF. Atrial fibrillation
was confirmed by 12-lead electrocardiography in all cases in which
recurrence was thought to have occurred.
Statistical Analysis
Patients' clinical details were compared using an independent samples t-
test for continuous variables and a Chi-squared test for categorical
variables. All results are expressed as mean ± standard deviation.
Predictive variables of focal AF were derived from univariate logistic
regression analysis. Multivariate logistic regression analysis was then
undertaken with all univariate predictors and also age, sex, duration of AF
prior to cardioversion and left atrial size in order to adjust for any possible
baseline imbalance between the groups. Relative risks were calculated in
preference to odds ratios for predictors of AF recurrence because the risk
of recurrence was > 50%.'1 P values less than 0.05 were deemed
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statistically significant. Statistical analysis was performed using the
software package SPSS 8.0.
Results
Clinical characteristics
Internal cardioversion was successful in restoring sinus rhythm in 50 of 54
consecutive patients. Mean age of these 50 patients was 60±10 years, 37
were male, and mean duration of AF episode prior to cardioversion was
26±32 months. The baseline clinical and echocardiography details of
these patients, classified according to the presence or absence of a focal
atrial arrhythmia post-cardioversion, are shown in table 8.1.
Evidence offocal arrhythmias
Evidence for at least one focal atrial arrhythmia was present in 20 of the
total group of 50 patients (Table 8.2) and 18 of the 33 patients (55%)
without structural heart disease based on the pre-defined criteria described
above. Sixteen patients had at least one run (> 5 beats) of self-terminating
monomorphic atrial tachycardia (Figure 8.1), with a mean of 16.2 ± 13.3
beats per episode. In 7 patients earliest endocardial atrial activation was
recorded at the coronary sinus electrode, in 7 the right atrial electrode, and
in 2 patients right and left atrial electrograms occurred simultaneously. In
all but one case the onset of surface P wave activity occurred earlier than
endocardial activity at these sites, indicating a site of origin distant from
the catheters themselves. The mean cycle length of tachycardia in these
patients was 342 ± 98ms.
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Table 8.1
Baseline Clinical and Echocardiographic Details of Patients According
to the Presence or Absence of a Focal Source of Atrial Fibrillation
Focal Atrial Fibrillation
Present Absent
Variables (n=20) (n=30) P
Demographic
Male / Female 14/6 23/7 0.61
Age (years) 60 ±9 60 ± 10 0.99
Clinical
Duration of persistent AF (months) 26 ±35 25 ±31 0.93
Prior history of paroxysmal AF 6/20 7/23 0.6
Previous DC cardioversion 7/20 14/30 0.29
Total duration AF history (months) 42 ±42 43 ±50 0.93
Mean number of previous AAD 1.9 ± 1.3 1.6 ± 1.0 0.35
Continuing amiodarone therapy 2 1
Aetiology of AF







Pulmonary Disease 0 1
Iatrogenic 0 1
Echocardiographic
FA Diameter (cm) 4.0 ± 0.4 4.2 ±0.7 0.28
FV Function
Normal 19 20 0.026
Reduced 1 10
AAD - antiarrhythmic drugs: LA - left atrial; LV - left ventricular
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Table 8.2
Summary of the Focal Atrial Arrhythmias Post-Cardioversion
Run (> 5 beats) of atrial tachycardia
Reproducible reinitiation of AF




Number of beats of tachycardia
Site of first activation










Mean tachycardia cycle length 342 ± 98 ms 193 ± 15 ms
* IRAF - spontaneous reinitiation of atrial fibrillation within 2-minutes of cardioversion
Figure 8.2 shows a series of self-terminating runs of monomorphic atrial
tachycardia in a patient with lone atrial fibrillation followed by
spontaneous reinitiation of atrial fibrillation in the same patient. The atrial
fibrillation in this case is triggered by an atrial tachycardia identical in
activation sequence to the previous self-terminating episodes of atrial
tachycardia. Three patients had both self-terminating atrial tachycardia
and IRAF. Of the 18 patients who experienced at least one episode of
spontaneous "immediate" reinitiation of AF (IRAF), 11 of these had more
than one episode and 7 had evidence of a reproducible initial atrial
activation pattern. These episodes of AF occurred at a mean of 29 ± 25
seconds following cardioversion. Figure 8.3 shows two episodes of
reinitiation of AF following successive cardioversions in a single patient.
The activation pattern, timing and electrogram morphology of the first 5
beats of atrial activation are almost identical in the 2 episodes, strongly
suggestive of a common "source" of reinitiation of AF. Figure 8.4 shows
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an example ofnon-reproducible IRAF, with marked differences in
electrogram cycle length and morphology, and figure 8.5 shows three
separate episodes of IRAF in a single patient with slowing of the cycle
length in the third episode of IRAF following administration of flecainide.
For the patients with a reproducible reinitiation of AF the mean cycle
length of the first 5 beats of reinitiation of AF was 193 ± 14 ms (range 176
-215 ms). As with the atrial tachycardias, earliest atrial activity at the
onset of IRAF was evident on the surface electrocardiogram before the
intracardiac electrograms, demonstrating that the catheters themselves
were not the origin of the recurrence.
Relationship offocal arrhythmias to clinical characteristics
A number of clinical variables were analysed for an association with a
focal source of atrial arrhythmia (Table 8.1): sex, age (>60 years), duration
of persistent AF (>12 months), prior history ofparoxysmal AF
(present/absent), previous cardioversions (present/ absent), total duration
of AF history (>12 months), left atrial size (>4cm), left ventricular
function (normal/impaired), aetiology (lone AF or not lone AF), and the
presence or absence of structural heart disease. Using logistic regression,
univariate predictors of a focal arrhythmia were normal left ventricular
function (p=0.026), the absence of structural heart disease (p=0.008) and
the diagnosis of lone AF (p=0.007). Multivariate analysis by stepwise
logistic regression of all variables revealed that the diagnosis of lone AF
was the only independent predictor of a focal atrial arrhythmia (p=0.028)
immediately post-cardioversion.
Clinical outcome
Ten of the 50 patients with initially successful shocks could not be
maintained in sinus rhythm for more than a few minutes despite repeated
shocks and left the electrophysiology laboratory in AF. One patient had
very frequent short bursts of AF following cardioversion (Figure 8.6) and
underwent successful radiofrequency ablation of a repetitively discharging
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focus in the left superior pulmonary vein. The remaining 39 patients were
discharged from hospital in sinus rhythm without antiarrhythmic therapy.
At one month follow up 25 of these 39 (64%) had suffered recurrence of
AF. A number of clinical parameters were examined as predictors of AF
recurrence after discharge from hospital (Table 8.3), including the
presence of structural heart disease and a diagnosis of lone AF. The only
significant predictor of AF recurrence was evidence of a focal source of
atrial arrhythmia immediately post-cardioversion, with a relative risk of
1.73 (1.1-2.7), p=0.015. Complications were minimal, but two patients
suffered haematomas as a consequence of the internal cardioversion
procedure, neither requiring an extension of hospital stay.
Table 8.3
Relative Risks of Clinical Variables for Recurrence of Atrial Fibrillation
Relative Risk 95% CI P
Male sex 0.69 0.45-- 1.05 0.15
Age (>60 years) 0.83 0.52-- 1.31 0.46
Duration of AF episode (>12 months) 1.19 0.75-- 1.87 0.47
Total duration of AF history (>12 months) 1.23 0.74--2.05 0.39
LA Diameter (>4.0cm) 1.12 0.70-- 1.79 0.63
Structural Heart Disease 0.84 0.49--1.43 0.49
Diagnosis of Lone AF 1.19 0.75-- 1.88 0.47
Presence of a Focal Source 1.73 1.10--2.72 0.015*
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Figure 8.1 Non-sustained run of monomorphic atrial tachycardia at a cycle length of
364ms in a patient 45-seconds post-cardioversion of atrial fibrillation. (RA: right atrial











Figure 8.2 (A) Non-sustained runs of monomorphic atrial tachycardia in a patient with
lone atrial fibrillation. (B) Initiation of atrial fibrillation by a further run of monomoiphic
atrial tachycardia in the same patient. (RA: right atrial electrogram, CS: distal coronary
sinus electrogram, RV: right ventricular electrogram, ms: milliseconds.)
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Figure 8.3 Reproducible IRAF. Two separate episodes of reinitiation of atrial fibrillation
shortly after successful internal cardioversion in a patient with lone atrial fibrillation. The
numbers represent the cycle length of endocardial activation in milliseconds. (IRAF:
immediate recurrence of AF, RA: right atrial electrogram, CS: distal coronary sinus
electrogram, RV: right ventricular electrogram.)
Figure 8.4 Non-reproducible IRAF. Two separate episodes of reinitiation of atrial
fibrillation shortly after successful internal cardioversion in a patient with cardiomyopathy.
The numbers represent the cycle length of endocardial activation in milliseconds. (IRAF:
immediate recurrence of AF, RA: right atrial electrogram, CS: distal coronary sinus
electrogram, RV: right ventricular electrogram.)
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Figure 8.5 Three separate episodes of IRAF shortly after successful internal cardioversion.
Following administration of flecainide the cycle length of the first 4 beats is prolonged by -20%,
with a similar degree of prolongation for each beat. The numbers represent the cycle length of
endocardial activation in milliseconds. (IRAF: immediate recurrence of AF, RA: right atrial
electrogram, CS: distal coronary sinus electrogram, RV: right ventricular electrogram.)






Figure 8.6 Surface electrocardiographic tracing showing successful cardioversion of persistent
atrial fibrillation to sinus rhythm with frequent self-terminating runs of atrial fibrillation.




The principal new finding of this study is that focal (monomorphic) atrial
tachycardias are common following cardioversion of patients presenting
with persistent atrial fibrillation. This raises the possibility that these
tachycardias, recently identified as the cause of AF in a highly selected
group of patients with frequently recurrent paroxysmal AF, also have a
role in the aetiology of persistent AF. The fact that they are particularly
common amongst those with a diagnosis of lone AF argues against their
presence being consequent upon valvular or myocardial disease and
supports a causative role in the generation of "idiopathic" persistent AF.
Furthermore, the association of focal atrial arrhythmias with subsequent
clinical recurrence of AF in this study highlights their pathophysiological
significance and indicates that catheter ablation of these tachycardias may
provide an important therapeutic approach to patients with the persistent
form of AF.
Previous studies ofinternal cardioversion ofpersistent AF
Most previous studies of internal cardioversion of persistent AF have had
an endpoint of restoration of sinus rhythm and have not reported on the
characteristics of atrial activity immediately post-cardioversion.7-10 Sra
and coworkers12 studied spontaneous reinitiation of AF in 4 patients
following internal cardioversion and reported that all instances of
spontaneous reinitiation were preceded by an atrial premature beat.
Timmermans and coworkers13 noted that 5 of 38 patients (13%)
undergoing successful internal cardioversion of AF experienced almost
immediate recurrence of AF (IRAF: defined as recurrence within one
minute), always initiated by an atrial premature beat with a short coupling
interval. Earliest atrial activity at the onset of IRAF was evident on the
surface electrocardiogram before the intracardiac electrograms,
demonstrating that the catheters themselves were not the origin of the
recurrence. No clinical or echocardiography characteristics were
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predictive of immediate reinitiation and the occurrence of IRAF did not
predict recurrence after discharge from hospital. Lau and coworkers14
have recently reported the results of radiofrequency ablation of focal
sources causing reinitiation of AF in a selected population of patients with
paroxysmal and persistent lone AF. In their study only 4 of 32 patients
(13%) with persistent AF showed evidence of a focal source, of whom two
had successful radiofrequency ablation. In the current study 20 of 50
patients (40%) had evidence of a focal source of AF. This was in spite of
the fact that the criteria for reproducible IRAF were stricter in the current
study (five beats rather than three) than that of Lau et al and that the
patient group were more representative of the general AF population. Lau
et al did not report the incidence of self-terminating atrial tachycardias
following cardioversion in their series and this may account for some of
the difference between the two studies.
Previous work on predictors of recurrence post-cardioversion
A number ofprevious studies have examined risk factors for recurrence of
AF following internal or external cardioversion. Previously identified risk
factors include duration of AF greater than 12 months,15"17 left atrial size
greater than 6cm,17'18 structural heart disease,17"19 and age greater than 65
years.18 No previous studies have identified any patterns of atrial
arrhythmia recorded at the time of cardioversion that are associated with
subsequent recurrence of AF. Subsequent to the publication of our study
Maounis et al showed that frequent atrial ectopy (>10 / hr) and runs of
non-sustained SVT (4 beats at >120/min) on post-cardioversion Holter
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monitoring were associated with an increased risk of recurrent AF. In the
current study the presence of a focal source was the strongest predictor of
AF recurrence on multivariate analysis.
Significance offocal atrial arrhythmias post-cardioversion
It could be argued that "spontaneous" focal atrial activity occurring post-
cardioversion may be a non-specific response of atrial myocardium or
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pulmonary veins to electrode catheter movement, surges of autonomic
activity or to the endocardial shock itself. It can also be postulated that
they are triggered by the sudden relative bradycardia that is common post-
21shock. The findings of this study argue against these possibilities,
however. Earliest atrial activity at the onset of focal arrhythmias was
evident on the surface electrocardiogram before the intracardiac
electrograms, demonstrating that the catheters themselves were not the
origin of the recurrence. In addition, the increased risk of subsequent
clinical recurrence of AF associated with their presence is strongly
supportive of an important pathophysiological role. One possibility is that
the post-cardioversion period reveals focal atrial activity that is the
underlying cause of the sustained arrhythmia. A series of animal studies22"
25 and clinical work26'27 suggests that the high atrial rates associated with
bursts of focal atrial activity may lead to a progressive alteration in
electrophysiological properties of the atria (atrial electrical remodelling)
that in turn makes perpetuation of AF more likely.
Are these arrhythmias truly focal?
In this study the term "focal" is used to indicate a site-specific activation
pattern without specific knowledge of the underlying mechanism (see
below). Whilst a localised source of monomorphic atrial tachycardia can
be demonstrated by the presence of a consistent pattern of atrial activation
throughout the arrhythmia, other criteria are required when an apparently
focal arrhythmia "degenerates" into AF with completely disorganised
atrial activity. One approach to this problem would be to perform detailed
endocardial mapping of the initiation of AF. This was not done in this
study because of the consequent requirement for additional DC
cardioversion shocks for each mapping position of the catheters. Instead
we restricted the definition of a focal source of IRAF to those cases in
which the initial atrial activation pattern was reproducible with repeated
IRAF episodes in terms of electrogram morphology, activation sequence
and tachycardia cycle length. The initiation of AF in these cases had some
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of the features of those of focal triggers of AF6 described previously by
Haissaguerre as originating from the pulmonary veins. In this study
repetitive focal discharges had a mean cycle length of 175msec (range 110
to 270 msec), similar to the characteristics of the bursts of atrial activity
reinitiating AF in the current study. Other focal sources identified in the
current study originated in the right atrium, as has been described recently
28in patients with paroxysmal AF.
Subsequent studies on persistent AF
Following completion of our study there have been further publications
examining the association between focal atrial arrhythmias and persistent
AF. Flaissaguerre and colleagues recently reported on catheter ablation
9Q
therapy for persistent AF targeting the reinitiating triggers. There are
more technical difficulties involved with this procedure, including the
frequent recurrence of AF following cardioversion necessitating repeated
DC cardioversion and the use of antiarrhythmic drugs (amiodarone and
flecainide). Patients more frequently required ablation of more than one
pulmonary vein (3 or 4 veins in > 50% of cases), and often the procedure
required to be repeated. Like paroxysmal AF the dominant trigger areas
are in the pulmonary veins but the long-term maintenance of sinus rhythm
is lower in the patients with persistent AF (60%). Oral et al found the
electrogram-guided approach disappointing for patients with persistent AF
with only 22% of patients free from AF following pulmonary vein
ablation.30
Natale and coworkers also published the results of ablation of APBs in
patients with persistent AF. Patients with persistent AF, minimal
structural heart disease and early recurrence of AF following electrical
cardioversion that appeared to be precipitated by frequent APBs
underwent mapping and ablation. Ablation resulted in 40 of the 48 patients
(83%) being in sinus rhythm at 1-year follow-up.
More recently the success of an anatomic approach involving isolation of
at least 3 of the 4 pulmonary veins in preventing AF has been reported.31
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A total of 251 patients with paroxysmal (179) and persistent (72) AF were
treated by circumferential radiofrequency ablation around pulmonary
venous ostia. Of these 152 (85%) of patients with paroxysmal AF and 49
(68%) with persistent AF were free from AF at a mean follow-up of 10±5
months.
Improved rates of maintenance of sinus rhythm can be achieved with the
use of radiofrequency ablation of AF 'triggers', however the ideal patient
and technique is yet to be defined. The studies performed so far suggest
that an anatomic approach may be more favourable than electrical
mapping of ectopy in patients with persistent AF. The anatomic approach
also isolates a portion of the posterior left atrial wall contiguous with the
pulmonary vein orifices. Isolation of this area may have additional
benefits in prevention of recurrent AF or alternatively in persistent AF the
origin of atrial ectopy may be more diffuse than in paroxysmal AF,
possibly forming a further link between triggers and substrate.
Localisation of the source of the atrial arrhythmias
Due to the limited intracardiac electrogram recordings available it was not
possible to determine the exact origin of the arrhythmias in this study.
Earliest activation in the high right atrium could be due to either a right
atrial source or the right superior pulmonary vein. It has recently been
shown that studying the timing of endocardial atrial activation sequences
in high right atrium, His bundle, proximal and distal coronary sinus allows
accurate localization of the origin of atrial ectopic beats. Right atrial foci
(SVC and crista terminalis) can accurately be discriminated from
pulmonary vein foci avoiding the requirement of trans-septal puncture in
the small subgroup of patients who have only right atrial triggers. In our
study we did not have either a proximal coronary sinus or a His catheter.
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Limitations of the study
The identification of a focal source of atrial arrhythmias post-
cardioversion does not address the underlying mechanism of lone AF on a
cellular or subcellular level. Automatic or triggered mechanisms might be
considered the most likely cause of repetitive electrical activity arising
from a "single" source, analogous to idiopathic ventricular tachycardia
arising from the outflow tract of the right ventricle.34 Reentrant
mechanisms cannot be excluded however, and Haissaguerre and
coworkers have identified features of reentry (continuous electrical
activity) associated with a pulmonary venous focus of AF.6 Recent work
has also suggested that stable microreentrant sources, principally located
in the left atrium, may underlie AF in the isolated sheep heart.35
Radio frequency catheter ablation of the presumed focal source of the
arrhythmias identified in this study was not performed (except in one
case). Although it might be thought that abolition of these arrhythmias by
local destruction of atrial tissue would lend considerable support to the
concept of a focal origin, 1) it would be impossible to be certain that
disappearance of the focal atrial activity was a consequence of the ablation
itself as in most cases only 2 or 3 episodes were identified (unlike the
frequent paroxysmal episodes in patients selected by Haissaguerre) and 2)
the absence of antiarrhythmic intervention (catheter ablation or drugs) in
this study allowed us to determine the natural history of the different
groups of patients with AF (focal and non-focal) relative to each other and
thereby the clinical significance of focal atrial arrhythmias in this patient
group.
Endocardial atrial activity was monitored for only a short period post-
cardioversion and in the absence of exogenous cathecholamines, in
contrast to electrophysiological studies previously performed in patients
with paroxysmal AF. As a consequence it is possible that the prevalence
of focal atrial arrhythmias reported in the study is an underestimate of the
213
true prevalence. It is also possible that some focal sources were missed as
a consequence of the strict definitions used in this study, contributing
further to a possible underestimation of the true prevalence.
Clinical relevance of the findings
The fact that patients with persistent "lone" AF are particularly likely to
demonstrate focal atrial activity suggests that this activity may be the
original cause of the arrhythmia in many of these patients. Furthermore,
the association of focal atrial arrhythmias post-cardioversion with
subsequent clinical recurrence of AF in this study indicates that catheter
ablation of these arrhythmias may provide an important therapeutic
approach to patients with the persistent form of AF. Whether such an
approach is likely to be curative depends upon whether these arrhythmias
are the sole cause of "idiopathic" persistent AF or rather act as important
triggers in the setting of an additional abnormality.
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9.1 Heart Rate Variability - Introduction and Review
The beat of the healthy heart is not absolutely regular. It varies as a result
of many factors, including exercise and both physical and mental stress. In
addition, the intervals between normal sinus beats vary periodically
because of respiration, blood pressure regulation, thermoregulation,
actions of the renin-angiotensin system, circadian rhythms, and other
unknown factors. Such periodic rhythms are in fact the predominant
source of heart rate variability. By using Holter recordings, these rhythms
can be analysed to provide a noninvasive measurement of the autonomic
input to the heart.
There are two approaches to measurement of heart rate variability (HRV):
analysis in the time domain or in the frequency domain. These measures
are based on the analysis of interbeat intervals of normal beats determined
from a 24-hour ambulatory electrocardiogram. Time domain analysis
addresses the question of "How much variability is there?" Time domain
values result from statistically based calculations performed on the set of
interbeat intervals. Frequency domain analysis addresses the question
"What are the underlying rhythms?" In the frequency domain, Fourier
analysis is used to partition the total variance of the heart rate into the
variance accounted for by underlying groups of frequencies, somewhat
like decomposing the sound of a symphony orchestra into the underlying
notes.
Time Domain
Time domain indexes are relatively easy to calculate. There are two
classes of time domain variables, one based on interbeat intervals and the
other based on comparisons of the lengths of adjacent cycles. Those based
on interbeat intervals include SDNN (the standard deviation of all normal
R-R intervals) and SDANN (standard deviation of the averages of the N-N
intervals in all the 5 minute segments, averaged over a 24-hour period). A
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geometric approach to quantifying interbeat interval-based HRV involves
measuring the baseline width (in msec) of the main triangle (HRV
triangular index) superimposed on the histogram of all N-N intervals. This
method has the advantage of being less dependent on accurate
classification of individual beats. Another time domain index of heart rate
variability, SDNN index is the average of the standard deviations of all N-
N intervals for all the 5-minute segments of the entire recording, an
intermediate between long and short-term variability. These interbeat
interval-based measures are broad-based and are influenced by both short-
term (for example, respiratory) and long-term (for example, circadian)
factors and are measured in milliseconds. The second class of time domain
variables based on comparisons of lengths of adjacent cycles includes
pNN50 (the proportion of adjacent cycles that are >50 msec apart,
measured in percent), and RMSSD (the root mean square successive
differences), which is the square root of the averaged sum of squared
differences in length between all adjacent N-N cycles. These variables are
virtually independent of long-term trends and predominately reflect vagal
tone. Table 9.1 summarises the main time domain indices of HRV.
Frequency Domain
Analysis in the frequency domain is mathematically more complex, and
requires a Holter system with an accurate timing track. Frequency domain
analysis yields information about the amount of the overall variance in
heart rate resulting from periodic oscillations of heart rate at various
frequencies. Because heart rate is measured in milliseconds, variance,
which is referred to as the "power" in a portion of the total spectrum of
frequencies, is measured in milliseconds squared.
The normal approach has been to classify the power spectrum into four
bands. High frequency power (HF), which is parasympathetically
mediated represents primarily respiratory variation, is in the 0.15 to 0.4 Hz
band. Low frequency power (LF), which is modulated by both the
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sympathetic and parasympathetic nervous systems and strongly affected
by the oscillatory rhythm of the baroreceptor system, is in the 0.04 to 0.15
Hz band. Very low frequency power (VLF, 0.0033 to 0.04 Hz band) and
ultra low frequency power (ULF, 1.15 x 10"5 to 0.0033 Hz) may represent
the influence of the thermoregulatory, peripheral vasomotor, or renin-
angiotensin systems. Measurement of ULF, which contains most of the
variance in the 24-hour spectrum, is based on the entire 24-hour recording
and also reflects circadian rhythms, whereas VLF may be obtained from a
15-minute sequence ofN-N intervals. Total power is the total variance in
the signal and represents the sum of HF, LF, VLF, and ULF. Since these
power frequency distributions are skewed for statistical purposes, the
natural log transform of power values is used.
Indices of HRV have been shown to be stable, at least over a 3 to 65-day
interval, and there is no placebo effect on HRV. This lack of
intraindividual variability over time makes measurement of HRV an
excellent tool for studying autonomic input to the heart.
223
Table 9.1 Definitions for time domain measures of heart period variability
Variable Units Definition
SDNN msec Standard deviation of all normal R-R intervals in
the entire 24-hr ECG recording (also referred to as
SDRR or CLV)
SDANN msec Standard deviation of the mean of all 5-min
segments of normal R-R intervals of a 24-hr
recording
pNN50 % Percent of adjacent normal R~R intervals that are
greater than 50msec apart computed over the entire
24hr ECG recording
RMSSD msec Root mean square of successive differences -
the square root of the mean of the sum of the
squares of differences between adjacent normal
R-R intervals over the entire 24-hr ECG recording
224
Utility of Heart Rate Variability
Initial interest in HRV was in the field of obstetrics following the
description of reduced HRV preceding foetal death.1 The study of HRV in
cardiology started with the description of an association between the
absence of sinus arrhythmia and an increased mortality shortly after
myocardial infarction.2 Since then a reduced HRV has been shown to be
associated with increased mortality following myocardial infarction (MI)
and in patients with heart failure.4 Changes in HRV have also been
associated with the onset of idiopathic ventricular arrhythmias5 and in the
onset of ventricular tachycardia in patients following MI.6
Heart rate variability has been of particular use in predicting future
arrhythmic events in MI survivors. A recent review of the value of non¬
invasive investigations in predicting future arrhythmic events in MI
survivors concluded that HRV has a potential clinical role in risk
stratifying patients with one of either reduced ejection fraction (<40%) or
an abnormal signal averaged ECG.7 This review of 11 previous studies
(n = 5,719 patients) found that reduced HRV had an average sensitivity of
around 50% with a specificity of around 85% for predicting major
arrhythmic events in the subsequent 2-year period.
Heart Rate Variability and Atrial Fibrillation
Paroxysmal AF
Coumel first proposed a link between the autonomic nervous system and
episodes of PAF with the description of parasympathetic and sympathetic
forms based on clinical criteria.8'9 Subsequently, studies showing changes
in heart rate variability prior to the onset of paroxysmal AF have had
inconsistent results with some workers finding an increase in sympathetic
tone10 and others an increase in parasympathetic tone.11 The autonomic
pattern prior to the onset of paroxysmal AF episodes appears patient
dependent,12 and may be linked to the presence or absence of structural
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heart disease with a sympathetic preponderance in patients with
underlying heart disease and a parasympathetic dominance in idiopathic
13AF. A parasympathetic dominance appears to be most marked in patients
with nocturnal episodes of idiopathic PAF.11 The limited data on HRV
prior to the onset of paroxysms of typical atrial flutter suggest an increase
in sympathetic modulation or vagal withdrawal.14
Patients with paroxysmal AF do not have abnormalities of autonomic
function as assessed by heart rate variability,15'16 but rather their cardiac
response to changes in autonomic tone is abnormal.15 The use of heart rate
variability to diagnose autonomically mediated AF, followed by
modification of cardiac autonomic tone by medical treatment, has
anecdotally been reported to be successful in alleviating episodes of
vagally induced paroxysmal AF.17
AF post CABG
Episodes of AF occurring after CABG are generally preceded by a shift to
sympathetic dominance by either increasing sympathetic tone18 or
withdrawal of vagal tone.19 This would be no surprise to the clinician as
patients developing AF following cardiac surgery tend to be older and
sicker than those who remain in sinus rhythm.20 In addition the efficacy of
B-blocker therapy in reducing the incidence of post-CABG AF has been
well documented.21,22
Heart rate variability as a remote predictor of AF onset
A reduced SDANN has been shown to be a strong predictor of the future
onset of AF, requirement for mitral valve surgery and death in patients
23
with chronic severe mitral regurgitation (over 2 years of follow-up). In
patients undergoing CABG a low vagal tone combined with a higher
frequency of supraventricular ectopic beats as assessed by Holter
monitoring pre-operatively has been shown to predict AF post¬
operatively.24 The increased risk of AF associated with a reduced vagal
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tone and a lower SDANN is likely to represent patients with more severe
underlying heart disease, a subgroup that is already recognised to be at
increased risk ofperioperative AF.
The Role of the Autonomic Nervous System in AF Stability
Recent experimental work in animals has assessed changes in the
25autonomic nervous system in sustained AF. Olgin and co-workers
showed that heterogeneous atrial sympathetic denervation, resulting in an
increase in dispersion of atrial refractoriness, increases the stability of
induced episodes of AF in dogs. The same group then went on to show
that following induction of sustained AF by 6-weeks of rapid atrial pacing
in dogs, there is a heterogeneous increase in atrial sympathetic innervation,
as measured by positon emission topography (PET) scanning and tissue
concentrations ofnorepinephrine.26 Other authors have also found an
increase in the sympathetic nerve innervation associated with AF in
rapidly paced dog atria.27 An important role for the sympathetic
innervation in promoting the maintenance of sustained AF is also
suggested by preliminary data that shows bilateral stellectomy, and the
resultant homogeneous atrial sympathetic denervation, to prevent the
induction of sustained AF in dogs by rapid atrial pacing. This failure to
induce sustained AF occurs despite atrial electrical remodelling resulting
in a similar reduction in atrial refractoriness in the stellectomised dogs as
control dogs (no stellectomy) that did develop sustained AF. These results
suggest that an increase in sympathetic innervation may be important in
the onset of stable AF.
Importance of the sympathetic nervous system in persistent AF in man
An increase in sympathetic tone such as occurs in thyrotoxicosis and
18
following cardiac surgery is associated with the onset of sustained AF.
The use of perioperative beta-blockers in cardiac surgery has been shown
to reduce the incidence of AF following cardiac surgery,21 and the use of
metoprolol following cardioversion of persistent AF has been shown to
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reduce the risk of subsequent AF recurrence.22 Although the underlying
action of the sympathetic nervous system in promoting AF is not clear,
sympathetic nervous system stimulation by head up tilt testing results in a
shortening of AF cycle length29 and isoproterenol infusion also shortens
AF cycle length.30
HRV after cardioversion of persistent AF
Previous studies of heart rate variability in patients with persistent AF
have focused on a potential role of the autonomic nervous system in
mediating recurrence of persistent AF. ' Using spectral analysis of 15-
minute heart rate recordings in patients following DC cardioversion of
persistent AF Lombardi and colleagues31 showed that recurrence of AF
was more common in patients with a LF/HF ratio > 2, suggesting
increased cardiac sympathetic modulation. Conversely other authors
studying time domain parameters of heart rate variability on 24-hour
Holter recordings have found that vagal influences (RMSSD) were higher
in patients with recurrent AF.32
HRV in AF
Atrial fibrillation and the irregularity of the ventricular response have
traditionally been felt to be a barrier to assessment of heart rate variability.
However, by using the patient as his or her own control Van den Berg et al
were able to show that HRV in AF was primarily controlled by the
parasympathetic nervous system.33 Of particular note was that there was
no difference in indices ofparasympathetic function in patients taking
digoxin.
Changes in HRV also have prognostic implications in AF patients. A
reduced SDANN (<100ms) in heart failure patients with AF was
associated with a markedly increased 1-year mortality34 and reduced high
frequency variability is associated with adverse outcomes in patients with
non-ischaemic mitral regurgitation.35
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9.2 Changes in Heart Rate Variability Following
Cardioversion of Persistent Atrial Fibrillation in Man
Introduction
The concept of atrial electrical remodelling (AER) is well established. The
rapid rate of atrial electrical activation that occurs in atrial fibrillation (AF)
and atrial flutter results in a reduction of the atrial refractory period
(AERP), reversal of its normal adaptation to rate and an increase in the
dispersion of atrial refractoriness.36"39 In addition to altering the
electrophysiology of atrial muscle, changes in sinus node function have
also been documented in association with atrial electrical remodelling.
Following a period of several weeks rapid atrial pacing in dogs40 or
chronic (mean 1-years) atrial flutter in humans41 intrinsic heart rate is
reduced40 and sinus node recovery times prolonged.40'41 These changes
partially recover following a week of sinus rhythm in dogs40or 3-weeks of
sinus rhythm in man.41
There is a considerable amount of data on the role of the autonomic
nervous system in paroxysmal AF. However, the role of the autonomic
nervous system in persistent AF in humans is not well documented. As
discussed in section 2.3 the autonomic nervous system can influence atrial
electrophysiology and promote AF. In particular the recent demonstration
of an increase in atrial sympathetic innervation in association with
sustained AF in dogs26'27 raises the possibility that changes in autonomic
input to the atria may be important in persistent AF.
We postulated that during a period of persistent AF changes in sinus node
function and /or autonomic innervation of the atria might occur. Using
Holter monitoring we measured intrinsic heart rate, as a marker of sinus
node function, and heart rate variability, as a marker of atrial autonomic
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activity, in a population of patients following cardioversion of persistent
AF or atrial flutter.
Methods
Patients
Consecutive patients presenting to the cardiac department of a general
hospital with persistent AF or atrial flutter (minimum duration of
presenting episode 3 months) documented by serial electrocardiograms
were considered for the study. Written informed consent was obtained
using an information sheet and consent form approved by the Central
Manchester Research Ethics Committee, which also approved the study
protocol.
Study Protocol
Initial clinical assessment included history, physical examination, 12-lead
surface ECG, thyroid function tests and trans-thoracic echocardiography.
Patients were admitted to hospital for DC cardioversion of persistent AF
or flutter after at least 4-weeks of adequate anticoagulation. All
antiarrhythmic and cardioactive medication was stopped 3 full days prior
to the procedure in all patients except those taking amiodarone (n = 5),
which was continued. Patients were internally cardioverted under heavy
sedation by a DC shock delivered between right atrial and coronary sinus
electrodes as described in Chapter 6.
Holter Monitoring and Tape Analysis
Patients were discharged the day following the procedure. Antiarrhythmic
therapy was not reinstituted following cardioversion (except amiodarone
which, ifpresent precardioversion, was continued throughout) but
anticoagulation was continued for at least 6 weeks. Patients underwent
Holter monitoring for measurement ofHRV at day-3, 1-week, 1-month
and 3-months post-cardioversion. Because of the risk of confounding
factors such as patient anxiety, the recognised increase in circulating
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catecholamines with cardioversion42 and the fact that patients remained in
hospital for 24-36 hours following the procedure assessment of HRV by
Holter monitoring was delayed until day-3. All tapes were analysed by a
single operator using the Reynolds Pathfinder 700 system. For the purpose
of analysis only QRS complexes with normal morphology and within 20%
of the preceding cycle length were analysed. Following editing time
domain variables of heart rate variability and mean sinus cycle length were
determined. The time domain variables measured were the standard
deviation of all normal-normal (NN) intervals (SDNN), the standard
deviation of the 5-minute averages of NN intervals (SDANN) and the
square root of the mean of the sum of squares of differences between
adjacent NN intervals (RMSSD). Data was excluded if the minimum
number of qualified sinus beats was less than 90% over the 24-hours.
Indices of spectral heart rate variability were not measured for the 24-hour
period due to the difficulty in interpreting the physiological mechanisms
responsible for low and high-frequency power components which cannot
be considered stationary during a 24-hour period.43
Statistical Analysis
Patients' clinical details were compared using an independent samples t-
test for continuous variables and a Chi-squared test for categorical
variables. Variation in heart rate variability over time was analysed using
ANOVA. All results are expressed as mean ± standard deviation. P values
less than 0.05 were deemed statistically significant. Statistical analysis was
performed using the software package SPSS 9.0.
Results
A total of 65 patients (49 male, mean age 60±9 years) were admitted for
cardioversion. Cardioversion was successful in 61 patients, but 12 of these
patients left the lab in AF due to repeated early recurrence of AF. Of the
49 patients leaving the lab in sinus rhythm 10 had recurrence of AF prior
to or during the first Holter on day-3 leaving 39 patients who completed
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the Day-3 Holter. AF recurred prior to the 1-week Holter in a further 12
patients. Therefore, a total of 27 patients completed the initial recording at
day-3 post-cardioversion and at 1-week. From this group (27 patients) 10
patients were excluded because the number of qualified sinus beats was
less than 90% over the 24 hours. This was due to frequent atrial ectopy in
all cases. Results are reported for 17 patients (AF - 15, flutter - 2). A
schematic of the exclusion criteria is shown in Figure 9.1. The clinical
details of the 17 patients are shown in table 9.2. These patients were
representative of the initial 65 patients.
The results showed a marked increase in SDNN and SDANN from day-3
to 1-week post-cardioversion and then a further small increase from 1-
week to 3-months (Figure 9.2). The RMSSD increased from day-3 to 3-
months but this change was not statistically significant. The mean sinus
cycle length and the frequency of APBs remained constant over the series
of recordings (see Table 9.3).
The day-3 Holter monitors for the 12 patients who had recurrence of AF
between the day-3 Holter and 1-week were also analysed. Of these 7 were
excluded because the number of qualified sinus beats was less than 90%
over the 24 hours. The HRV data for the 5 remaining patients was similar
to that on day-3 of the 17 patients in the study. SDNN was 99.6±18.7ms,
SDANN 78.6±19.9ms and RMSSD 40.2±27.3ms (all P > 0.2).
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Table 9.2 Clinical details of the 17 patients
Male / Female 11/6
Age (years) 61.7 ± 9.3
Duration AF/F1 (months) 12.3 ±9.6










LA - left atrium; LV - left ventricular; AF - atrial
fibrillation; F1 - atrial flutter; IHD - ischaemic heart disease
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Figure 9.1 Diagram of pathway for inclusion in the study
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Time Mean RR (ras) RMSSD (ms) APB
Day-3 876 ± 135 29.7 ± 11.7 509 ±459
1 -week 890 ± 135 34.9 ± 17 329 ±281
1-month 898 ± 148 37.7 ±22.3 254 ± 245
3-months 852 ± 101 37.5 ± 15 569 ±532
P value 0.8 0.54 0.11
Table 9.3 Results of the mean sinus cycle length (RR), RMSSD and frequency of









Day 3 1-week 1-month 3-months
Time of Holter Recording
Figure 9.2 Results of SDNN and SDANN. The P-value






This study demonstrates that following cardioversion of persistent
AF/flutter to sinus rhythm there is a significant increase in the SDNN and
SDANN measures of heart rate variability between day-3 and 3-months
post cardioversion. Spontaneous sinus cycle length does not change over
this period.
Changes in HRV following restoration of sinus rhythm
Changes in HRV have previously been described in man following
• • • T9
cardioversion of persistent AF and in goats during recovery of atrial
electrical remodelling.44 Kanoupakis and coworkers32 studied patients with
persistent AF, in drug washout undergoing internal DC cardioversion. The
authors concentrated on the utility of HRV in predicting recurrent AF
following DC cardioversion. They found a higher RMSSD and pNN50 on
the first and second days post-cardioversion in patients with AF
recurrence. In addition, they noted a steady increase in SDNN and
SDANN indices of HRV with time following cardioversion in patients
without AF recurrence. Indices of vagal modulation (RMSSD and pNN50)
showed a decrease from day-1 to day-2 following cardioversion but then
stabilised. These early changes may have been related to the cardioversion
procedure. We did not find any difference in indices of HRV between
those patients with recurrent AF and non-recurrers.
Using the rapid atrial pacing goat model of AF Blaauw and coworkers44
found that during the recovery of atrial electrical remodelling there was an
increase in the SDNN and RMSSD indices of HRV. Accompanying this
increase in time domain parameters there was a significant decrease in the
ratio of low frequency to high frequency power (LF/HF) in the frequency
domain implying an increase in vagal input or reduction in sympathetic
input. Despite the similarity to our own results it is possible that the
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reduction in sympathetic input may have reflected increased familiarity of
the goats with the experimental set-up.
Possible mechanisms for changes in HRV following cardioversion of AF
There is evidence from this study of changes in HRV following
cardioversion of persistent AF in man. There are several possible
mechanisms that could underlie these changes:
1) Sinus node remodelling - it is possible that sinus node remodelling
secondary to atrial electrical remodelling is manifest as a reduced HRV
rather than changes in intrinsic heart rate. Sinus node remodelling
might result in a reduced sensitivity of the sinus node to autonomic
input and therefore changes in HRV.
2) Improved haemodynamics - the onset of AF is associated with loss of
atrial systole and an associated reduction in cardiac output. Restoration
of sinus rhythm results in an improved cardiac output43 due to the
return of atrial function46 and the return of a regular cardiac rhythm.47
Changes in HRV following cardioversion may be due to improved
haemodynamics and changes in neurohumoral hormones many of
4.8
which are increased in AF.
3) Mechanoelectrical feedback - the relationship between atrial stretch
and changes in atrial electrophysiology is well documented.49'5 Atrial
stretch also influences sinoatrial node function by increasing heart
rate.51 Experimental work designed to explain the reduced HRV
associated with heart failure52 has shown that sinoatrial node stretch in
anaesthetised pigs causes a reduction in SDNN. It is possible that AF-
induced atrial dilatation37 followed by a reduction of atrial size on
returning to sinus rhythm53 may explain the observed changes in HRV.
4) Autonomic remodelling - recent experimental work in animals has
assessed changes in the autonomic nervous system in sustained AF.
Induction of sustained AF by 6-weeks of rapid atrial pacing in dogs
results in an increase in atrial sympathetic innervation.26'27 Intact
sympathetic innervation also appears to be essential in the maintenance
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of sustained AF in dogs.28 These results suggest that an increase in
sympathetic innervation may be important in the onset of stable AF.
Changes in autonomic input to the atria, such as increased sympathetic
innervation, secondary to persistent AF may explain the reduced HRV
following cardioversion.
Sinus node function
This study has failed to show any changes in intrinsic heart rate following
cardioversion of persistent AF/flutter. The difference between these
findings and the previous findings of Elvan40 and Sparks41 may relate to
different methodologies. In both these studies sinus node function was
assessed by electrophysiological testing under autonomic blockade.40'41
However, Elvan et al40 also noted a reduced spontaneous cycle length
following cessation of rapid atrial pacing. A prolonged sinus node
recovery time has been found in man following cardioversion ofpersistent
AF54 indicating that it is possible that sinus node dysfunction may indeed
have been present in our patients but that more detailed
electrophysiological testing may be required for its detection.
An important advantage of this study is that medications were not altered
during the study and most patients were in drug washout. Although
amiodarone has not been shown to affect indices of HRV55'56 other
57 58
antiarrhythmic drugs such as beta-blockers which increase HRV, ' and
Class Ic antiarrhythmic drugs which reduce HRV56'59 were not used in the
study patients.
Conclusion
During the first week of sinus rhythm following DC cardioversion of
persistent AF/flutter there is a significant change in HRV. The increases in
SDNN and SDANN over this period of time reflect either a change in
intrinsic sinus node function or altered input to the sinus node following a
period of sinus rhythm (1-week). More detailed assessment of sinus node
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function and/or pharmacological manipulation will be required to
determine the underlying mechanism of these changes.
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